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SUMMARY 
The purpose of this thesis was to evaluate microinvasive 
technology for the management of non-palpable mammographic findings 
with high risk for breast cancer. The specific objectives were, for the 
first part, to evaluate the Advanced Breast Biopsy Instrumentation 
System (ABBI) as a diagnostic and therapeutic tool for breast disease. 
For the second part, the objective was to evaluate Iymphoscintigraphy 
with a malignancy specific radioactive agent (99mTechnetium Sestamibi) 
as a non-surgical staging tool for breast cancer. 
Design: 
The thesis consists of two observational studies. The first study 
was partially retrospective and partially prospective. The second study 
was prospective. The research was conducted between September 1997 
and December 2001. 
Methods: 
For the first study 262 women with non-palpable mammographie 
abnormalities were enrolled. Of these, 260 women underwent an ABBI. 
The ABBI procedure was performed by 3 surgeons in two hospitals in 
Montreal. The files of 531 women with similar findings who underwent a 
wire localization excisional biopsy in the same hospitals by the same 
surgeons were retrospectively reviewed. Data obtained included 
technical success, macroscopic and microscopic clarity of margins, need 
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for supplemental surgery and residual cancer, volume of breast tissue 
excised, patient satisfaction, surgeon volume-performance association 
and health care costs. 
For the second study, 110 women with confirmed operable primary 
breast cancer who required axillary Iymph node dissection were 
enrolled. Ali the patients underwent two Iymphoscintigraphies. The first 
(preliminary) Iymphoscintigraphy took place at least 2 weeks before 
su rgery and the second (preoperative) took place 2-24 hours before 
surgery. For the preliminary Iymphoscintigraphy, 47 (42.7%) of the 110 
women were tested with 99mTechnetium Sestamibi and 63 (57.3%) were 
tested with 99mTechnetium Sulphur Colloid. For the preoperative 
Iymphoscintigraphy ail patients were tested with 99mTechnetium Sulphur 
Colloid. Ail patients underwent axillary Iymph nodes dissection. The data 
reviewed was the presence of metastasis in the axillary Iymph nodes 
excised and the Iymphoscintigraphy gamma camera imaging and gamma 
probe digital outcomes. The ROC curve was used to define the most 
probable cut-off points for the distinction between gamma counts 
representing positive and negative for metastasis axillary Iymph nodes. 
Results: 
For the first study, diagnostic effectiveness of the ABBI was 99.6% 
and the mean volume of excised breast tissue was 40cc. No serious 
complications were reported. For wire localization, the diagnostic 
effectiveness was 98.0% and the mean volume of excised breast tissue 
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was 102cc. severity of complications was similar between the two 
techniques. The therapeutic effectiveness of the ABBI was 76.3%, 
supplementary surgery was required in 27.6% of the patients, and 
residual cancer was detected in 23.8%. The therapeutic effectiveness of 
wire localization biopsy was 47.0%, 53% of the patients underwent 
supplementary surgery and residual tumor was found in 48.0%. Of the 
260 patients who underwent an ABBI, 51 % reported a good level of 
satisfaction and 23% reported excellent. A significant association was 
shown between volume and therapeutic effectiveness for ail 3 surgeons. 
On the average, the ABBI resulted in a cost reduction of $5,352 CAO 
(2000). 
For the second study, the sensitivity of 99mTechnetium Sestamibi 
Iymphoscintigraphy imaging was 50%, the negative predictive value was 
83.8% and the proportion of false negative results was 17.1 %. Logistic 
regression showed a statistically significant (p<0.001) association 
between the gamma probe counts and axillary Iymph node metastasis. 
Using 3,080 counts as cut-off point on the ROC curve the sensitivity and 
false negative rate were 100%, the specificity was 94.3%, and the 
positive predictive value was 83.3%. 
Conclusion: 
The results of the first study show that the ABBI offers a safe and 
weil tolerated microinvasive surgical technique, with superior therapeutic 
effectiveness, less invasiveness, and better cost effectiveness than wire 
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localization excisional biopsy. The strong volume-performance 
association shows that the therapeutic effectiveness of the ABBI can 
improve with proper training and experience. 
The results of the second study show that 99mTechnetium 
Sestamibi Iymphoscintigraphy imaging was 50% the negative predictive 
value was 83.8% and the proportion of false negative results was 17.1 %. 
A significant association was shown between the intensity of 
radioactivity in the hot node as measured by the gamma-probe counts 
and the presence ofaxillary Iymph node metastasis. 
ln conclusion, this thesis demonstrates that both the ABBI and 
Iymphoscintigraphy with 99mTechnetium Sestamibi are superior to 
conventional techniques used for the management of mammographie 
abnormalities and specifically breast cancer. Proper training of surgeons 
in highly qualified training centers with a high volume of cases can help 
further improve the effectiveness and increase the practise of these 
techniques in Canadian hospitals. This may in turn increase the benefits 
for the patients and reduce the healthcare costs for the management of 
breast disease and specifically breast cancer in Canada. 
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RÉSUMÉ 
Cette thèse est une combinaison de deux études observationnelles 
possédant une intention commune; l'évaluation de la technologie 
innovatrice microeffractive pour la gestion du cancer du sein. Les 
objectifs spécifiques étaient en premier lieu, d'évaluer 'the Advanced 
Breast Biopsy Instrumentation System (ABBI)' comme instrument de 
diagnostique et de thérapie pour les maladies du sein (ou maladie 
mammaire) puis en deuxième lieu, d'évaluer Iymphoscintigraphie avec 
un agent radioactif malin spécifique (99mTechnetium Sestamibi) comme 
outil de stadification non-chirurgical pour le cancer du sein. La 
recherche fut effectuée entre septembre 1997 et décembre 2001. 
Design: 
Cette these comprends deux études d'observations. La première 
étude est partiellement retrospective et partiellement prospective. La 
recherche a été exécutée entre septembre 1997 et décembre 2001 
Méthodes 
Pour la première étude 262 femmes avec des anomalies mammographies non-
palpable ont été choisies. De celles-ci, 260 femmes ont subit un ABBI. La procédure 
ABBI a été effectué par 3 chirurgiens dans deux hôpitaux dans la région de Montréal. 
Les fiches de 531 femmes avec des résultats similaires et qui ont subit une biopsie 
excisionelle dans les mêmes hôpitaux et par les mêmes chirurgiens ont aussi été 
revisés. L'information obtenue inclus: succès de la technique, la marge 
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macroscopique et microscopique, besoin de chirurgie supplémentaire et cancer 
résiduel, volume de tissue du sein excisé, satisfaction du patient, association du 
volume-performance du chirurgien et les coûts de la santé. 
Pour la seconde étude, 110 femmes avec un cancer du sein 
opérable et qui nécessitait une dissection des glandes lymphatiques 
auxiliaires ont été recrutées. Toutes les patientes ont subit deux 
Iymphoscintigraphies. La première Iymphoscintigraphie (préliminaire) a 
eu lieu au moins deux semaines avant la chirurgie et la seconde (pré-
chirurgie) a eu lieu 2 à 24 heures avant la chirugie. 
Pour la premiere Iymphoscintigraphie, 47 (42.7%) des 110 femmes 
ont été testées en utilisant 99mTechnetium Sestamibi et 63 femmes 
(57.3%) ont été testées en utilisant 99mTechnetium Sulphur Colloid. 
Toutes les patientes ont été testées en utilisant 99mTechnetium Sulphur 
Colloid. Toutes les patientes ont subi une dissection des glandes 
lymphatiques auxiliaires. 
La première partie de cette thèse démontrait que, pour la gestion 
des anomalies mammographiques qui ont un risque élevé d'avoir un 
cancer du sein, le procédé d'instrumentation avancé de biopsie du sein 
(cABBI) offre une efficacité thérapeutique supérieure, moins invasive, et 
moins coûteuse que le fil localisateur guidant la biopsie excisionnelle. 
De plus, il a été démontré que le procédé d'cABBI est sécuritaire et bien 
toléré par la plupart des patientes. La forte association volume-
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performance démontre que l'efficacité du procédé d'cABBI augmentera 
si les chirurgiens reçoivent une formation adéquate. 
La deuxième partie de la thèse démontrait que la 
Iymphoscintigraphie avec le Technétium99m Sestamibi, lorsque pratiqué 
adéquatement, offre une technique très précise et non-invasive pour la 
détection de métastases au niveau des ganglions axillaires au stade 
primaire du cancer du sein. Cependant, ceci est vrai uniquement 
lorsque la sonde actuelle à détection gamma est utilisée. L'imagerie 
Iymphoscintigraphique n'était pas précise pour la détection de 
métastases. Avec une formation adéquate et de l'expérience, 
l'implantation de la Iymphoscintigraphie avec le Technétium99m 
Sestamibi pourrait aider à minimiser la morbidité associée à la 
dissection conventionnelle des ganglions axillaires. De plus, cela 
pourrait réduire la probabilité d'omettre des métastases. 
En conclusion, les résultats de cette thèse démontrent que les 
techniques d'cABBI et de Iymphoscintigraphie avec le Technétium99m 
Sestamibi peuvent toutes les deux aider à améliorer l'efficacité de la 
gestion actuelle des anomalies mammographiques et du cancer du sein. 
Une formation adéquate des chirurgiens pour ces deux techniques, dans 
des centres de formation très spécialisés avec un volume élevé de cas, 
pourrait aider à améliorer l'efficacité de ces techniques. Ceci pourrait 
augmenter les avantages liés au traitement pour les patientes et réduire 
les coûts des soins de santé pour la gestion de la maladie du sein et 
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spécifiquement le cancer du sein au Canada et dans d'autres régions du 
monde. 
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STATEMENT OF ORIGINALITY 
The two studies included in this thesis evaluate the effectiveness 
of a minimally invasive surgical diagnostic technique, the Advanced 
Breast Biopsy Instrumentation System (ABBI) and a non-surgical staging 
technique, Iymphoscintigraphy, for the diagnosis and surgical treatment 
of breast cancer. 
The ABBI has been evaluated previously. However, in the current 
study the following are important differences from previous studies. 
First, this is a prospective multi-center study with data from many 
surgeons; second, the outcome measures were ascertained by an 
observer that was not involved in conducting the procedure, thus 
minimizing bias. The evaluation of the association between surgeon 
experience and effectiveness or volume performance is an original 
contribution of the current study. The economic assessment and 
description of patient satisfaction within the Canadian Healthcare 
System are also original contributions of the current study. 
Sentinel Iymph node biopsy with the guidance of 
Iymphoscintigraphy has been evaluated in other studies. The purpose of 
Iymphoscintigraphy is first, to reveal, with the help of a radioactive 
agent, the Iymphatic drainage pathway of the particular area of the 
breast where the cancer is located. Second, to guide the detection and 
the dissection of the first Iymph node to potentially receive malignant or 
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benign tumor cells from the area of the breast where the tumor is 
located, called the sentinel Iymph node. The current study evaluated the 
use of Iymphoscintigraphy with 99mTechnetium Sestamibi, a malignant 
cell specifie agent, to accurately detect axillary Iymph nodes with 
metastatic invasion from the tumor in the breast area under 
investigation. This is an original contribution of the current study since 
this method has never been evaluated. 
The thesis candidate conceived and designed both studies, was 
the author of the protocols, conducted ail data collection, data analysis 
and reporting for both studies. The candidate also collaborated in 
modifications in the development of the ABBI. In addition the candidate 
will be responsible for the preparation and publication of manuscripts 
reporting the results of these two studies. 
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PROLOGUE 
This thesis presents two research projects that have a common 
goal; the evaluation of microinvasive techniques for the diagnosis and 
staging of breast cancer. The common underlying theme of these two 
projects is the use of minimally invasive or non-invasive procedures for 
the diagnosis and surgical management of breast cancer. 
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1 STATEMENT OF THE PROBLEM AND RATIONALE 
1.1 INTRODUCTION 
1.1.1 PROLOGUE 
The purpose of the current chapter is to describe the current state 
of knowledge and to establish the rationale for the two studies included 
in this thesis. The chapter will be comprised of a brief review of the 
epidemiology of breast cancer and a description of the methods 
currently used for diagnosis, staging, and treatment of early breast 
cancer. 
The use of microinvasive methods for the diagnosis and 
management of early breast cancer will be presented in comparison to 
alternative more conventional and invasive techniques. Finally, a review 
of the literature on the two techniques evaluated in the current thesis 
will be presented, thus defining the knowledge gap and establishing the 
need and rationale for the studies presented in this thesis. 
The two techniques evaluated in this thesis have one main 
common characteristic; the use of microinvasive technology for the 
management of breast cancer. The first is a surgical technique that aims 
to accurately localize and excise breast tumors, which are detected in a 
mammogram but are too small to palpate, with the least possible 
excision of surrounding healthy breast tissue. The second involves the 
combination of radiolabelled isotopes along with an imaging, acoustic 
and digital technique. The aim is to detect axillary Iymph node 
- 21 -
metastasis from the cancer in the ipsilateral breast without the need for 
surgical excision ofaxillary Iymph nodes. In essence the common goal 
of both techniques is to diagnose and manage breast cancer while 
minimizing surgical invasiveness without compromising patient care. 
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1.1.2 EPIDEMIOLOGY OF BREAST CANCER 
ln the last two decades, breast cancer is the most frequently 
diagnosed cancer in Canadian women, accounting for 30% of ail cancer 
cases in women 1-4. The number of new breast cancer cases diagnosed 
increased, rising from 10,175 in 1981 to an estimated 21,600 in 2005 
(Figure 1 )3.5. However, breast cancer mortality rates have declined 
steadily since 1993 (Figure 2)3. 
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Figure 1: Age-Standardized Incidence Rates (ASIR) for Selected Cancer 
Sites, Females, Canada, 1976-2005, National Cancer 
Institute of Canada. Canadian Cancer Statistics, 2005. 
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Figure 2: Age-Standardized Mortality Rates (ASIR) for Selected Cancer 
Sites, Females, Canada, 1976-2005, National Cancer 
Institute of Canada. Canadian Cancer Statistics, 2005. 
According to Canadian Cancer Statistics, it is estimated that in 
2005 approximately 21,600 women will be diagnosed with breast cancer 
and 5,300 will die because of this disease 3 . For the same year, 
approximately 150 men will be diagnosed with breast cancer and 45 will 
die because of the disease 3 . It is estimated that in 2005 an average of 
415 Canadian women will be diagnosed with breast cancer each week 
and 102 Canadian women will die each week because of breast cancer3 . 
Estimates for 2005 show that approximately 29% of breast cancers 
are diagnosed at 70 years of age or older, 50% between 50 and 69 years 
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and 21 % occur in women younger than 50 years of age 3 . Breast cancer 
at ages 20-49 is the most common cancer in women in this age group, 
with 4,520 new cases diagnosed of which 625 will die because of the 
disease (Figures 3 and 4)3. 
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Figure 3. Distribution of Breast Cancer by Age Group in Canada, 2005 
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Figure 4. Mortality of Breast Cancer by Age Group in Canada, 2005 
According to the World Health Organization, more than 1.2 million 
people will be diagnosed with breast cancer worldwide in 2005 6,7. For 
the same year, the American Cancer Society estimates that 
approximately 211,240 women in the United States will be diagnosed 
with breast cancer8 ,9. An estimated 40,410 women and 460 men will die 
from breast cancer in the United States in 2005 8 ,9. According to the 
American Cancer Society, the chance that breast cancer will be cause of 
death for a woman's is about 1 in 33 (3%)9. 
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1.1.3 CLiNICAL AND PATHOLOGICAL STAGING OF BREAST 
CANCER 
The purpose of cancer staging is to determine the anatomical 
extent of the disease and the tumor's likelihood for metastasis in order 
to make decisions about the most appropriate treatment. For adequate 
staging of the disease, physical (clinical) findings and pathological data 
from the excised cancer must be combined. 
The most common system used to describe the stages of cancers 
is the American Joint Committee on Cancer (AJCC) TNM system. This 
staging system classifies cancers based on both physical findings and 
the pathological assessment of the excised tumor and axillary Iymph 
nodes (Appendix 1-3) 10. The following classification scheme is used: 
a. T (0 - 4) describes the tumor size and spread to the skin or chest 
wall under the breast. Higher T numbers indicate a larger tumor 
and/or wider spread to tissues near the breast. 
b. N (0 - 3) indicates whether the cancer has spread to Iymph nodes 
near the breast and, if so, how many Iymph nodes are affected. The 
higher the number, the higher the level of Iymph nodes invaded. 
c. M (0 - 1) indicates whether the cancer has spread to distant organs 
or to Iymph nodes draining any organ in the body other than the 
breast. Distant organs could be the liver, brain, and bones among 
others. 
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According to the 2002 American Joint Committee on Cancer 
(AJCC) TNM System there are five possible stage classifications (0, l, Il, 
III, IV). Stage 0 tumors have the best prognosis and almost ail are 
curable. Stage 1 cancers are localized to the breast and are small in 
size. Stage Il is reserved for cases with regional Iymph node metastasis 
and has a worse prognosis than 1 and 0 but better than III and IV. Stage 
ilia denotes invasive breast cancer in which the tumor is larger than Scm 
or the tumor has spread to Iymph nodes, and the nodes are clumping or 
sticking to one another or surrounding tissue. Stage Illb describes 
invasive breast cancer in which a tumor of any size has spread to the 
breast skin, chest wall, or intramammary Iymph nodes. Stage IV cancers 
are generally non-treatable and involve distant metastases 10 (Appendix 
4). 
This study concentrates on early breast cancer because the ABBI is 
applicable only to tumors with a 2cm or smaller diameter. The TNM 
classification for early breast cancer is as follows: 
a. Stage 0 (Tis, NO, MO) refers to pre-invasive cancers (tu mors in situ) 
that have yet to penetrate the basement membrane of the ductile or 
lobule. There are no regional or distant metastases. 
b. Stage 1 (T1, NO, MO) refers to invasive tumors without metastases. 
c. Stage liA describes undetectable (TO, N 1, MO) or small tumors with 
regional metastases (T1, N1, MO) or larger primary tumors without 
metastases (T2, NO, MO). 
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1.1.3.1 Prognostic Factors for Breast Cancer 
Clinical characteristics that determine the prognosis of breast 
cancer are tumor size and location. The probability that breast cancer 
has metastasized is directly related to the size of the tumor. A 
metanalysis performed by Nemoto et al showed a strong association 
between increasing tumor size and probability ofaxillary node 
metastasis 11. After reviewing published literature of a total of 12,981 
patients, Nemoto reported that tumors of 0.1-1 Omm in diameter have a 
24.7-28.6% probability ofaxillary metastasis compared to tumors 11-
30mm where the probability of metastasis increases to 42.1 %. 
Furthermore, tumors with a diameter greater than 31 mm have more than 
50% probability of metastasis 11-13. 
The location of the primary tumor has prognostic importance for 
tumors without axillary Iymph node metastasis. While the risk for axillary 
Iymph node metastasis is considered greater for lateral versus medial 
breast cancers, there are data suggesting that patients with medial 
tumors have a worse prognosis than those with lateral tumors due to an 
increased risk of local recurrence 11-19. 
An additional prognostic factor is the presence and sensitivity of 
estrogen and progesterone receptors in the tumor. Absence of both 
estrogen and progesterone receptors has been associated with an 
increased risk for breast cancer recurrence due to resistance to anti-
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estrogen therapy. The status of hormone receptors is therefore useful in 
decision-making about hormonal anti-cancer therapy18.19. 
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1.1.4 DIAGNOSIS AND MANAGEMENT OF BREAST CANCER 
The diagnostic algorithms presented in Figures 5A-G are based on 
the Recommendations of the Canadian Steering Committee on Clinical 
Practice Guidelines for the Gare and treatment of Breast Gancer20 . 
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Figures 5A: Algorithm for the management of breast disease 
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a: excisional biopsy = complete excision of the 
tumor 
b: residual tumor = tumor remaining in the 
breast - incomplete 
excision 
c: follow-up = mammogram + clinical 
exam at 6 & 12 months. 
If normal, routine screening 
d: SPM = supplemental excision of 
breast tissue surrounding 
residual tumor 
Figures SC: Algorithm for the management of Category IV 
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Once an abnormality is detected on a screening mammogram it 
requires further investigation with clinical assessment and a higher 
sensitivity mammogram (diagnostic mammogram)(Fisure SB). Clinical 
evaluation should include a medical history and complete examination of 
the breast, both axillae and the supraclavicular areas (Figure 6). 
t Lateral axillary nodes 
2, 3. Pectoral nodes 
4. Svbscrapular nodes 
:;. Cen~r:aj axillary nodes 
6.lnmaviCillar nodes 
7.Pa~alnodes 
8. Svpradavlcutar oodes 
Figure 6: Lymphatic system serving the breast. Lamarque J-L, ed. 
Anatomy and embryology. In: An atlas and text of the breast: 
Clinical radiodiagnosis. London: Wolfe Medical Publications, 
1984: 17-2821 
The diagnostic mammogram should include a more detailed image 
of the abnormality with multiple views. If there is doubt or suspicion of 
malignancy additional imaging should be obtained with magnified views 
and spot compression of the area of interest (Figure SB). Magnification 
offers an enlarged and more detailed image of the abnormal features 
and spot compression applies local pressure to displace some of the 
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tissue surrounding the finding thus obscuring the view. This allows a 
better definition of detail and thus a better image of the lesion 20. 
As defined by Morrow and colleagues and adapted by the American 
College of Radiology the following classification is used to define the 
level of suspicion and further investigation recommended, on the basis 
of the diagnostic mammography20,22: 
Category Levelof suspicion Investigation 
recommended 
1 : Benign; no suspicion of cancer. None 
2: Low risk; probability of cancer <2% CBE + mammogram at 6 and 12 months 
Image guided Fine 
3 Intermediate risk; probability of cancer 2%-10% Needle Aspiration (FNA) 
or core biopsy 
4: High risk; probability of cancer> 10% Complete excision 
Table 1: American College of Radiology classification of mammographie 
findings 
According to the Canadian Clinical Practice Guidelines, patients 
with category 1 abnormalities do not require any further investigation 
and should be followed with routine screening (Figure 5B)20. Patients 
with Category 2 lesions should be followed-up with periodic clinical 
examination (Figure 5B). Follow-up examination of category 2 
abnormalities should be carried out at approximately 6 and 12 months. If 
the abnormality is stable, examination should be repeated annually for 2 
to 3 years thereafter. 
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Those with Category 3 mammographie findings, require only a 
sample of cells or tissue from the tumor obtained by incisional biopsy. If 
the tumor is not palpable, the biopsy should be guided by either 
ultrasonography or stereotaxis, to allow visu al localization of the lesion. 
Category 3 widespread calcifications or lesions that cannot be localized 
in the stereotactic views should be undergo a surgical biopsy (Figure 
SC) 20,23-27. 
Category 4 abnormalities should be completely excised (excisional 
biopsy) (Figure SC). If the lesion is not palpable it should be localized 
with the guidance of either ultrasonography or stereotactic imaging. 
Once localized, a wire is inserted as close to the lesion as possible and 
stabilized in place. During surgery, the surgeon localizes (finds) the 
lesion by following the wire into the breast. This combination of image 
guided localization and open excisional biopsy is referred to as "wire 
localization excisional biopsy" and is the conventional surgical technique 
used today for the excision of non-palpable mammographie 
abnormalities. 
When surgical biopsy is carried out for category 4 abnormalities 
the lesion must be completely removed with no remnants of tumor 
(residual tumor) neither in the breast nor in the surrounding margins of 
the excised specimen. The intact pathology specimen should be 
examined radiographically to confirm that ail abnormalities observed in 
the mammogram have been removed 29 -36 . 
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ln addition to Category 4 mammographic lesions, other indications 
for wire localization excisional biopsy are: a) disagreement between the 
assessment of the mamographic finding and the results of the incisional 
biopsy; b) noticeable change in the mammographic findings over time; c) 
the incisional biopsy demonstrates atypical hyperplasia. This is 
associated with over 50% risk of multiple malignancies coexisting, 
known as multicentricity 14, 15. 
The following factors may be obstacles in the success of 
conservative surgery for breast cancer treatment39-68 , 72,77,78,80. Larger 
tumors are more difficult to remove with enough surrounding healthy 
breast tissue without removing a large portion of the breast91 -99 . The 
presence of an intraductal component is often associated with widely 
spread malignant microcalcifications through a very large area of the 
breast. Because they are so widespread, it is very difficult to achieve 
complete excision of these microcalcifications with conservative 
surgery91-99,104. Surgical scars and cicatricial tissue in the breast do not 
allow the lesion to be visualized clearly. Consequently, it cannot be 
local ized accurately and excised adequately 102-104. The you nger the 
patient the higher the density of the breast tissue. The accuracy of 
detection of mammographic findings decreases as breast density 
increases 104. 
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1.1.5 WIRE LOCALIZATION EXCISIONAL BIOPSV 
The following sections describe the wire localization technique, 
its advantages, and limitations. 
Non-palpable breast tumors present a challenge because these 
tumors cannot be localized with physical examination. Therefore, 
preoperative mammogram followed by wire localization is required for 
the surgeon to find the lesion and perform the biopsy. Before surgery, 
the lesion is localized under mammographie, ultrasonographic, or 
stereotactic guidance and a wire is inserted as close to the lesion as 
possible and stabilized in place to prevent the wire from moving away 
from the lesion. This wire acts as a guide for the surgeon to find the 
les ion in the breast or the area of the breast with the lesion and to 
excise it. 
The size of breast tissue removed by wire localization excisional 
biopsy is affected by two opposing requirements. On the one hand the 
surgeon aims to achieve adequate local control of the disease by 
removing the tumor within wide enough healthy breast tissue and 
microscopically clear margins while on the other hand trying to remove 
the least possible breast tissue in order to avoid disfiguring of the 
breast. The main determining factors of the amount of tissue removed 
are the proximity of the tip of the wire to the target lesion and the size of 
the lesion to be excised 36 ,37. The success rates reported in the literature 
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in placing the tip of the wire-guide within 10 mm from the lesion is 
between 80% and 96%36-41. 
ln centers where this approach has been employed as a definitive 
therapeutic procedure to remove the tumor, 40-59% of patients require 
further supplementary surgery after the biopsy36,46,47. Based on these 
results, the therapeutic role of wire-guided biopsy remains 
controversiaI 47 ,48. 
1.1.6 MARGINS, RESIDUAL DISEASE AND LOCAL RECURRENCE 
Current advances in surgical assessment and treatment of breast 
cancer are aimed at maximizing conservation of breast tissue. The most 
important parameter that indicates whether or not a tumor has been 
completely excised, with conservative surgery, is the clarity of the 
surgical margins. Surgical margin refers to the width of healthy breast 
tissue surrounding the tumor within the excised specimen. It is 
measured as the shortest distance between the outer edge of the tumor 
and the external border of the excised specimen (E) as shown 
schematically in figure 7 below. 
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A = malignant tumor 
B = healthy breast tissue 
C =external border of excised 
specimen 
D =involved margin 
E =clear margin 
Figure 7: Schematic of specimen with negative (clear) margins and 
positive (involved) margins. 
The term "clear margins" means that the tumor has been removed 
with enough healthy tissue around it to consider that the excision is 
complete and the entire tumor has been removed (Figure 7). Contrary, 
the term "involved margins" means that the tumor touches the external 
border of the excised specimen or that the healthy breast tissue 
surrounding the tumor is not wide enough for the excision to be 
accepted as complete (Figure 7). In other words, when a tumor is 
excised within involved margins there is reason to believe that part of 
the tumor has remained in the breast after the biopsy. 
Data in the literature show that approximately 50% of excisional 
biopsies, with a range between 20% and 70%, have involved margins 
and residual malignancy in the surgical margin or within 1 mm from the 
outer border of the excised specimen 49-52. It has been shown that 
surgical margins of tumorectomies that are infiltrated by malignant cells 
or equivocal (either because of a faulty specimen or because of lesion 
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fragmentation) are associated with approximately 48% (ranging from 29-
65%) probability of residual disease in the breast at the area of the 
excised tumor47 ,53-58. 
The tendency of breast cancer to spread subclinically into the 
surrounding breast parenchyma make it difficult to assess histological 
margins50 ,51. This may explain why 30% of those biopsy excisions with 
clear margins subsequently had residual tumor upon re-excision while 
48% of patients diagnosed with involved margins had no residual 
tumor41 . 
The most common reason for a false-negative assessment of 
surgical margins is an incomplete examination of the outer surface of the 
specimen. To prepare a specimen 2 cm in diameter for histological 
analysis, it is sliced by the microtome to approximately 3,000 sections 
which are dyed and processed on slides for microscopie assessment. 
The larger the specimen the higher the number of si ides prepared. 
Therefore, in order to analyse a complete 2cm specimen, the pathologist 
needs to examine more than 3,000 slides. Due to limitations in time and 
budget, this is unfeasible so pathologists resort to a random examination 
of as many sections as possible 50 . As a result, the assessment is 
incomplete. Since the diagnostic accuracy of the surgical margins is 
directly related to the number of sections assessed an incomplete 
assessment has an increased probability of a taise negative analysis of 
clear margins 50 . 
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The controversy on the width of surrounding healthy tissue 
required for the surgical margins to be considered as "clear" is still 
ongoing and differs depending on the type of tumor. For invasive ductal 
carcinomas the minimum margin width considered as safe varies 
between 1 mm and 2 mm 40-47 ,53-90. Intraductal carcinomas otherwise 
referred to as non-invasive or carcinoma in-situ, are the least aggressive 
cancers that are usually widespread but rarely metastasize outside of 
the breast. However, due to the multifocality of intraductal carcinomas, 
the controversy is more complicated. Until recently, a clear margin was 
considered as that with a width of at least 1 mm 53 -68 ,91-99,151. In 1999, 
Silverstein retrospectively evaluated the impact of radiotherapy in 
relation to the width of surgical margins on 469 patients, treated at the 
Van Nuys Breast Center, who had been submitted to breast conservation 
surgery for intraductal carcinoma. The results of this study indicated that 
postoperative radiation therapy did not reduce the risk of local 
recurrence for patients with surgical margins of 10mm or more. However, 
for patients with margins less than 1 mm wide, radiotherapy significantly 
reduced the risk for local recurrence. For the patients with margins 
greater than 1 mm and less than 10mm, the risk was not significantly 
reduced by submitting the patients to postoperative radiation therapy 53. 
ln 2003, further evaluation of the same patients as weil as additional 
patients with DCIS treated at the Van Nuys Breast Center and at the 
USC/Norris Comprehensive Cancer Center produced similar results as in 
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1999 for margins 10mm or greater and less than 1 mm 54 . Contrary, the 
results changed for patients with intermediate margins (1 mm to less than 
10mm) showing a statistically significant decrease of risk for local 
recurrence after postoperative radiotherapy54. 
Due to the strong association between the clarity of reported 
surgical margins with the incidence of local recurrence rate over 3 to 5 
years postoperatively, it is considered mandatory to assess the margins 
of the excised tumor and breast tissue (specimen) immediately after 
excision 69-so. This is done by cutting a piece of the specimen, deep 
freezing it and marki ng the edges with a specifie dye (referred to as 
frozen sections). However, the usefulness of frozen sections has been 
limited by the relatively high proportion of false negativess1 ,s4. The use of 
frozen sections has been discouraged for small «10mm) and 
nonpalpable breast lesions because of the fear that manipulation of the 
specimen may render the tumor undetectable or permanent sections 
from the frozen piece (frozen block) may be suboptimal or even useless 
for definitive diagnosis7o,s3,s4. Thus, no optimal method for assessing the 
microscopie margins of a breast tumor specimen has been established. 
1.1.6.1 Post-biopsy residual malignancy 
Residual malignancy is defined as remnants of malignancy in the 
area of the breast from where a malignant tumor has been removed. The 
presence of residual malignancy after breast conserving therapy is 
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responsible for the majority of early recurrences close to the primary 
site39-4153,54, 72-99. 
As mentioned above, the size of the tumor, intraductal carcinoma, 
scar tissue and breast density present a challenge for the success of 
conservative breast surgery. In addition, the presence of residual 
microcalcifications on post-biopsy mammograms, the pathologic status 
ofaxillary Iymph nodes and preoperative chemotherapy have also been 
shown to be directly associated with the risk of residual 
mal ig nancy40,42,58,68, 70, 100-108. 
Evidence has shown a strong association between tumor pathology 
and residual cancer. The probability that a tumor will be excised with 
involved margins is 82% for patients with intraductal carcinoma, 75% for 
those with invasive lobular carcinoma (highly multifocal) and 50% for 
patients with invasive ductal carcinoma (one lesion)39-41,52,53,76-78,91-
103,151 
1.1.7 RATIONALE FOR THE NEED OF ALTERNATIVE SURGERY 
OPTIONS 
Wire localization excisional biopsy is currently the surgical 
technique of choice for non-palpable breast lesions detected only with 
mammography. The advantages of wire localization excisional biopsy 
are primarily the excision of an adequate specimen for an accu rate 
- 44-
histopathological diagnosis, the minimal post-operative complications, 
the removal of less breast tissue than partial mastectomy, and the 
shorter hospitalization of the patient41 -44 . 
However, wire localization excisional biopsy has certain 
disadvantages. First, it is a multiple step process. The patient begins the 
process in radiology, where the wire-guide is inserted in the breast 
under mammographie guidance. The patient is then taken to the 
operating room for the biopsy, which may be done under local or general 
anaesthesia, depending on the preference of the surgeon 105 . The lesion 
is then localized, and the specimen is excised containing the wire guide 
and the part of breast tissue surrounding it. 
The excised specimen is taken to radiology where it is X-rayed and 
evaluated for the following three criteria; a) to determine if the specimen 
contains the target lesion, b) if the whole lesion is excised and c) if the 
margins of the specimen are clear. If ail three criteria are satisfied the 
biopsy is considered complete. If one or more of the above criteria is not 
satisfied the surgeon excises more breast tissue around the borders of 
the surgical cavity (opening) and removes a second specimen which is 
also send to radiology. The process is repeated until the complete 
excision with ail the specimens included satisfies the three criteria listed 
above (a-c). This results in a longer duration of surgery, and 
anaesthesia, especially if general anaesthesia is used, and multiple 
fragmented specimens which make the final pathological assessment of 
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margin clarity very difficult27 -34 ,81,84,100-124. Evidence shows that in as 
much as 20-25% of the cases the lesion is not found in the initial 
specimen and that the macroscopic margins are involved in 59.4%, 
ranging from 47% to 92%35-40,52-99,116-124. 
Considering the importance of radiologic imaging for the success 
of wire localization excisional biopsy it is important to note that the 
accuracy of imaging in predicting the status of the specimen's margins 
or the presence of residual tumor has been shown to be limited 31 -40 . In 
40-59% of the cases, specimens considered to have clear margins by 
imaging, were shown to have involved margins after the specimen was 
examined by pathologl3,31-40. This is important because the reported 
rates of residual cancer at re-excision after positive surgical margins 
vary significantly between studies from 22_64%23.32.36.86.116-124. 
Given these problems with localization and excision accuracy with 
wire localization excisional biopsy, more accu rate techniques that would 
improve the intraoperative localization of the tumor and the verification 
of its removal within the excised specimen have been sought. In the late 
1990s, the ABBI, a breast biopsy system was developed which combines 
stereotactic imaging (3-dimensional localization of the lesion under 
digital mammography guidance) along with a large 2cm coring device 
used to excise the tumor. 
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1.2 ABBI EQUIPMENT DESCRIPTION 
The Advanced Breast Biopsy Instrumentation (ABBI) system 
involves the stereotactic localization and the excision of a core shaped 
breast tissue specimen 20cm in diameter in one step, under local 
anaesthesia. A surgeon performs the ABBI procedure with the 
assistance of a radiology technician in the day-surgery outpatient clinic, 
whereas wire localization excisional biopsy, is done in the operating 
room and requires hospitalization of the patient. 
The ABBI has four parts. First, there is a custom designed table 
for the patient to lie on. The second part is a computer, equipped with 
customized software for stereotactic localization. The computer is 
connected to the table which has a built-in digital mammogram x-ray 
machine (the third part) and then ail of this is connected to a small 
surgical coring device (the fourth component), which actually performs 
the biopsy. The detailed description of the ABBI components is in 
Appendix 5. 
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2 REVIEW OF THE LITERATURE 
A search of the medical literature for publications on the 
evaluation of the ABBI identified 313 studies of which 282 were 
excluded. Of these, 179 were excluded because they were individual 
case reports, studies with less than 10 patients enrolled or not focusing 
on the ABBI system in the management of non-palpable mammographie 
findings. Another 77 were narrative reviews, 21 were expert opinions, 
and 5 were repeated publications. There were 26 remaining clinical 
studies used in the literature review. These are discussed in the 
following section and are listed in appendix 6A 125-150. 
2.1 SAFETY 
Adverse events were reported in only 14 of the 26 reviewed 
studies 125 ,126,128,131,134-137,139,140,142,144,148-150. The overall incidence of 
the adverse events reported in these 14 studies is low (2.5%) and not 
clinically significant. On the other hand, there was no predefined 
categorization of adverse events, hence, the definition of adverse events 
between the studies varied. Given the above, a detailed quantification of 
the adverse events reported in the literature and a credible synthesis of 
the safety data of the ABBI procedure is difficult. 
A total of 165 (5.6%) adverse events and complications were 
reported among the 2949 total patients enrolled in ail 14 studies 
reporting adverse events (Appendix 6B,6C). Among these, technical 
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failure or mechanical malfunction was reported in 81 cases 
(2.8%) 126,130,136,139,146. Technical prablems included poor calibration, 
cautery / snare failure, T-bar failure, computer malfunction, lesion 
displacement. The most frequent treatment related adverse event in the 
reviewed studies was haematomas, reported in 47 cases or 1.6% of the 
total ABBls p e rf 0 r me d 1 25,1 26, 1 28,1 30, 1 33 -1 36,1 38, 1 39,1 41 . Followed by 
vasovagal reactions 130,133,139 and wound infections, reported in 8 and 7 
cases respectively 133,135,139,141. 
2.2 EFFECTIVENESS 
2.2.1 MICROSCOPIC SURGICAL MARGINS CLEAR OF MALIGNANCY 
A total of 940 ABBI biopsies were performed in the 16 studies that 
reported the margin status of the excised specimens 
125,126,136,138,141,143,145,148-150 Of these, 328 (35%) tumors were excised 
within clear healthy margins (Appendix 6D). The proportion of involved 
microscopie margins was 65% ranging from 57-95% of the malignant 
tumors. Amongst the 940 biopsies performed, 210 (22%) tumors were 
diagnosed as malignant. 
2.2.2 DURATION OF PROCEDURE 
There were 20 studies that reported duration of procedure 126,128-
141,143,145-149. The mean duration of the ABBI was approximately 35 
minutes, varying fram 20 to 80 minutes. In the majority if these studies it 
- 49-
was not clear whether the time taken to complete the procedure included 
only the time required for the actual excision of the specimen or the 
preparatory stage as weil, including the time required for initial 
localization of the lesion, haemostasis, suturing and wound dressing. 
2.2.3 UNSUCCESSFUL EXCISION 
Two authors Smathers and Bloomston reported 2 cases in 100 
(2%) and 1 of 55 (1.8%) respectively of unsuccessful excisions where 
the lesion was not found in the excised specimen but remained in the 
breast 126 ,145. 
2.2.4 SUPPLEMENTARV SURGERV REQUIRED 
The type of supplementary surgery required after an ABBI 
procedure is either a lumpectomy or a modified radical mastectomy. Of 
the 663 patients enrolled in the 8 studies reporting supplemental 
surgery, 117 (18%) were submitted to either lumpectomy or modified 
radical mastectomy. The frequency of subsequent surgery ranged from 
8% to 42%, with lumpectomy being the supplementary surgery in most 
cases (Appendix 6E)125,126,128,131,136,138,139,141. 
2.3 PERFORMANCE VOLUME ASSOCIATION 
None of the studies explored a possible association between the 
effectiveness of the ABBI and the characteristics of the surgeon. 
- 50-
2.4 PATIENT SATISFACTION 
Four of the 26 studies reported patient satisfaction 125,134,135,139. 
The assessment tools and outcomes varied. La Raja et al i nterviewed 
patients by telephone 24 to 48 hours after the ABBI and reported 
excellent satisfaction in general without any specifie data 135 . Perelman 
et al reported local pain and discomfort during the procedure in 4 (12%) 
of the patients 139. Atallah et al reported in general that women tolerated 
the procedure we11 125 . Kelley et al reported only on prescription 
analgesics used post-operatively134. They stated that 2.4% of their 
patients used prescribed pain medication. Overall, ail 4 authors reported 
that patients were satisfied with the ABBI but detailed information has 
not been presented. 
2.5 ECONOMie EVALUATION 
None of the published studies included a cost-effectiveness 
evaluation of the ABBI. Matthews et al reported an average hospital 
patient charge for an ABBI of $2,377 versus $3,028 for wire localization 
excisional biopsy (P <0.05), an average saving of $650 per patient138 . 
LaRaja et al reported an average savings with the ABBI as compared to 
wire localization excisional biopsy of $1,000 per patient135 . Most of the 
savings are shown to be the result of the ABBI procedure being 
performed as an outpatient procedure with the use of local anaesthesia, 
thereby eliminating the fee for preoperative testing, anaesthesia, 
- 51 -
operating room, and recovery room. Most studies reported direct costs 
of the ABBI compared with other procedures without taking into 
consideration the cost of the patient's complete surgical management 
including supplementary surgery. 
2.6 COMPARATIVE STUDIES 
Among the 26 studies reviewed 3 presented a comparison between 
the ABBI and wire localization excisional biopsy. One study reported 
only clinical results, two compared clinical results and patient 
satisfaction and one reported only patient satisfaction (Appendix 6F-
6G)127,129,146. D'Angelo et al compared 23 patients treated with an ABBI 
and 23 patients operated by wire localization excisional biopsy 129. Equal 
numbers of breast cancers were excised by both techniques, ail of which 
were excised with involved margins. Even though the quantity of blood 
loss reported was less for the ABBI the statistical significance of this 
d ifference was not reported. Detection of resid ual cancer was reported 
in more ABBI cases than in wire localization excisional biopsies but 
again the statistical significance of this difference is not 
mentioned 127, 129, 146. 
Velanowich compared 104 ABBls to 520 wire localization 
excisional biopsys and 245 core needle biopsies 146. Technically 
successful biopsy was defined as a case for which the radiologist or 
surgeon performing the procedure was satisfied that enough tissue had 
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been removed to produce a pathologie diagnosis. There was no 
significant difference between the three techniques in technical success 
rate. Significantly more malignant tumors were excised with wire 
localization excisional biopsy (35%) versus ABBI (14%) and core needle 
biopsy (20%) (p<0.01). The effectiveness of the ABBI to excise the 
breast lesion was 100% while the effectiveness of the core needle 
biopsy was (87.5%). Respective values for wire localization excisional 
biopsy were not reported. The subgroup of patients, for which repeat 
biopsy was required, included cases of technical failure occurring and 
conflicting mammographie 1 pathologie interpretations. The authors 
report that ail the ABBI reexcisions resulted from technical failure in the 
first 30 cases. No technical failure occurred in the remaining 74 cases. 
Technical failure accounted for 25 of the reexcisions in the patients 
undergoing wire localization excisional biopsy 146. 
ln patients with malignant lesions, 63.6% of ABBI biopsies had 
positive margins, of which 71.4% had residual carcinoma on reexcision 
or mastectomy. In comparison, of the malignant lesions diagnosed with 
wire localization excisional biopsy, 50.9% had positive margins, of these 
70.4% had residual carcinoma in the definitive lumpectomy or 
mastectomy specimen. Even though the statistical significance level of 
this difference is not reported, it is mentioned to be not statistically 
significant (Appendix 6F). With regards to safety, the author reported 30 
cases of technical failure with the ABBI, ail of which occurred in the first 30 
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cases, but did not report any safety data on the wire localization excisional 
biopsy cases. D'Angelo reported no complications in any of the 23 cases 
evaluated 129 . 
D'Angelo et al reported that patient acceptance of the ABBI was 
high, with 21 (91.3%) of the 23 patients evaluated reporting subjective 
assessment of comfort as excellent, 2 as good and 1 as poor. For 
patients operated by wire localization excisional biopsy, patient 
satisfaction has been reported in general as high, without any further 
information. For the ABBI, cosmetic results were 'excellent', according 
to a subjective assessment by both the patient and the surgeon. In 
comparison, cosmetic results after wire localization excisional biopsy 
were rated as acceptable by both the patient and the surgeon 129 
(Appendix 6G)129. 
Chun performed a retrospective telephone interview, two years 
post-operatively, comparing the cosmetic results and satisfaction of 20 
patients treated with the ABBI and 20 treated with wire-Iocalization 127. In 
this study 95% of ABBI patients reported excellent satisfaction with the 
cosmetic results of the technique and 75% reported excellent overall 
satisfaction; 25% were dissatisfied. Among the wire localization 
excisional biopsy patients, 25% reported excellent cosmetic satisfaction 
and 55% evaluated the results as acceptable cosmetically. However, 
more (90%) wire localization excisional biopsy patients reported 
excellent overall satisfaction with the technique as compared to 75% for 
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the ABBI. The statistical significance of these differences was not 
reported. The Velanovich study did not report patient satisfaction or 
cosmetic results 127. 
2.7 CONCLUSIONS OF THE LlTERATURE REVIEW 
A total of 26 studies were reviewed of which 15 were observational 
non-randomized tri al s 125 ,126 ,128-130 ,133-137 ,139 ,141-143 ,148-150 and the 
remaining 9 were retrospective reviews of patient 
ch arts 127,131,132,138,140,144-147. 
The most frequently reported adverse event was haematoma, with 
a frequency of 1.6%, vasovagal reactions (0.3%) and wound infections 
(0.2%). The adverse events associated with the ABBI were more often 
the result of equipment failure. 
ln order to evaluate effectiveness, researchers have compared the 
ABBI with wire localization excisional biopsy and core needle biopsy. 
When comparing the ABBI with core needle biopsy, diagnostic 
effectiveness was similar. On the other hand, technical problems are 
more frequent with the ABBI versus core needle biopsies. 
Compared to wire localization excisional biopsy, duration of 
procedure and mean blood loss were lower for the ABBI. The frequency 
of reported supplementary surgery is lower among the ABBI cases than 
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wire localization excisional biopsy. No significant differences were found 
between the two techniques for clarity of surgical margin. 
Patient satisfaction with the ABB 1 was generally reported to be 
from good to excellent. In conclusion, the results from these studies 
have suggested that the ABBI may cost less than wire localization 
excisional biopsy but be associated with higher risk of surgical 
complications. Similar successful excisions of tumors with clear margins 
have been reported for the ABBI and wire localization excisional biopsy. 
Therefore, more studies are needed to determine whether the ABBI 
should be used as a diagnostic and therapeutic procedure for breast 
cancer. The performance volume association for the ABBI has not been 
evaluated. This is important for the decision to implement the ABBI. 
Economic evaluation has been conducted for the ABBI but not within the 
Canadian Healthcare System. The current study addresses these needs. 
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3 PURPOSE, MATERIALS AND METHODS 
3.1 RATIONALE AND PURPOSE 
3.1.1 RATIONALE 
For any new surgical technique to be implemented in routine 
clinical practice it must be proven to be superior to or more cost 
effective than other techniques indicated for the management of the 
same condition. Ideally, the technique under investigation should 
combine both clinical superiority and higher co st effectiveness over the 
traditional technology used. 
Mammographically guided wire localization combined with open 
excisional biopsy has been the standard evaluation of non-palpable 
mammographie lesions. The investigation and management of non-
palpable mammographie findings requires the complete surgical excision 
of the lesion within safe surgical margins (at least 1 mm of peripheral 
healthy tissue). Traditionally, this is performed by mammographically 
guided wire-Iocalization combined with open excisional biopsy under 
either local or general anaesthesia. The probability of invaded margins 
after a wire localization excisional biopsy ranges from 29.5% to 79% 
with a mean of 59.4% 36-40,55,65-67. Depending on the protocol followed at 
the institution where the surgery is performed and the experience of both 
the surgeon and the radiologist involved in the procedure, 40-59% of 
patients req uire post-biopsy supplementary surgery27, 28,34. 
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The type of anaesthesia used during the excisional biopsy of the 
wire-Iocalized lesion is either general or local. Data in the literature 
suggest that the type of anaesthesia does not affect the accuracy of 
tumor localization but local anaesthesia has a negative impact on the 
ability of the surgeon to achieve clear surgical margins 27-34,81,84,lOO-124. This 
is more prominent for lesions located deeper that 3cm in the breast, for 
lesions located by a needle travelling for longer than 3 cm in the breast, 
or for microcalcifications because they are more difficult to localize86 . 
On the average, 66% of ail wire guided open excisional biopsies in North 
America are performed with general anesthesia 86 . 
It is estimated that 40-59% of ail patients submitted to wire 
localization excisional biopsy will require a supplemental partial 
mastectomy and approximately 26-40% of these are operated under 
general anaesthesia 27-34,81,84,lOO-124. Therefore, the probability that a patient 
who underwent wire localization excisional biopsy excisional biopsy will 
be submitted to general anaesthesia twice within a very short time 
period of 2-4 weeks is 10-24%. 
A significant disadvantage of wire localization excisional biopsy is 
that it involves a three-step process. First, the patient must be taken to 
radiology for the lesion to be localized and the wire inserted, second, to 
the operating room for the biopsy and third, to the recovery room, where 
the patient will remain until discharge which may be from 24-72 hours 
after surgery. 
- 58-
The ABBI combines stereotactic imaging (3-dimensional 
localization of the lesion under digital mammography guidance) along 
with a 2cm. coring device. The ABBI allows the stereotactic localization 
and the excision of the whole tumor in one step, under local anaesthesia 
and in the day-surgery outpatient clinic. 
Given the limitations of the currently used methods, a new 
technique that may be more effective, safe, and cost-effective would be 
useful. The ABBI has been developed to address this need. The current 
study evaluated the ABBI as a diagnostic and therapeutic intervention 
for the management of breast disease. 
3.1.2 STUDY OBJECTIVES 
The objectives of the study are: 
1. To evaluate the diagnostic effectiveness of the ABBI system for the 
management of breast disease; 
2. To evaluate the therapeutic effectiveness of the ABBI system for the 
surgical management of breast cancer; 
3. To evaluate the safety of the ABBI system as a surgical technique for 
the management of breast lesions; 
4. To describe patient satisfaction with the ABBI; 
5. To evaluate the volume performance of the ABBI; 
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6. To describe the cost evaluation of the ABBI. 
3.2 STUDY DESIGN 
The study was initiated in the Montreal General Hospital in 
September 1997 and enrolled patients both retrospectively and 
prospectively. The data of patients that underwent an ABBI between 
October 1995 and September 1997 were abstracted retrospectively from 
patient charts in the Montreal General Hospital Archives and the 
Montreal General Hospital Breast Clinic. From September 1997 until 
December 2001 patients operated on with the ABBI were enrolled 
prospectively. Between September 1997 and July 1999 the patients 
enrolled in the study were operated only in the Montreal General 
Hospital and from July 1999 to December 2001 patients were also 
recruited and operated at the Sacré Cœur Hospital of Montreal. 
3.2.1 PATIENTS: 
Ali women referred to the Breast Clinics of the Montreal General 
Hospital, the Sacré Cœur Hospital of Montreal or St. Mary's Hospital for 
further evaluation of a non-palpable mammographie finding were eligible 
to participate in the study. 
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3.2.1.1 Recruitment Procedures: 
Doctors from these three breast clinics recruited patients and 
referred them to the Montreal General Hospital or the Sacré Coeur 
Hospital of Montreal where the ABBI was performed by one of three 
surgeons that performed the ABBI. The first and second surgeons 
operated on ail their patients in the Montreal General Hospital and the 
third operated in the Montreal General Hospital from September 1997 to 
July 1999 and the Sacré Coeur Hospital from July 1999 to Deeember 
2001. 
Ali potentially eligible patients underwent physieal examination and 
their mammograms were reviewed by the treating or referring surgeon. 
Those with non-palpable mammographie findings requiring further 
surgieal investigation were given the ehoiee, by the treating surgeon, 
between two different surgical techniques, the wire localization 
excisional biopsy or the ABBI. The surgeon described both techniques to 
the patient and explained the advantages and disadvantages of each. 
Patients selected the technique on their own. Patients selecting the 
ABBI were included in the study. 
3.2.1.2 Inclusion Criteria: 
Patients who chose the ABBI and fulfilled ail of the following 
inclusion criteria were enrolled in the study: 
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1. Non-palpable mammographie finding with a maximum diameter 
less than 2cm. 
2. Mammographie finding of a lesion requiring excisional biopsy and 
appropriate for the ABB 1. 
3. Distance of at least 15 mm between the tumor and the chest wall. 
4. Able to lie prone for the duration of the procedure. 
5. No medical history of severe cardiac or pulmonary disease. 
6. Not pregnant. 
7. Understand and sign an informed consent form agreeing to 
undergo the procedure. 
3.2.1.2.1 Explanation of Inclusion Criteria 
1. Non-palpable mammographie finding with a maximum diameter less than 
2em. 
The size of the tumor was recorded as the length of the longest 
diameter. According to clinical guidelines, tumors eligible for an 
excisional biopsy with the ABBI system should not be larger than 2cm in 
diameter, as measured by digital mammography. This restriction is 
placed because of two reasons: 
a. Lesions larger than 2cm in diameter are usually large enough to 
palpate so there is no need for image-guided localization; 
therefore, the lesion does not qualify for an ABBI. 
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b. At the time of the study the larger coring device available for the 
ABBI had a diameter of 2cm. Any tumor larger than 2 cm would 
exceed the coring device and would not be excised completely. 
There is one exception to this rule. Microcalcifications that were 
widespread through the breast, consuming an area larger than 2 
cm. In this case, the ABBI was performed solely for diagnostic 
purposes. 
The distinguishing feature of the shape and distribution of 
microcalcifications that would raise a suspicion of a possible 
malignancy is that of dense groups together or clusters. Any 
specific area in the affected breast where the calcifications are 
more densely grouped together or actually form clusters was 
chosen as the most representative of the pathology of the /esion 
and was thus chosen as the target to be excised by the ABB/. 
Types of mammographie findings eligible for an ABBI biopsy are, i) 
a soft tissue nodule or mass, defined as any group of cells clustered 
together more densely than the surrounding tissue; ii) 
microcalcifications, characterized by minute calcium deposits «0.5 mm 
in diameter) in the breast and iii) a combination of both soft tissue 
nodule and microcalcifications. Microcalcifications are indications of 
early breast cancer. In 95% of ail DelS and 75% of occult cancer they 
occur alone, as the only mammographie abnormality91-99. 
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2. Distance of at least 15mm between the tumor and the chest wall 
One of the most important criteria for eligibility for an ABBI biopsy, 
is the thickness (width) of the breast under tight compression. This is 
directly proportional to the size of the breast. Figure 8 is a graphie 
description of the breast compressed between the two ABBI compression 
plates which are the X-Ray receptor and the surgical window panel. 
b 
Breast 
Lesion 
X-Ray receptor 
FIGURE 8: Graphie description of breast compression 
b = 12mm thick, c = a + b 
Eligible if: c - d > 15mm or if p + b > 15mm 
Where: 
• a = breast thickness 
• b = surgical panel thickness 
• c = breast compression as measured 
• d = depth of the target lesion 
• p = posterior margin or distance between the target and the opposite side of the 
breast which corresponds, in this case, to the X-Ray receptor inner surface. 
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Breast compression is measured as the distance between the outer 
surface of the surgical window panel (b) and the X-Ray receptor. As 
shown in figure 8, the thickness of the surgical panel, is 12 mm. Hence, 
the actual thickness of the breast (a) is the breast compression (c) -
12mm. In order to ensure an adequate excision with a safe poste ri or 
margin, so that the surgical cannula will not cross through to the 
opposite side of the breast, the thickness of the breast under 
compression should exceed the depth of the target by at least 15 mm or 
the posterior margin (p) plus the surgical window panel totals at least 
15mm. 
3. The patient should be able to lie prone for the duration of the procedure 
The average duration is estimated to be between 50 and 60 
minutes for less experienced surgeons and approximately 15-30 minutes 
for more experienced surgeons. The patient should be able to lie prone 
for the appropriate amount of time. It is obligatory to remain motionless 
throughout the procedure so as to prevent the target from moving. This 
makes it even more difficult for patients with cardiac or pulmonary 
disease. The slightest movement of the breast could result in 
spontaneous movement of the target and thus the initial dimensions 
measured would be non-applicable and the localization would need to be 
repeated. 
4. No medical history of severe cardiac or pulmonary disease 
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A patient suffering from severe cardiac or pulmonary disease may 
not be able to remain in the prone position for the duration of the 
procedure. 
5. The patient should not be pregnant 
The ABBI operating table is not designed for pregnant patients. 
This makes it difficult for pregnant women to lie prone on the table, for 
the duration of the procedure. 
6. The patient should understand and sign an informed consent form 
agreeing to undergo the procedure. 
A bilingual informed consent form was given to the patient prior to 
surgery and after the description of the procedure and demonstration of 
the equipment. For ethical reasons, it was obligatory for the patients to 
understand and sign the consent form in order to be enrolled in the 
study Appendix 7. 
3.2.1.3 Exclusion Criteria: 
Patients with one or more of the followi ng criteria were not 
eligible to participate in the study: 
1. The lesion could not be visualized by digital mammography 
2. Palpable les ion with a diameter greater than 2 cm. 
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3. Inability of the patient to understand the description of the 
technique and sign the operative consent form. 
3.2.1.3.1 Explanation of Exclusion Criteria 
1 Inability to visualize the lesion with digital mammography 
If the lesion detected in the breast is either at the extreme superior 
part of the upper quadrant or extreme posterior part of the breast near 
the chest wall, it cannot be positioned within the boundaries of the 10 X 
10 cm operating window for the image to be taken. This makes it 
impossible for the lesion to be visualized by the digital mammography. 
2 Palpable lesion or lesion with a diameter greater than 
2 cm 
Lesions that are 2 centimetres or more in diameter are usually 
palpable and can be detected by self-examination or a physical 
examination. A palpable tumor of this size is manually localized and 
easily removed without the need for guidance by imaging technology. 
3 Incapacity of the patient to comprehend the description of the 
technique and sign the operative consent form 
Every effort was made to communicate to the patient the 
advantages and disadvantages of the ABBI and to describe and 
demonstrate the technique and the equipment to the patients or the 
accompanying person if the patient was not capable of understanding or 
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communicating in English or French. If the patient still could not 
communicate, the procedure could not take place for two reasons. The 
equipment used and the environment the ABBI is performed in are not 
the traditional operating room that the patient may recognize. This will 
create an additional discomfort and anxiety for the patient. This 
discomfort will be increased by the fact that the procedure is performed 
under local anaesthesia and requires the patient to remain motionless 
and to express only verbally the occurrence of discomfort or pain. The 
inability of the patient to communicate her feelings will normally result in 
nervous movement. Any movement of the patient may easily move the 
breast and the target lesion from the precalculated coordinates. This will 
result either in missing the lesion during the excision or to the necessity 
to repeat the entire procedure. Furthermore, complete understanding of 
the procedure and the study are essential for informed consent. These 
patients were excluded for practical and ethical reasons. 
3.3 DATA SOURCES, STORING AND ANALYSIS: 
Data were abstracted and entered by the candidate (Fotini 
Sampalis) and stored in Excel™ spreadsheets. Data analysis was 
performed with SPSS 11.0 for Windows. From October 1995 until 
September 1997 data were abstracted from patient charts 
retrospectively. Charts were reviewed either at the Montreal General 
Hospital Archives or the Montreal General Hospital Breast Clinic. From 
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September 1997 until July 1999 at the Montreal General Hospital and 
from July 1999 to December 2001 at the Sacré Coeur Hospital, patient 
demographics were recorded immediately prior to surgery and surgical 
data were recorded directly after the procedure. Information on 
histological analysis, adjuvant therapy recommendations, details on 
adjuvant therapy performed and patient follow-up was abstracted from 
the patient charts in the respective clinics. Between July 1999 and 
December 2001 data of patients operated at the Montreal General 
Hospital were abstracted from patient charts at the Montreal General 
Hospital Archives or the Montreal General Hospital Breast Clinic. 
3.4 THE VARIABLES OF THE STUDY 
The variables used in this study and the source of the data are 
described in the following section. These variables are described in the 
study "Case Report Form" included in Appendix 8. 
3.4.1 PATIENT'S CHART: 
The data abstracted fram the patient's chart were the patient 
demographic information, past medical history, mammographic report 
results, histology report results, information on supplementary surgical 
treatment, adjuvant therapy suggested by the oncology board and follow-
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up for the duration of the study. In detail, the specific variables derived 
from the patient's chart were: 
1. Basic Demographics: 
a. Medical record number 
b. Date of birth 
c. Ethnic background 
2. Medical History Unrelated To Breast: 
3. Medical History Related To Breast: 
4. Mammographic Report 
a. Date of last mammogram 
b. Level of suspicion for the lesion detected as reported by the 
radiologist 
c. Indication for procedure: (type of mammographic finding) 
d. Quadrant: where the lesion was located 
e. Mammographic size of lesion 
5. Histologic Report: 
a. Tumor pathology classified as benign or malignant. Benign 
tumors included fibroadenomas, cysts, sclerosing adenosis, 
fibrocystic breasts, and atypic hyperplasia. Malignant tumors 
included infiltrating ductal carcinoma, ductal carcinoma in situ 
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(DelS), mixed infiltrating ductal carcinoma and DCIS, 
infiltrating lobular carcinoma, lobular carcinoma in situ (LCIS) 
and mixed infiltrating ductal carcinoma and LCIS. 
b. Evaluation of the microscopie margins of the excised lesion in 
order to microscopically (with the use of histologie 
preparation and microscopie inspection) confirm that the 
les ion has been excised within safe margins, meaning that it 
is surrounded by at least 1 mm of healthy breast tissue. 
6. Supplementary surgical treatment required, as advised by the 
oncology board. This is mainly partial mastectomy with axillary 
Iymph node dissection. 
7. Follow-up for cosmetic results, complications, or recurrences 
through-out the 5 years of the study. 
3.4.2 SURGICAL REPORT: 
The details of the ABBI procedure including the duration of the 
procedure, description of the lesion and surgical complications were 
abstracted from the "Surgical Report". The detailed variables derived 
from the Surgical Report were: 
1. Date of the ABBI 
2. Digital size of the lesion as seen in digital mammography 
3. ABBI approach of excision (the side of the breast from which the 
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distance from the skin to the target is the shortest. 
4. Breast compression (the thickness of the breast in mm after it has 
been compressed between the operating window and the image 
receptor) (Figure 8). 
5. Depth of the les ion (Z-axis) (the perpendicular distance between 
the skin and the target, with the breast under compression) 
(Figure 8). 
6. Posterior margin; the distance between the target and the opposite 
side of the breast which corresponds, in this case, to the X-Ray 
receptor inner surface (Figure 8). 
7. Blood loss (in cc) estimated from the number of gauzes used 
during surgery. 
8. Duration of the procedure in minutes; the time from localization to 
excision of the lesion and removal of the ABBI cannula from the 
breast. 
9. Results of the evaluation of the post-biopsy digital mammogram 
for the presence of tumor remaining in the breast. This allowed the 
surgeon and the radiologist to assess whether the tumor was in 
the excised breast tissue (specimen) and if any parts of it are still 
remaining in the breast. 
10. Results of the assessment of the digital image of the excised 
specimen for the identification of the target tumor in it. This 
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allows the surgeon and the radiologist to assess whether the 
tumor has been excised within the specimen as weil as if it was 
excised completely. 
11. Evaluation of the macroscopic (gross) margins of the excised 
lesion. The specimen is imaged and macroscopic margins are 
assessed with the naked eye. This is done to confirm that the 
les ion has been excised with enough healthy breast tissue around 
it, as can be seen by the naked eye. 
12. If the assessment of the post-operative mammogram, the image of 
the specimen and/or the evaluation of the macroscopic margins 
indicated that the tumor was not excised completely, an immediate 
re-excision was performed. This was done either with a repeat 
ABBI or under direct vision like a conventional excisional biopsy. 
Ali reexcisions were reported. 
3.5 PATIENT GROUPS ANALYSED: 
Analyses was performed for the entire study sam pie as weil as for 
subgroups of patients classified according to the following: 
3.5.1 TYPE OF MAMMOGRAPHIC FINDING DETECTED: 
Patients were divided in the following three subgroups 
according to the type of les ion detected by mammography: 
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a. Soft tissue nodule, 
b. Microcalcifications 
c. Combination of soft tissue nodule with microcalcifications. 
3.5.2 LESION SIZE 
The largest diameter of the lesion was recorder in millimetres. 
3.5.3 QUADRANT OR LOCATION OF THE LESION 
One of the important determinants of the ability of the surgeon 
to accurately localize and excise a tumor with the ASSI system 
is the location of the les ion . 1 n order for the les ion to be 
localized and excised it must be placed in the center, or as 
close as possible to the center of the 1 OX1 0 cm operating 
window through which the surgery will be performed. Positioning 
the lesion near the edges of the operating window will not allow 
enough space for the coring device to pass through at a 90° 
angle to the breast.lt is thus important that the efficacy of the 
ASSI is assessed not only for the total group of lesions but also 
within the subgroup of patients categorized by the quadrant of 
the breast the lesion is located in. 
Women in this subgroup were divided in 5 categories depending 
on the quadrant of the breast the lesion was located: 
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a. Left or right breast: 
i. lower outer 
ii. lower inner 
i i i. upper outer 
iv. upper inner 
v. central 
3.6 SPECIFIC METHODS TO ADDRESS STUDY OBJECTIVES 
OBJECTIVE 1: Ta evaluate the diagnostic effectiveness of the ABBI 
for the surgical management of breast disease; 
The diagnostic effectiveness of the ABBI is measured by its 
ability to successfully localize and adequately excise the targeted lesion 
for histopathological diagnosis. This was determined by the radiologie 
assessment of the specimen. The radiologie image allows the radiologist 
and the surgeon to verify that the target lesion was removed completely. 
The diagnostic effectiveness of the ABBI was defined as the 
proportion of excised specimens found to contain the target lesion 
among ail specimens excised. This is calculated as the 
Diagnostic Effectiveness (DE) = ~umber of excised specimens con!aining th~ target lesio~ X100% ~ Total number of exclsed specimens J 
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The analysis was based on malignant les ions only because 
therapeutic effectiveness is not relevant for benign lesions. Furthermore, 
once the lesion has been diagnosed as benign by the pathologist, no 
further treatment or reexcision is conducted, even if the margins are not 
clear. In many cases the pathologist may not report margin clarity for 
benign lesions. 
OBJECTIVE 2: To evaluate the therapeutic effectiveness of the ABBI 
for the surgical management of breast cancer; 
The therapeutic effectiveness of the ASSI is measured by its 
ability to successfully excise the targeted malignant tumor within 
sufficient surrounding healthy breast tissue for clear surgical margins 
(>1 mm), in order to avoid the need for supplementary excisional surgery. 
This was determined by the pathologist who examined the excised 
specimen. 
The clarity of microscopie margins was determined by the 
histological examination of the specimen. Immediately upon excision, 
the margins of the specimen are labelled as upper, lower, lateral, or 
medial. The specimen was then sent to the pathology department where 
the margins were stained with a dye that adheres to tissue and is visible 
under the microscope. This procedure is simple and does not interfere 
with histologie evaluation. Its advantage is that it clearly distinguishes 
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surgical margins from margins formed by the cutting of the specimen 
with the microtome for histological evaluation. This is essential to 
assess if the excision of the tumor was complete (clear margins) or 
incomplete (involved margins). 
The decision on whether supplementary surgical treatment is 
required depends on the clarity of ail the microscopie margins around 
the excised tumor. If any of these margins is not clear, additional 
excisional surgery or partial mastectomy is required. The need for 
subsequent supplementary surgical excision of further breast tissue in 
order to achieve clear surgical margins is a direct measure of the 
effectiveness of the ABBI as a therapeutic surgical technique for 
malignant breast tumors. 
Therapeutic effectiveness assessment was based only on the 
evaluation of the malignantlesions biopsied. This was defined as the 
proportion of malignant lesions excised with clear microscopie margins: 
Therapeutic Effectiveness (TE) =Ember of malignant lesions excised with clear marqi~ Xl00% 
Total number of malignant lesions excised '7 
OBJECTIVE 3: To evaluate the safety of the ABBI system as a 
surgical technique for the management of breast 
lesions 
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1. Estimated Blood Loss 
The safety of the ABBI was evaluated by the amount of estimated 
blood loss and the frequency and seve rit y of surgical or post-surgical 
complications. 
The amount blood lost during the procedure was estimated from 
the gauzes used during surgery. According to the Canadian Guidelines 
for Clinical Practice, blood transfusion is indicated after an acute blood 
loss greater than 20% of the total blood volume, regardless of the 
patient's hematocrit. For a 70kg adult, this amounts to approximately 
70cc/kg 152-161. 
2. Surgical Complications 
The incidence of surgical complications was determined by the 
data abstracted from the surgical report. 
OBJECTIVE 4: To describe patient satisfaction with the ABBI; 
A survey consisting of 14 multiple choice questions relating to 
the patients' satisfaction with the ABBI was used. The questionnaire was 
given to the patients immediately after they left the ABBI room and was 
completed before leaving the hospital. The questions included in the 
survey are listed in Appendix 9. 
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The survey used was developed for the current study using 
similar questions to those used in other studies on the ABBI. There are 
no validated standardized questionnaires for the assessment of patient 
satisfaction with the ABB 1. It was decided not to use a general patient 
satisfaction questionnaire since the items had to be specifie to the ABBI. 
The patient satisfaction results were analyzed descriptively only without 
the calculation of a score. Therefore, use of a validated tool was not 
essential. 
OBJECTIVE 5: To assess the volume-performance association for 
the ABBI 
ln order to assess the volume-performance association and 
surgeon effect for the ABBI the performance indicators used were 
diagnostic and therapeutic effectiveness. Diagnostic effectiveness was 
assessed by the need for re-excision based on the presence of involved 
macroscopic margins. Therapeutic effectiveness was assessed by the 
presence of involved microscopie margins for malignant tumors. 
Therapeutic effectiveness was not assessed for benign tumors since 
involved microscopie margins reports for the benign lesions are not 
clinically relevant and are not reported by the pathologist. 
The independent variable describing the surgeon was simply a 
categorical variable with a randomly selected value ranging from 1-3 to 
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represent each one of the three participating surgeons. In this analysis, 
for each patient, prior ABBI volume of the surgeon was defined as the 
number of ABBI procedures that the surgeon had performed prior to the 
date of the ABBI. 
ln order to assess the crude association between surgeon and 
the performance indicators described above the Chi-Square statistic was 
used. A simple logistic regression model was used to assess the effect 
of prior ABBI volume on diagnostic and therapeutic effectiveness. 
Multivariate-Iogistic regression models were used to asses the 
independent effect of surgeon and prior ABBI volume on diagnostic and 
therapeutic effectiveness. The multiple logistic regression models 
included a dummy variable with two levels representing the surgeon, a 
continuous variable representing prior ABBI volume and the surgeon x 
volume interaction term. The interaction term was included to investigate 
whether there is a d ifference between su rgeons with respect to the 
volume-performance association. 
OBJECTIVE 6: To describe the cost evaluation of the ABBI 
Economic evaluation of the ABBI was aimed at assessing 
whether management of patients with the ABBI results in cost reductions 
when compared to excisional biopsy with wire localization. The results 
in the literature have shown that the rate of supplementary surgery for 
the ABBI to be between 8% and 42% while that for the wire localization 
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excisional biopsy to be between 17% and 
76%38,39,43,44,125,126,136,138,141,143,145,148-150,162-164. In the current study we 
observed a 23.7% rate of involved microscopie margins for the ABBI. 
This rate was 53% of the 531 patients that underwent a wire localization 
biopsy that had malignant tumors. These results suggest that 
therapeutic effectiveness is higher for the ABBI when compared to wire 
localization biopsy. In consideration of the above, cost-effectiveness 
analysis would not be required if cost-minimization was demonstrated for 
the ABBI compared to wire localization excision biopsy. 
ln the economic analysis only total direct health costs were 
considered. These included the cost for the ABBI or wire localization 
excisional biopsy and the cost for any supplemental surgery required. In 
the current study the supplemental surgery considered was partial 
mastectomy since this was the only procedure used subsequent to the 
ABBI or wire localization excisional biopsy. Cost estimates for the ABBI, 
wire localization excisional biopsy and partial mastectomy were obtained 
from the costs centers of the participating institutions. The detailed list 
of the items included in the calculation of these costs is included in 
Appendix 10. Ali costs estimates were in 2000 Canadian Dollars. 
ln order to obtain precise estimates of the need for 
supplemental surgery the data from studies reporting supplementary 
surgery for the ABBI and wire localization excisional biopsy in the 
literature were combined with those obtained in our study. The data 
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used to produce these estimates are described in Appendix 11. 
Accordingly the estimated rate for supplemental surgery for the ABBI 
was 14.9% (95% CI: 12.6% - 17.2%) and that for wire localization was 
30.2% (95% CI: 27.7% - 32.8%). 
Cost assessment was based on a simulation of a hypothetical 
cohort of 1,000 patients that underwent the two alternative procedures, 
specifically the ABBI and wire localization biopsy. For each of the two 
procedures the point estimate of supplemental surgery rates described 
above were used. Sensitivity analysis was conducted to determine the 
possible ranges of total costs for each procedure using the upper and 
lower 95% confidence intervals limits for the need of supplemental 
surgery. Accordingly, the worst case scenario was that in which the 
upper 95% CI limit for supplemental surgery was used for the ABBI 
(17.2%) and the lower limit (27.7%) was used for the wire localization. 
The best case scenario was that in which the lower limit was used for 
the ABBI (12.6%) and the upper limit (32.8%) was used for the wire 
localization. The two intermediate scenarios were based on using the 
upper (ABBI: 17.2% and wire localization: 32.8%) and lower (ABBI: 
12.62% and wire localization: 27.7%) limits for both alternatives. 
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3.7 AB BI SURGICAL METHOD DESCRIPTION 
A detailed technical description of the ABBI method is presented in 
appendix 12. This description is included because it may be useful to the 
reader to appreciate the ABBI procedure. 
Ali ABBI patients had agreed and given their written consent to 
undergo the procedure. Ali ABBI biopsies were performed at the day-
surgery clinic under local anaesthesia. Prior to the procedure each 
patient was briefed about the ABBI equipment and was then given a 
description of the procedure. 
3.8 RESULTS 
3.8.1 PATIENT ENROLMENT AND CHARACTERISTICS: 
This research project enrolled patients since the first year of 
development and implementation of the ABBI system in the two 
participating centers. In October 1995 the first two patients were 
enrolled. Since then, 2 additional patients were operated during the first 
year (1995), for a total of 4 or 1.5% of the total 262 patients enrolled. In 
the following years the number of ABBls performed each year increased 
progressively. Forty-eight (18.3%) patients were operated on in 1996, 
followed by 50 (19.1%) in 1997, 60 (22.9%) in 1998, and 80 patients 
(30.5%) in 1999. The number of ABBI procedures decreased to 14 
(5.3%) and 6 (2.3%) in 2000 and 2001 respectively. 
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Two hundred and sixty-two women (262) with a mean age (SD) of 
57.4 (11.5) years ranging from 31 to 83 years who underwent a breast 
biopsy with the use of the ABBI system were included in this study 
(Figure 9). 
AGE DISTRIBUTION 
60..------------------, 
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40 
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55.0 65.0 75.0 85.0 
Figure 9: Age distribution of patients submitted to an ABBI 
3.8.1.1 Mammographie Indication for the Procedure 
The mammographie indication for the diagnostic procedure 
was microcalcifications for 175 cases (66.8%), a soft tissue nodule 
for 79 cases (30.2%) and in 8 cases (3.1 %) a combination of 
microcalcifications and soft tissue nodules. 
3.8.1.2 Description of Lesions and Surgical Approach 
The distribution of the location of the lesion in the breast is 
described in figure 10. The majority of the excised les ions (56.1 %) were 
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located at the left upper outer quadrant, followed by 10.7% in the right 
upper outer quadrant of the breast. 
QUADRANT 
Ille 
III LI 
I!fjlO 
lIIul 
lIIuo 
Figure 10: Distribution of the location of the lesion in the 
breast 
Excision surgical approach refers to the side of the breast at which 
the incision will be performed for the biopsy. The choice of excision 
approach was depended on the distance between the point of incision 
and the target lesion (Figure 11 and 12). The approach that permitted 
the removal of less breast tissue without jeopardizing the complete 
excision of the target lesion within surgically safe margins was chosen. 
The most frequent approach was lateral, used in 117 (44.7%) of the 
patients. In 77 (29.4%) patients the inferior approach was used and the 
superior was used in 28 (10.7%) cases, and the medial in 22 (8.4%). In 
the remaining cases a combination of different approaches was used 
such as oblique/inferior and oblique/medial. The lateral approach was 
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preferred because it offers greater freedom and ease of movement for 
the surgeon. 
A = dark area indicates tumor 
B = light pink highlighted area 
indicates tissue removed at 
lumpectomy 
C = lateral approach 
o = oblique-inferior approach 
E = superior approach 
F = medial approach 
G = inferior approach 
H = oblique-medial approach 
Figure 11: Description of possible excision approaches 
Excision Surgical Approach 
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Figure 12: Distribution of excision surgical approaches used in the study 
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3.8.1.3 Breast Compression 
The compression of the breast ranged from 28mm to 89mm with a 
mean (SO) of 52.7mm (11.4). The depth of the most superficial lesion 
excised was 7mm. from the skin and that of the deepest lesion was 
45mm. with a mean (SO) depth of 29.7 mm (8.3). Ali tumors were 
excised without any damage to the opposite side of the breast (within 
safe posterior margins). 
3.8.1.4 Tumor Size 
The length of the largest diameter of the tumor was recorded as an 
indicator of tumor size. As measured by digital mammography, the tumor 
size ranged between 1 mm and 30mm with a mean (SO) of 8.5mm (4.9). 
The majority of the tumors (43.9%) ranged between 5.1 and 10.0 mm. in 
diameter. Of the remaining, 32.4% ranged between 1.0mm and 5.0 mm, 
16.4% from 10.1 mm to 15 mm and 6.1 % from 15.1 mm to 20.0 mm. Even 
though the inclusion criteria restricted the size of the tumor to 20 mm or 
less, in 2 cases (1.2%), the calcifications were widely spread reaching a 
total size of greater than 20mm. In these cases, the ABBI was performed 
for purely diagnostic purposes and was recorded as such. These cases 
were not included in the analysis. 
The excised specimen measured 20 mm. or less in diameter and 
from 15 to 35 mm. in length, with a mean (SO) volume of excised breast 
tissue of 40cc (36). The mean (SO) volume of excised breast tissue from 
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20 biopsies with wire localization excisional biopsy excisional biopsy 
was 102cc (59). 
3.8.2 MEASURES OF EFFECTIVESS: 
3.8.2.1 Evaluation of the diagnostic effectiveness of the AB BI for 
the management of breast disease 
Among the 260 specimens excised, 259 contained the target lesion 
for an overall diagnostic effectiveness of 99.6% with 95% confidence 
intervals (97.02, 99.97). In one case no lesion was identified in the 
specimen image or in the post-biopsy mammogram. Histological analysis 
of the specimen diagnosed fibrocystic breast tissue. Immediate re-
excision was required in 42 (15.6%) of the 260 cases. 
The data in table 2 describe the diagnostic effectiveness by lesion 
location. These results show that that the rate of successful lesion 
excision was not affected by the location of the lesion (chi-square value 
18.819, p=0.403). 
MICROMARGIN 
QUADRANT n=259 (99.6%) Total 
CLEAR INVOLVED 
Central 16 (6.2%) 1 (0.4%) 17 
Lower inner 23 (8.9%) 3 (1.2%) 26 
Lower outer 18 (6.9%) 4 (1.5%) 22 
Upper inner 20 (7.7%) 1 (0.4%) 21 
Upper outer 162 (62.5) 11 (4.2%) 174 
Total 239 (92.3%) 20 (7.7%) 259 
Table 2: Clarity of micromargins by lesion location 
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3.8.2.2 Evaluation of the therapeutic effectiveness of the ABBI for 
the management of breast cancer 
3.8.2.2.1 Histological Distribution of Excised Margins 
Therapeutic effectiveness is defined as the proportion of les ions 
excised within clear micromargins. In order to appreciate the overall 
therapeutic effectiveness of the ABBI, verification of the histological 
assessment of the lesion and the microscopie margins are important. 
ln total, of the 260 excised tumors (184 benign and 76 malignant) 
240 were excised within clear margins. Of the 184 benign tumors, 182 
(98.9%) were excised within clear margins. Therefore, the overall 
therapeutic effectiveness of the ABBI to adequately excise tumors within 
clear margins is 92.3% with 95% confidence Intervals between 89.2% 
and 95.6%. Of the 76 malignant tumors, 58 (76.3%) (CI 74.9%, 78.3%) 
were excised within clear surgical margins. (Figure 13). However, the 
Tumors 
260 
Figure 13: Microscopie margins of excised tumors 
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therapeutic effectiveness is only relevant for malignant tumors. As 
mentioned earlier, this was 76.3% with 95% confidence intervals 
between 74.9% and 78.3% (Figure 14). 
1 
Tumors ~ 260 
1 
Malignant 1 1 Benign ~ 76 184 
1 1 
1 
Microscopie ~ 1 Microscopie ~ Margins Margins 
CLEAR ]J II INVOLVED ~ CLEAR Il II INVOLVED II 
1 1 1 1 
II 58 ~ 1 18 IJ 1 182 ~ 1 2 Il (76.3%) (23.7%) (98.9%) (1.1%) 
FIGURE 14: Histologie distribution and microscopie margins of excised 
tumors 
The distribution of the histological assessment of the excised 
tumors is described in tables 3 and 4. Of the 260 tumors excised, 184 
(70.2%) were benign tumors and 76 (29.8%) were malignant. Of the 184 
benign tumors, 112 (60.9%) were diagnosed as fibrocystic changes, 54 
(29.3%) were mainly fibroadenomas, adenosis, fat necrosis, fibrosis, 
papillomas, sclerosing adenosis and cysts, and 18 (9.8%) were 
diagnosed as atypic hyperplasia (a potentially pre-malignant condition 
requiring a more careful follow-up than other benign tumors). 
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Of the 76 malignant lesions excised, 21 (27.6%) were intraductal 
(DCIS) carcinoma and 36 (47.4%) infiltrating (invasive) ductal cell 
carcinomas. There were 19 (25.0%) mixed cancers of which, 17 (22.4%) 
were infiltrating ductal carcinomas with intraductal components and 2 
(2.6%) lobular cell in situ (LCIS) carcinomas with focal Lobular 
infiltration (Table 3 and 4). 
BENIGN TUMORS Frequency Category (%) Total % 
Fibrocystic breast 112 60.9 43.1 
Benign tumour 54 29.3 20.7 
Atypic hyperplasia 18 9.8 6.9 
Table 3: Histological distribution of the excised tumors 
MALIGNANT TUMORS Frequency Category (%) Total % 
DCIS 21 27.6 8.1 
Infiltrating Ductal Ca 36 47.4 13.8 
DCIS + Infiltrating Ductal Ca 17 22.4 6.5 
LCIS + Infiltrating Lobular Ca 2 2.6 0.8 
Total 260 100 100 
Table 4: Histological distribution of the excised tumors 
Complete excision is essential mainly for malignant tumors in order 
to avoid residual malignancy which may lead to metastasis and recurrent 
disease. The effectiveness of the ABBI to excise malignant tumors within 
clear microscopie margins (at least 1 mm healthy breast tissue 
surrounding the tumor), defined as therapeutic effectiveness, was 76.3% 
(95% CI 66.7%, 85.9%) (Figure 15). Eight (23.7%) of the 36 infiltrating 
ductal carcinomas were excised within involved microscopie margins. 
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Infiltration of the surgical margins was detected in 4 (19.0%) of the 21 
DCIS, and 6 (35.3%) of the 17 mixed tumors. Ali LCIS were sufficiently 
excised free of tumor. 
MALIGNANT 
TUMORS 
(76) 
Figure 15: Therapeutic effectiveness of the ABBI to excise malignant 
tumors 
3.8.2.2.2 Therapeutic Follow-Up 
Of the 76 patients with a malignant tumor, 21 (27.6%) required 
additional surgical treatment. More specifically, of the 36 women 
diagnosed with infiltrating ductal carcinomas, 9 (25%) underwent a 
supplementary partial mastectomy combined with axillary Iymph node 
dissection. However, in ail nine of these cases the original tumor 
excision was shown to be complete and no residual tumor was found. 
Four (19.0%) of the 21 patients with DCIS were submitted to partial 
mastectomy. Residual tumor was found in three (14.3%) of the 21 cases. 
Finally, eight (47.1%) of the 17 mixed tumors with mixed infiltrating 
ductal carcinomas and DCIS were submitted to a supplementary partial 
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mastectomy, of which 2 had residual cancer. None of the two mixed 
infiltrating lobular carcinomas with LCIS required further excision. 
Overall, 5 (23.8%) of the 21 patients who had supplementary surgery 
had residual malignancy in the surrounding breast tissue excised. The 
remaining 55 (72.4%) of the 76 patients with malignant tumors were 
submitted to a combination of radiotherapy, chemotherapy and/or 
Tamoxifen. Supplementary mastectomy was not required for benign 
tumors since there is no known possibility of recurrence in case of 
residual disease. 
3.8.2.3 Evaluation of the safety and tolerability of the ABBI 
system as a surgical technique for the management of 
breast tumors 
Safety was assessed by total blood loss during surgery and 
incidence of complications. The total blood loss during surgery was 
estimated from the gauzes consumed and ranged from 1 to 200 cc. 
(mean 26.3 cc.) which is below the accepted limits. 
The following peri-operative complications occurred: For two 
patients, the cannula malfunctioned before reaching the target in the 
breast. In both cases the gear was drawn off the breast manually and 
the tumor was excised under direct vision. One of these two patients had 
mentioned an increased sensitivity in the neck and shoulder due to a 
previous accident complained of pain. 
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For one patient, the T-crossbar did not deploy. In this case the 
specimen was not securely attached in the cannula of the ABBI. When 
the cannula was removed from the breast the specimen remained in the 
cavity attached only at the posterior breast tissue, from where it was cut 
and excised under direct vision. 
For one patient no specimen was retrieved with the ABBI during 
the first attempt but the second attempt was successful. The most 
possible explanation for this is that the T -crossbar may not have 
deployed completely so the specimen was only partially attached to the 
cannula, which made it possible to remove the specimen with the second 
attempt. 
Two women presented with greater than usual bleeding during the 
ABBI followed by difficulty with haemostasis during the closure of the 
surgical cavity. After the bleeding was controlled and the cavity was 
sutured, both women remained Iying su pi ne on the LoRad table with a 
sandbag on the breast for 30 minutes. A sandbag is usually made of 
cotton and filled with a heavy and fine material such as sand. It is used 
as a way to apply pressure in the bleeding area to facilitate blood 
clotting and haemostasis. 
One patient complained of inability to further remain in the supine 
position. The procedure was terminated before the post-biopsy 
mammogram and the patient was allowed to turn in the supine position. 
There was no case of loss of conscience or vomiting. 
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ln the post-operative phase the following complications or 
discomforts were reported. Three women presented post-operatively 
with mild wound infections which were successfully managed with partial 
removal of sutures and saline bathing. One patient developed a delayed 
haematoma which was drained and the incision was re-sutured. Three 
more patients developed a mild haematoma which was treated 
conservatively with pressure and cold compresses. 
3.8.2.4 Description of patient satisfaction with the AB BI 
experience 
Because the fourth objective was added in the study during the 
final 3 years, only the last 100 patients were asked to participate in a 
brief survey that consisted of 13 questions and was administered 
immediately after the procedure and during the brief recovery period 
before the patient was permitted to leave the clinic. The survey 
responses are summarized in the following table. The detailed survey is 
presented in Appendix 9. 
Of the 100 patients who answered the questionnaire, the majority, 
85 % (95% CI 78% - 92%) chose the specifie clinic (medical center) 
because they were referred there by their treating physician. Only 5% 
(95% CIO. 7% - 9.3%) admitted that they had an "excellent" 
understanding of their therapeutic options whereas 65% (95% CI 55.7% -
74.3%) rated their knowledge as "very good". On the other hand, 45% 
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(95% CI 35.2% - 54.8%) and 25% (95% CI 16.5% - 33.5%) of these 
patients reported that their knowledge of the differences between the 
ABBI was "very good" and "moderate" respectively. Most patients, 65% 
(95% CI 55.7% - 74.3%) selected the ABBI because they trusted their 
physician and 20% (95% CI 12.2% - 27.8%) because they preferred local 
rather than general anaesthesia. The patients' understanding of the 
advantages and disadvantages of the ABBI compared to other options 
was "very good" for 33% (95% CI 23.8% - 42.2%), "good" for 30% (95% 
CI 21.0% - 36.0%) and "moderate" for 22% (95% CI 13.9% - 30.1 %). 
The waiting time for the procedure ranged from 1-8 weeks; 45% 
(95% CI 35.2% - 54.8%) of patients waited for 1-2 weeks, 35% (95% CI 
25.7% - 44.3%) for 2-4 weeks and 20% (95% CI 12.2% - 27.8%) 5-8 
weeks. The majority of the patients (51 % / 95% CI 41.2% - 60.8%) 
received their biopsy results 1-2 weeks after the procedure and the 
remaining 49% (95% CI 39.2% - 58.8%) between 2-4 weeks post-
su rgery. 
Of the 100 patients who responded to the questionnaire, 40% (95% 
CI 30.4% - 49.6%) rated their level of general satisfaction with the 
facility as "very good", 35% (95% CI 25.7% - 44.3%) as "excellent" and 
20% (95% CI 12.2% - 27.8%) as "good". 
Comfort during the procedure was rated as "very good" by the 
majority (57%) (95% CI 47.3% - 66.7%) of the patients. The remaining 
patients were divided between "excellent" for 11 % (95% CI 5.8% -
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17.5%), "good" for 12% (95% CI 5.6% - 18.4%) and "moderate" for 13% 
(95% CI 6.4% - 19.6%). However, their level of comfort after the 
procedure was rated by 63% (95% CI 53.5% - 72.5%) as "very good" and 
by 21 % (95% CI 13.0% - 29.0%) as "good". 
The majority of the patients (51 %) (95% CI 41.2% - 60.8%) 
reported a "very good" level of satisfaction with the actual procedure 
while 23% (95% CI 14.8% - 31.2%) reported their level of satisfaction as 
"excellent" and 18% (95% CI 10.5% - 25.5%) as "good". Eighty percent 
(95% CI 72.2% - 87.8%) of these 100 patients had no regrets for 
choosing the ABBI and 49% (95% CI 39.2% - 58.8%) returned to normal 
activity within the same day. 
3.8.2.5 Evaluation of the volume-performance association for the 
ABBI 
3.8.2.5.1 Diagnostic Effectiveness as Performance Indicator: 
Table 5 shows the re-excision rates for each one of the three 
surgeons participating in the study. Although surgeon #2 had the 
highest re-excision rate and surgeon #3 the lowest, this difference did 
not achieve statistical significance (Chi-Square = 0.659, P = 0.719). 
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Re-Excision 
SURGEON No Yes 
N % N % 
1 115 83.3% 23 16.7% 
2 41 80.4% 10 19.6% 
3 61 85.9% 10 14.1% 
Table 5: Re-Excision rates by Surgeon: 
Table 6 summarizes the results of the simple logistic regression 
model for the evaluation of the association between prior ABBI volume 
and diagnostic effectiveness. In this model the dependent variable was 
the need for re-excision defined as 1 = yes and 0 = no. These results 
show that there is a significant association between prior ABBI volume 
and performance as measured by the surgeon's ability to completely 
excise the target tumor. The logistic regression odds ratio of 0.975 was 
significant (P<0.001) and shows that with every additional ABBI 
performed the risk for re-excision decreases by a factor of 0.025. It 
should be noted that although the estimated odds ratio is relatively 
small, it measures the effect of volume as a continuous variable. 
Variable Parameter S.E. P- Odds 95 % CI for estimate(B) Value. Ratio Odds Ratio 
Prior ABSI Volume 
-0.026 0.003 0.001 0.975 0.968 1 0.981 (continuous) 
Table 6: Simple Logistic Regression Model Results (Diagnostic 
Effectiveness) 
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Figure 16 describes the estimated probability (risk) for re-excision 
by prior ABBI volume. The probability for re-excision was estimated from 
the odds ratio obtained using the logistic regression parameter for each 
case in the sample. The following formulae were used: 
Odds Ratio (OR) = evo/ume x -0.026 Probability = OR / (1 +OR) 
These results show that for a re-excision risk of 20% 
approximately 40 - 50 procedures must have been performed by the 
surgeon. This is however, an exploratory analysis demonstrating the 
association between volume and performance. Establishing performance 
- risk thresholds will require further analysis and consideration of 
patient risk tolerance as weil as economic impact. 
- 99-
0.50 
c 
.2 0.40 
tn 
.~ 
W 
ci> 
a: 
'0 0.30 
~ 
:c 
CU 
.a e 0.20 
I:L. 
" ~ 
E 
~ 0.10 
W 
0.00 
~~~~~~~~ww~~~~~œœœ~~oooooo~~~~~~~~~~~~ 
bbbw~~~~w~~~~w~~~~w~~~~w~ooo~~~~~ww 
ooooooooooooooooooooooooo~~~~~~~~~~ 
00000000000000000000000000000000 
0000000000 
Volume (Number of Previous ABBls) 
Figure 16: Estimated probability of re-excision by previous ABBI volume: 
Table 7 summarizes the results of the multi-variate logistic 
regression models for diagnostic effectiveness. These results show that 
both the surgeon and prior ABBI volume have a significant association 
with the need for re-excision. For the surgeon effect, more precisely, the 
significant effect was noted between surgeon # 3 and surgeon # 2.ln 
addition a significant surgeon - prior ABBI volume interaction effect was 
observed. This would suggest that an analysis assessing the prior ABBI 
volume effect stratified by surgeon would be required. 
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Parameter P- Odds 95 % CI for Odds Variable: estimate S.E. 
(B) Value. Ratio Ratio 
Prior ABBI Volume -0.037 0.009 0.001 0.964 0.947 0.980 
Overall Surgeon Effect 0.012 
Surgeon 3 vs. 2 -1.266 0.436 0.004 0.282 0.120 0.664 
Surgeon 3 vs. 1 -0.401 0.654 0.539 0.669 0.186 2.411 
Surgeon * volume 0.005 
Surgeon 3 vs. 2 by volume 0.032 0.010 0.002 1.032 1.012 1.054 
Surgeon 3 vs. 1 by volume -0.006 0.028 0.816 0.994 0.941 1.049 
Table 7: Multi-Variate Logistic Regression Model Results (Diagnostic 
Effectiveness) 
Table 8 summarizes the results of the simple logistic regression 
models assessing the association between prior ABBI volume and 
diagnostic effectiveness stratified by surgeon. These results show that 
although the prior ABBI volume effect was significant for ail surgeons, 
the strongest effect was observed for surgeon #2. 
Parameter P- Odds 95 % CI for Odds SURGEON Variable 
estimate(B) S.E. Value Ratio Ratio 
1 Volume -0.020 0.003 0.001 0.980 0.973 0.986 
2 Volume -.0057 0.015 0.001 0.944 0.917 0.973 
3 Volume -0.037 0.009 0.001 0.964 0.947 0.980 
Table 8: Stratified Simple Logistic Regression Model Results (Diagnostic 
Effectiveness) 
3.8.2.5.2 Therapeutic Effectiveness as Performance indicator: 
Therapeutic effectiveness was evaluated only for the malignant 
tumors. 
Table 9 describes the microscopie margin assessment by surgeon. 
These results show that although surgeon # 1 had the highest rate of 
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involved margins, the difference was not statistically significant (Chi -
Square: 1.535, P = 0.646). 
Microscopie Margins 
SURGEON Clear Involved Total 
N % N % 
1 33 71.7% 13 28.3% 46 
2 12 80.0% 3 20.0% 15 
3 13 86.7% 2 13.3% 15 
Table 9: Microscopic margin results by surgeon: 
Table 10 summarizes the results of the simple logistic regression 
model for the evaluation of the association between prior ABBI volume 
and therapeutic effectiveness. In this model the dependent variable was 
the presence of involved margins defined as 1 = yes and 0 = no. These 
results show that there is a significant association between volume and 
this performance indicator. The logistic regression odds ratio of 0.980 
was significant (P<0.001) and shows that with every additional ABBI 
performed the risk for re-excision decreases by a factor of 0.020. 
Variable Parameter S.E. P- Odds 95 % CI for 
estimate(Bj Value. Ratio Odds Ratio 
Prior ABBI Volume 
-0.021 0.005 0.001 0.980 0.970 1 0.989 (continuous) 
Table 10: Simple Logistic Regression Madel Results (Diagnostic 
Effectiveness) 
Figure 17 describes the estimated probability (risk) for having an 
involved margin by prior ABBI volume. The probability an involved 
margin was estimated from the odds ratio obtained using the logistic 
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regression parameter for each case in the sample. The following 
formulae were used: 
Odds Ratio (OR) = evo/ume x -0.021 Probability = OR / (1 + OR) 
These results show that for an involved margin rate of 20% 
approximately 65 procedures must have been performed by the surgeon. 
This is however, an exploratory analysis demonstrating the association 
between prior ABBI volume and performance. Similarly with the 
diagnostic effectiveness, establishing performance - risk thresholds will 
require further analysis and consideration of patient risk tolerance as 
weil as economic impact. 
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Figure 17: Estimated probability of involved margin by previous ABBI 
volume 
Table 11 summarizes the results of the multi-variate logistic 
regression models for therapeutic effectiveness. These results show that 
only prior ABBI volume had a significant association with the risk for 
involved having microscopie margins. The association for surgeon was 
not significant and the surgeon-volume interaction effect was also not 
significant. 
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Variable: Parameter S.E. P- Odds 95 % CI for Odds 
estimate(B) Value. Ratio Ratio 
Prior ABBI Volume -0.048 0.022 0.029 0.953 0.913 0.995 
Overall Surgeon 0.302 Effect 
Surgeon 3 vs. 2 1.071 0.852 0.208 2.919 0.550 15.488 
Surgeon 3 vs. 1 0.433 1.592 0.368 4.191 0.185 94.961 
Surgeon * volume 0.375 
Surgeon 3 vs. 2 by 0.019 0.025 0.440 1.019 0.971 1.071 
volume 
Surgeon 3 vs. 1 by 
-0.057 0.064 0.378 0.945 0.833 1.072 
volume 
Table 11: Multi-Variate Logistic Regression Model Results (Therapeutic 
Effectiveness) 
Table 12 summarizes the results of the simple logistic regression 
models assessing the association between prior ASSI volume and 
therapeutic effectiveness stratified by surgeon. This analysis was 
conducted for descriptive purposes although it may have not been 
required since a significant surgeon-volume interaction effect was not 
detected. These results show that although the volume effect was 
significant for ail surgeons, the strongest effect was observed for 
surgeon #2. 
SURGEON Variable Parameter S.E. P- Odds 95 % CI for 
estimate(B) Value. Ratio Odds Ratio 
1 Volume -0.016 0.005 0.001 0.984 0.975 0.994 
2 Volume -0.060 0.027 0.024 0.942 0.894 0.992 
3 Volume -0.048 0.022 0.029 0.953 0.913 0.995 
Table 12: Stratified Simple Logistic Regression Model Results (Therapeutic 
Effectiveness) 
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3.8.2.6 Description of the cost evaluation of the AB BI 
The results of the economic evaluation comparing the ABBI to wire 
localization biopsy are summarized in Table 13. These results show that 
on the average the ABBI would result in a cost reduction of $5,352 CAO 
(2000). Under the worst case and best case scenarios using the ABBI 
would result in a co st reduction of $4,847 CAO (2000) and $5,853 CAO 
(2000) respectively. Intermediate cost reductions were $5,703 CAO 
(2000) and $5,627 CAO (2000). 
1 n consideration of the observed lower total cost or cost-
minimization and higher rates of therapeutic effectiveness for the ABBI 
in comparison to the wire localization biopsy, further economic 
evaluation based on cost-effectiveness was not pursued. 
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Scenario: Point Estimate Worst Intermediate (Low) Intermediate (High) Best 
Procedure: ABBI WL ABBI WL ABBI WL ABBI WL ABBI WL 
Number of Cases 1,000 1,000 1000 1000 1000 1000 1000 1000 1000 1000 
, ~ 
" ':l:Wi?''' ill ili, " 
~~ ., 
w 
Cost per Case $653 $2,027 $653 $2,027 $653 $2,027 $653 $2,027 $653 $2,027 
Total Cost For $653,000 $2,027,000 $653,000 $2,027,000 $653,000 $2,027,000 $653,000 $2,027,000 $653,000 $2,027,000 1,000 Cases 
:,2>, ' ,- ~ ::,'1[< 
" 
, 
Supplemental 14.9% 30.3% 17.2% 27.8% 12.7% 27.8% 17.2% 32.8% 12.7% 32.8% Surgery Rate 
Numberwith 
Supplemental 97 614 112 564 82 563 112 664 83 665 
Surgery 
_r 
; "", <-~, ~~" v " ~ ," 
,", 
, 
.. , 
Cost per case of 
Supplemental $7,697 $7,697 $7,697 $7,697 $7,697 $7,697 $7,697 $7,697 $7,697 $7,697 
Surgery 
Total Cost for ail 
Supplemental $748,895 $4,727,351 $864,496 $4,337,306 $638,320 $4,337,306 $864,496 $5,117,397 $638,320 $5,117,397 
Surgery 
:,*"Wi '-"""-, '", :j5"'W-='~· 
" " " , ;, :t: " ':..,'~ ~ 
,,, , 
Total for Surgical 
Management of $1,401,895 $6,754,351 $1,517,496 $6,364,306 $1,291,320 $6,364,306 $1,517,496 $7,144,397 $1,291,320 $7,144,397 
1,000 Patients 
Total Cost Per $1,402 $6,754 $1,517 $6,364 $1,291 $6,364 $1,517 $7,144 $1,291 $7,144 Patient 
Cost Difference 
-$5,352 -$4,847 -$5,703 -$5,627 -$5,853 (ABBI-WL) 
1 
Table 13: Summary of Cost Analysis of ABBI versus Wire Localization Blopsy: WL = Wire Localization Biopsy 
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3.9 DISCUSSION 
National mammographic screening programs for the early detection 
of breast cancer have led to a continuously increasing number of new 
breast cancer cases detected each year. According to the Canadian 
Steering Committee on Clinical Practice Guidelines for the Care and 
Treatment of Breast Cancer, once an abnormality is detected in a 
screening mammogram a combination of further radiologic work-out and 
clinical examination is initiated. The objective is to acquire a more 
accu rate description of the abnormality and to estimate the level of 
suspicion or risk for cancer20 . The decision on the appropriate 
management is based on the estimated level of risk of the mammographic 
finding and is taken after discussion and agreement between the treating 
physician and the patient. Depending on the level of risk (Category 1-4) 
and the preference of the patient, management options may range from 
observation with a 6-month follow-up mammogram, incisional biopsy 
(tissue sampling) or excisional biopsy (complete removal of the lesion). 
Once the decision is made for complete removal of the lesion, the 
choice of surgical technique is based on whether the abnormality is 
palpable or non-palpable. For non-palpable lesions, the current standard 
surgical technique is wire localization excisional biopsy. This technique 
combines image-guided localization and surgical excision of the lesion 
with a conventional open biopsy. The advantages of wire localization 
excisional biopsy are the excision of a specimen that is sufficient for an 
accurate histopathological diagnosis, the minimal post-operative 
complications, the removal of less breast tissue than partial mastectomy, 
and the shorter du ration of hospitalization of the patient41 -44 . 
A disadvantage of wire localization excisional biopsy is that it is a 
repetitive multiple step process involving radiology and surgery until the 
excision is considered complete. In approximately 20-25% of the cases 
the les ion is not found in the initial specimen and in 59.4% of the cases 
the surgical margins are not clear of malignancy35-40,52-99,116-124. This 
results in a longer duration of surgery and anaesthesia and a larger 
amou nt of breast tissue removed (mean volu me 1 02cc )27-34,81,84,100-124. 
Therefore, the use of wire localization as a diagnostic tool is acceptable 
but not ideal. 
Microscopie assessment of the excised specimen has shown a 40-
59% false negative rate for specimens with clear macroscopic margins. 
Approximately 59.4% of patients require further local surgery23,31-40,46,47. 
Based on these results, the therapeutic utility of wire localization biopsy 
is questionable47 ,48. 
Because of the disadvantages of wire localization excisional biopsy 
an alternative minimally invasive image-guided excisional biopsy 
technique, the ABBI, has been developed. The ABBI was evaluated in this 
study. The diagnostic effectiveness of the ABBI in the series of 260 
patients was 99.6%. This was similar to the reported 98% for wire 
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localization excisional bi opSy265. However, re-excision was required in 
15.6% of the patients who underwent an ABBI compared to 20-25% as 
reported in the literature for wire localization excisional biopsy35-40,52-
99,116-124,146 
Both the ABBI and wire localization excisional biopsy are considered 
microinvasive since they aim to excise the tumor with clear surgical 
margins and with the removal of the least amount of healthy peripheral 
breast tissue as possible. Breast conservation is therefore an important 
consideration in the management of breast disease at this stage. 
Given that the overall effectiveness as diagnostic procedures of 
both techniques is similar, the size of the excised specimen becomes an 
important consideration. The mean volume of the specimen excised with 
the ABBI was 40.2cc versus 102cc for the 531 wire localizations 
performed in the same hospitals during the same time period and by the 
same surgeons. Clearly the ABBI achieved a similar diagnostic 
effectiveness as the wire localization biopsy with a smaller amount of 
tissue excised. 
ln the current study, the therapeutic effectiveness of the ABBI was 
76.3% as compared to 53% for the 531 wire localization biopsies 
reviewed. As reported in the literature, the probability of invaded margins 
after a wire localization excisional biopsy ranges fram 29.5% to 79% with 
a mean of 59.4%. Nevertheless despite this finding the 24.7% probability 
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of involved microscopie margins is too high for the technique to be 
considered as a therapeutic procedure for breast cancer. Based on these 
results both the wire localization excisional biopsy and the ABBI should 
not be used as therapeutic interventions. 
Another important factor for the assessment of the therapeutic 
effectiveness of a microinvasive surgical technique for breast cancer is 
the requirement for supplementary surgery and the probability of residual 
disease found in the peripheral breast tissue excised. In the current 
study, the rate of supplementary surgery for the ABBI patients was 27.6% 
compared to 53% for the 531 wire localization patients. Residual 
malignancy was found in 23.8% of the post-ABBI patients compared to 
48% of the post wire localization excisional biopsy patients. 
The complications reported with the ABBI during the current study 
were minimal. The technique was weil tolerated by most patients with 51 % 
and 23% reporting good and excellent level of satisfaction with the 
procedure respectively. 
The results of this study as reported above have shown that the 
diagnostic effectiveness of the ABBI is similar to that of the wire 
localization excisional biopsy. With respect to therapeutic effectiveness 
the ABBI is superior when compared to wire localization excisional biopsy, 
although none of the techniques is ideal. Consequently, cost effectiveness 
is an important consideration for the implementation of the technique. 
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Comparison of the direct health costs of the two techniques shows that, 
on the average, the ABBI may result in a cost reduction of $5,352 CAO 
per patient. This would be associated with no loss in diagnostic 
effectiveness and potential increase in therapeutic effectiveness. 
Based on the above the continuation of research aimed at improving 
the therapeutic effectiveness of the ABBI by reducing the percentage of 
tumors excised within involved microscopic margins is justified. 
A significant surgeon effect and volume - performance association 
was observed in the current study. This would suggest that adequate 
training and experience of the surgeon would be required for achieving 
the maximum benefits from the ABBI. From the patient and societal 
perspective this is an important finding since it suggests that the 
effectiveness of the procedure will be influenced by the surgeon's training 
and experience. Consequently, the establishment of specialized centres 
with high volume of cases and properly trained surgeons may be the 
appropriate approach for implementing the ABBI. Indirectly, this may 
explain why the ABBI has not been presently accepted in many centers. 
The requirement for additional training and understanding of stereotactic 
and computerized technology for the successful practice of the ABBI may 
be an obstacle to its general acceptance. 
The results of the current study are in agreement with the published 
literature with respect to ail outcomes measured except for the clarity of 
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microscopic margins. The studies in the literature report rates of involved 
margins between 57% and 95% as compared to 24% in the current study. 
A possible explanation for this discrepancy is that ail three surgeons 
participating in the current study have extensive experience in breast 
cancer surgery and are experts in micro-invasive surgery of the breast. 
The expertise of the surgeons providing data for the other studies is not 
known. 
The weaknesses of this study are that it is partially retrospective 
and non-randomized. Data collected retrospectively may be affected by 
recall bias and inaccuracy of information in the hospital charts. As a non-
randomized trial selection bias may have operated by which the patients 
that selected the ASSI may be different from those that opted to have the 
ASSI. Selection bias may have also operated when the surgeons solicited 
patients to be enrolled in the study. This may have happened if the 
surgeons selecled patients with a higher likelihood of having a better 
outcome with the ASSI. An additional potential problem with the current 
study may be that it enrolled patients over a five-year period with surgeon 
experience changing from naïve to very experienced. As a result, the 
leaning curve effect has biased the results and consequently under-
estimating the effectiveness of the ASSI. 
The strengths of the study include the fact that it took place in 
multiple centers using data from three different surgeons. This improved 
the possibility of generalization of the results to more than one surgeon. 
Page 113 
ln addition, by using patients treated by more than one surgeon the study 
provide the opportunity to assess the surgeon effect. Furthermore, by 
studying the ABBI from its initial implementation the volume-performance 
effect was evaluated. This was an original and very important component 
of the current study. 
Although recall and ascertainment bias may have operated in the 
retrospective part of the study, the outcome measures for both 
retrospective and prospective parts of the study, specifically diagnostic 
and therapeutic effectiveness, were based on objective assessments 
conducted by radiologists and pathologists. The data for these outcomes 
were obtained from surgical, radiological and histopathology results 
reported by highly trained and experienced professionals who were not 
aware of the study. The extent and potential impact of selection bias 
could not be accurately assessed in this observational non-randomized 
study. However, the current study was aimed at assessing real-life 
effectiveness. In a real-life setting both the surgeon and patient will have 
an active role in deciding whether or not the ABBI will be used. This is 
very different from a randomized controlled trial where the treatment 
selection is random and not affected by the surgeon. In addition, in the 
real-life setting, the surgeon plays typically will selectively offer a 
procedure only to those patients that have a higher likelihood of success. 
Therefore, the current study by its observational nature simulates real-life 
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settings and the results can be generalized to routine clinical practice 
when compared to those obtained in controlled clinical trials. 
3.10 CONCLUSION: 
The results of the current study demonstrate that the ABBI is a safe 
and weil tolerated and cost effective microinvasive surgical procedure 
which offers a higher success rate for clear microscopie margins, with 
less breast tissue excised, lower requirement for supplementary surgery 
and less residual tumor in the supplemental peripheral breast tissue 
removed. Given the significant volume-performance association and the 
better therapeutic effectiveness of the ABBI as compared to the wire 
localization biopsy, a weil organized training program may help improve 
the therapeutic effectiveness and increase the practice of the ABBI in the 
management of breast disease in Canada. Establishment of highly 
specialized centers offering this procedure would maximize the benefit 
and reduce costs even more. 
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Evaluation of the Effectiveness of Lymphoscintigraphy with 
99mtechnetium Sestamibi as a Non-Invasive Staging Tooi for 
Breast Cancer 
The following sections include a brief description of the anatomy of 
the Iymphatic system surrounding the breast with emphasis on the 
process for cancer metastasis. This introduction is useful for the reader to 
understand the importance of Iymph node assessment for breast cancer 
and the potential impact of Iymphoscintigraphy guided biopsy that is 
evaluated in the cu rrent study. 
4 INTRODUCTION 
4.1 LYMPHATIC DRAINAGE OF THE BREAST 
Once breast cancer has been confirmed by histological or 
cytological testing, further management directly depends on the stage of 
the disease. Cancer staging is determined by the extent of disease in 
regional or local tissues or organs. The single most important predicting 
factor for long term prognosis in breast cancer is Iymph nodes metastasis. 
Hence, accurate knowledge of the Iymphatic drainage of the breast is 
essential for the comprehension of breast cancer staging. 
4.1.1 LYMPH FLOW AND DRAINAGE OF THE BREAST 
Understanding of the Iymphatic drainage of the breast is essential 
for the proper appreciation of the importance of sentinel Iymph nodes. 
Metastasis occurs predominantly via Iymphatic routes. Contrary to the 
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blood circulation, normal Iymphatic flow is unidirectional and has 
preferential flow from the periphery toward the right side of the heart. In 
inflammatory disease or cancer, the Iymph flow is obstructed and 
Iymphatic flow is reversed. This is detected microscopically as metastases 
within the Iymphatic flow known as endolymphatic metastases. This 
obstruction and reversai of Iymphatic flow is responsible for neoplastic 
growth in local and regional sites distant from the primary malignancy. 
Metastasis begins with the local invasion of the surrounding tissue 
by either single or clustered malignant cells from the primary tumor and 
subsequently penetrates the vascular or the Iymphatic channels adjacent 
to the tumor. Malignant cells either remain and grow at the sites of 
penetration or they move on to other tissues, through the circulatory 
system or in the Iymphatics where they arrive at the Iymph draining nodes 
where they proliferate and are transported to adjacent Iymph nodes or 
through the blood stream. The first node to receive drainage from a 
cancer-containing area of the breast is the "sentinel" node. 
Two additional or accessory directions for Iymphatic flow from the 
breast have been described; the transpectoral and the retropectoral 
routes (Figure 18)165: 
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1. Lateral axillary nodes 
2, 3. Pectornl nodes 
4. Su bscrnpular !'It'ldes 
5. Centra 1 axillary node$ 
S.lnfradavirular nooes 
7, Parastemal nodes 
8. Supradavicular oodes 
Figure 18. Lymphatic system serving the breast. 
Lamarque J-L, ed. Anatomy and embryology. An atlas and text of the 
breast: Clinical radiodiagnosis. London: Wolfe Medical 
Publications, 1984: 17-28 
1. The transpectoral route includes Rotter's or interpectoral Iymph 
nodes. It begins in the loose areolar tissue of the retromammary 
plexus and spreads between the pectoral fascia and breast to 
perforate the pectoralis major muscle and follow the course of the 
thoracoacromial artery and terminate in the subclavicular node 
group. 
2. The retropectoral route drains the superior and internai aspects of 
the breast. Lymphatic vessels from this region of the breast join 
Iymphatic vessels from the posterior and lateral surface of the 
pectoralis major and the pectoralis minor muscles. This is the major 
Iymphatic drainage by way of the external mammary and central 
axillary nodal groups or Levels 1 and Il respectively. 
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The internai mammary nodal group is located in the retrosternal 
interspaces between the costal cartilages appraximately 2 to 3 cm within 
the sternal margin. This group of Iymph nodes traverses and runs parallel 
to the internai mammary vasculature. The internai mammary Iymphatic 
trunks eventually terminate in subclavicular nodal groups. The right 
internai mammary nodal group enters the right Iymphatic duct and the left 
enters the main thoracic duel. 
Lymphatic permeation and obstruction of the i nferior and the deep 
cervical group of nodes of the jugular-subclavian confluence result in the 
presence of supraclavicular nodes. Detection of supraclavicular node 
metastasis is an indication of Stage IV disease. Supraclavicular nodes are 
found beneath the lateral margin of the inferior aspect of the 
sternocleidomastoid muscle beneath the clavicle. 
A cross-communication of connecting dermal Iymphatic channels 
provides Iymphatic flow to the contralateral breast and axilla. Internai and 
external intercostal muscles have extensive Iymphatic drainage parallel to 
the course of the major intercostals blood supply. Infiltrating breast 
cancer of the lateral breast will thus have direct Iymphatic flow towards 
the axilla while metastatic cells fram tumors of the medial breast will flow 
towards the internai mammary nodal groups. Bi-directional metastases are 
evident with invasive central or subareolar cancers. 
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4.1.2 AXILLARY LYMPH NODES 
Three groups of Iymph vessels drain Iymph centrifugally away from 
the nipple: lateral, medial (pectoral), and inferior (subscapular). The 
primary Iymphatic drainage (75%) is via the outer, lateral vessels to the 
axillary nodes in the axilla. Il consists of 10 to 30 axillary nodes in 
clusters of 1-6 nodes. The medial (central) vessels lead to seven 
parasternal or internai mammary nodes followed by eight to the 
supraclavicular nodes. The inferior vessels reach the infraclavicular nodes 
and the Iymphatic system of the opposite breast. 
A different classification (Level 1-111) ofaxillary Iymph nodes, 
commonly used in surgery, is in association with the pectoralis minor. 
This is described in Figure 19. 
Figure 19. Levels ofaxillary Iymph nodes 
©2005 Copyright SDSU CCS QAP. Ali rights reserved. The National 
Lymphedema Network, Inc. 
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1. Level 1: 
These Iymph nodes are located lateral to or below the lower border of 
the pectoralis minor. They include the external mammary, axillary vein 
and scapular Iymph node groups. 
2. Level Il: 
These Iymph nodes are located in deep or posterior to the pectoralis 
minor and they include the central and part of the subclavicular Iymph 
node groups. 
3. Level III: 
The last group of Iymph nodes is located medial or superior to the 
upper border of the pectoralis minor. They include the subclavicular 
Iymph node group. 
4.1.3 Axillary Lymph Node Dissection 
An important component of the physical examination of the breast 
is the palpation of the axilla for the detection of palpable Iymph nodes. 
This may be an indication of metastasis from a primary breast cancer. 
Nevertheless, the absence of palpable axillary Iymph nodes cannot be 
considered as an accu rate indicator of Iymph node metastasis and 
assessment of the stage of the disease. If breast cancer is present 
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axillary Iymph node metastasis could only be detected by surgical 
dissection of the nodes and their histological examination. 
Axillary Iymph node dissection is mainly performed for staging of the 
disease. Controversy exists as to whether the removal ofaxillary Iymph 
nodes with metastatic invasion offers only staging information. It is 
possible that it also provides regional control of disease by reducing the 
probability of metastasis in the axilla. In a retrospective review of patients 
that underwent lumpectomy without axillary dissection, 28% recurrence in 
the axilla over a 10-year period. This recurrence rate varied with tumor 
size, from 10% for T1 a and T1 b primary tumors, 26% for T1 c tumors, and 
33% for T2 to T4 tumors 166 . Data in the literature have shown that in 
clinically node-negative patients, simple mastectomy without axillary 
dissection is associated with an axillary recurrence rate of 17.8% to 
19.0% 167-171. On the other hand, wh en modified radical mastectomy was 
performed with axillary dissection, the recurrence rates varied from 0.3% 
to 3.1 % for node-positive patients and 1.0% to 2.1 % for node-negative 
patients 167-171. Data fram several studies, including over 3,500 patients 
that were negative for axillary Iymph node metastasis, have shown that 
the 5-year probability of recurrent cancer in the axillary Iymph nodes 
ranged from 19% when no nodes were removed to 3% when more than 5 
or 6 nodes were removed167-171. 
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Although the controversy regarding therapeutic benefit ofaxillary 
Iymph node dissection is not yet resolved, there is strong evidence that 
the removal of the metastasized nodes reduces the probability of local 
recurrence of cancer. Traditional axillary Iymph node dissection involved 
removal of more than 15-20 Iymph nodes. Recent research has shown that 
the removal of fewer nodes is adequate to achieve staging and regional 
control of disease. However, the number ofaxillary nodes needed to be 
removed could be reduced even further if the nodes with metastasis could 
be identified and excised. Given that only the presence of nodal 
metastasis is important, the removal of relatively more nodes with 
metastasis and less healthy nodes would improve the control of disease 
and could reduce morbidity associated with surgery as described in the 
following section 172-175. 
Axillary Iymph node dissection is associated with a high risk of both 
immediate and late post-operative complications, mainly Iymphedema and 
sensory motor d istu rbances 172-184. The frequency and seve rit y of post-
dissection morbidity varies with the extent ofaxillary surgery 
performed172-184. Postoperative infection of the breast and axilla has been 
reported in 5% to 14% of cases172-175. Damage to the intercostobrachial 
nerve causes numbness and dysesthesia in the inner side of the upper 
arm in almost 80% of patients and restriction of shoulder movement in an 
estimated 17% of patients undergoing axillary Iymph node dissection 172-
184 
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The most serious and resistant to treatment complication ofaxillary 
dissection is Iymphedema of the arm ipsilateral to the dissected axilla. 
The frequency of this complication varies with the extent of the operation 
from 2% to 27% 172,177-184. 
4.2 SENTINEL LYMPH NODE BIOPSY 
Recently, in an effort to reduce the complications associated with 
traditional axillary node dissection, the dissection and assessment of the 
sentinel node has been evaluated for its accuracy in establishing the 
metastatic status of the remaining axillary Iymph nodes. As defined by 
Morton and colleagues the sentinel node is the first Iymph node on a 
direct drainage pathway from the primary lesion 185,186. Sentinel-node 
biopsy is based on the principle that cells that detach fram a primary 
malignant tumor in the breast will most likely metastasize in the first node 
that receives Iymph fram the affected area of the breast184-189. 
Sentinel Iymph node biopsy involves the surgical removal of the 
sentinel node(s). These are marked by a radiopharmaceutical before 
surgery, and are identified with the use of a gamma-ray tracer, the 
gamma-probe. A small dose of radiolabeled particles is injected close to 
the tumor at least 2 hours before surgery. The radioactive tracer migrates 
through the Iymphatic capillaries and reaches the first sentinel Iymph 
node. Both the tumor and the sentinel node can be identified through 
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scintigraphie images which are obtained 15, 30, 60 and 180 minutes after 
injection. During surgery, sentinel node biopsy is performed with the aid 
of a gamma ray detection probe (Figure 20). 
Gamma 
probe 
~<, .. 
Digital 
r 
Figure 20. Gamma probe and digital meter 
The gamma probe is a small tube capable of detecting the radioactivity 
emitted from the node that has received the injected radiopharmaceutical, 
known as the "hot node". The gamma probe transduces the radioactivity 
signal into acoustic signais and also creates a digital readout. The 
intensity and frequency of the auditory signal are directly proportional to 
the radioactivity detected. Aided by the probe, the surgeon is able to 
locate the lesion and determine the shortest surgical access path to the 
node. 
4.3 CLiNICAL PHARMACOLOGY OF RADIOPHARMACEUTICALS 
Technetium has become the most widely used radionuclide for 
diagnostic Nuclear Medicine. It is preferred due to its short half-life, low 
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energy of its mono-energetic gamma ray and its ease of chelation, which 
facilitates its incorporation into a wide range of radiopharmaceuticals. It is 
formed from the decay of the parent radionuclide, molybdenum-99. 
When Iymphatic mapping is performed with a radiolabelled colloid, 
the choice of rad iocolloid is important because the distri bution depends 
on particle size. The ideal radiocolloid particle size is reported to be 
between 1 0-200nm 190-193. Commonly used radiocolloids in Europe and 
North America are 99mTechnetium Colloidal Albumin and 99mTechnetium 
Sulphur Colloid. Success rates reported for identifying sentinel node with 
radiocolloid alone are between 88-99% 190,191. Particle size of these 
radiocolloids are: colloidal albumin (Iess than 80 nm) and 200-1000 nm 
(Albu-Res, Sorin Biomedica Diagnosis, Saluggia, Italy)) and sulphur 
colloid (200-1000 n m) 192-193. 
99mTechnetium Sestamibi is a cationic 99mTechnetium complex. The 
accumulation of 99mTechnetium Sestamibi in tumours is likely related to a 
number of variables. 99mTechnetium Sestamibi is a lipophilic monovalent 
cation (an isonitrile compound). It enters the cell via passive diffusion 
across plasma and mitochondrial membranes. It is postulated that 
99mTechnetium Sestamibi accumulates within the mitochondria and 
cytoplasm of cells on the basis of electrical potentials generated across 
the membrane bilayers. At equilibrium it is sequestered largely within 
mitochondria by a large negative transmembrane potential. The agent is 
fixed intracellularly as long as cell membrane integrity is intact and 
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nutrient blood flow persists 149. Mitochond ria are organelles that supply 
cells with energy. Complex metabolic changes in malignant cells cause 
mitochondrial damage which in turn triggers the release of cytochrome-c, 
and apoptosis and increased membrane permeability. 
There are many advantages to using Technetium rather than 
Thallium for scintigraphie imaging. Technetium's shorter physical half-life 
permits the use of a higher dose of the radiopharmaceutical. This 
translates to a higher count rate, which will shorten imaging times and 
provide sharper pictures. The gamma energy of Technetium (140 KeV) is 
optimal for use with the detector crystal used in the gamma camera and 
will undergo less attenuation and scatter. Technetium is also readily 
available and produced daily from a Molybdenum generator in most 
Nuclear Medicine departments. 
4.4 CANADIAN CLiNICAL PRACTICE GUIDELINES FOR BREAST 
CANCER 
Whether axillary Iymph node dissection is required for the 
management of early stage clinically node negative breast cancer is a 
subject of controversy. Some argue that due to the significant rates of 
axillary node involvement and due to its potential benefit for control of 
metastasis in the axilla, an axillary node dissection is indicated for ail 
breast cancer patients 194. 
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The following are the relevant sections of the Canadian Clinical 
Practice Guidelines for the management of breast cancer194 : 
a. Removal and pathological examination ofaxillary Iymph nodes 
should be standard procedure for patients with early, invasive breast 
cancer. 
b. For accu rate staging and to reduce the risk of recurrence in the 
axilla, level 1 and level Il nodes should be removed. 
c. Patients should be made fully aware of the frequency and seve rit y of 
the potential complications ofaxillary dissection. 
d. Increased caution should be practised during radiotherapy of the 
axilla after axillary dissection. 
e. Omission ofaxillary dissection may be considered when the risk for 
axillary metastasis is very low or when knowledge of node status will 
have no influence on therapy. 
The Steering Committee on Clinical Practice Guidelines for the 
Care and Treatment of Breast Cancer was convened by Health Canada in 
1997. Since then, evidence has shown that the removal of fewer nodes 
specifically the metastasized Iymph nodes, would offer sufficient staging 
information and control of local recurrence. Consequently, this would lead 
to reduced morbidity after axillary dissection. 
ln 2001, the Steering Committee revised the Guidelines giving the 
option to patients of having sentinel Iymph node biopsy under the 
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following conditions 195. Axillary dissection continues to be the standard of 
care for the surgical staging of operable breast cancer. If a patient opts 
for SLN biopsy, the benefits and risks as weil as what is and is not known 
about the procedure should be clearly explained to the patient. 
Specifically, patients should be informed of the number of SLN biopsies 
performed by their surgeon and the surgeon's success rate with the 
procedure, as determined by the identification of the SLN and the false-
negative rate. Furthermore, the surgeon must perform breast cancer 
surgery frequently, should become familiar with literature on the topic and 
the techniques needed to perform the procedure and follow a defined 
protocol for ail 3 aspects of the procedure (nuclear medicine, surgery, 
pathology). It is also recommended that the first 30 sentinel Iymph node 
biopsies with are followed by complete axillary dissection. Of these 30 
cases, at least 10 should have metastatic disease in the axilla. After an 
85% success rate in identifying the sentinel Iymph node and a 5% or lower 
false-negative rate the surgeon can perform sentinel Iymph node biopsy 
without full axillary dissection as long as the sentinel Iymph node excised 
is negative for metastasis. A positive sentinel Iymph node biopsy result or 
failure to identify an SLN should be followed by full axillary dissection. 
ln summary, the Canadian Clinical Practice Guidelines for axillary 
Iymph node dissection in the management of breast cancer continue to 
recommend the excision of Level 1 and Il nodes. Sentinel Iymph node 
biopsy is offered under strict conditions only if the patient requests it. One 
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of these conditions recommends a full axillary Iymph node dissection if 
the sentinel Iymph node is positive for metastasis. Hence, more healthy 
axillary Iymph nodes will continue to be excised among those with 
metastasis. This will not help reduce the morbidity associated with axillary 
Iymph node dissection. On the other hand, there remains, depending on 
the surgeon's success rate, a 6.8% probability of a false negative sentinel 
1 ym p h n od e 43,191,198,200,203-207 ,209 ,212 ,215,217 ,219,221,223,224,227-230,232 ,235,236,238-243,245, 
246,248-250. According to the Guidelines, if the sentinel node is negative for 
metastasis, no further axillary dissection should be performed, given that 
the surgeon fulfills the conditions described above. Consequently, in order 
to minimize the false negative rate, the need for a detection technique 
specifie to metastasized nodes is now higher. This could be made 
possible by more research aimed towards the validation of a minimally 
invasive technique that first, will accurately identify Iymph nodes with 
metastatic infiltration and second, will offer proper direction for the 
surgeon to locate and excise these nodes. The objective of this study is to 
evaluate the accuracy of Iymphoscintigraphy with a malignancy specifie 
radioactive agent to identify axillary Iymph nodes with metastasis from a 
primary breast cancer in a specifie area of the ipsilateral breast. 
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5 SENTINEL LYMPH NODE BIOPSY - LITERATURE REVIEW 
A search of the medical literature identified 163 studies related to 
sentinel Iymph node biopsy, of which 104 were excluded. Of these 104 
studies, 22 were excluded because they were published in a foreign 
language, 66 were narrative reviews, 3 were commentaries, 2 were 
conference proceedings, 2 were repeated publications, 1 was telephone 
survey and 9 were technical assessments. The remaining 60 studies that 
were used in this literature review are listed in Appendix 1343 ,191,196-198,200-
252. The main conclusions of the literature review are summarized in the 
following sections. 
Axillary dissection used primarily for staging of the axilla for Iymph 
node metastasis in breast carcinoma patients has been associated with 
substantial morbidity, su ch as Iymphedema, pain, sensory and mobility 
d istu rbances of the arm 169, 179-181,196-198,256. Senti nel Iymph node 
dissection, removal of fewer Iymph nodes results in reduced risk for this 
cond ition 179-181,196-198,256. 
Microscopie analysis of fewer sentinel nodes removed could be 
more elaborate and detailed since the detailed analysis of only one or two 
sentinel nodes requires a significantly smaller number of sections to be 
evaluated than that for the larger number of nodes included in a 
traditional axillary dissection. Newly implemented techniques such as the 
detailed microscopie analysis with haematoxylin & eosin (H&E) staining, 
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immunohistochemistry using monoclonal antibodies against cytokeratin 
and reverse transcriptase-polymerase chain reaction (RT -PCR) have 
significantly improved the accuracy of micrometastasis detection in the 
sentinel Iymph node. This in turn has increased the accuracy of sentinel 
Iymph node assessment and its ability to accurately represent the 
metastatic status of the axi lia ry nod es 185, 186, 189,206. 
The most important issue with respect to sentinel Iymph node 
biopsy is whether the metastatic status of the sentinel node could be used 
to determine the status of the remaining axillary Iymph nodes. The 
relevant efficacy parameter of sentinel Iymph node biopsy (SLNB) for the 
identification ofaxillary Iymph node metastasis is therefore false negative 
rate. Given that the detection of even one Iymph node with malignant 
infiltration is sufficient for the diagnosis of metastasis, a false positive 
result is not possible. Therefore a metastasized sentinel node confirms 
metastasis regardless of the status of the other axillary Iymph nodes. 
Contrary, a false negative sentinel Iymph node would lead to the false 
diagnosis of no axillary Iymph node metastasis. According to the 
Canadian Guidelines, a negative for metastasis sentinel node should not 
be followed by further axillary dissection 195. Therefore, the patient will not 
be staged correctly and will not follow the appropriate adjuvant treatment. 
The efficacy of SLNB and the proportion of false negatives was 
reported in 35 of the 60 studies reviewed, including a total of 15,052 
patients and 7,708 sentinel Iymph node biopsies 43 ,191,198,200,203-
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207,209,212,215,217,219,221,223,224, 227 -230,232,235,236,238-243,245,246,248-250. 1 n th es e s tu dies 
the mean proportion of false negatives was 6.8% (standard deviation 
2.8%), ranging from 0% to 46%. The most frequently reported false 
negative rate was 0% in 6 of the 35 articles (16.7%) involving a total of 
339 patients43 , 198,204,209,217,235. 1 n 30 (85.7%) of the 35 studies, the 
reported false negative results range between 0% and 9%43,191,198,200,203-
206,209,212,215,217,219,221 ,224,227,228,230,232,235,236 1 n 9 e ne rai, ail a utho rs 
concluded that sentinel Iymph node biopsy is efficacious and may replace 
traditional axillary Iymph node dissection in tumors smaller than 1 cm in 
diameter. The frequency of the false negative rates in published literature 
between January 1991 and July 2005 is described in Appendix 14. 
Of the 7,708 patients who underwent a sentinel Iymph node biopsy in 
these 35 studies, 1,995 (25.8%) had sentinel nodes correctly diagnosed 
as positive for metastasis. In compliance with the Canadian Clinical 
Practise Guidelines, ail 7,708 of these patients would require full axillary 
Iymph node dissection to determine the extent of metastatic disease. 
However, with the implementation of sentinel Iymph mode biopsy, 5,713 
(74.8%) patients could have been spared this invasive procedure. The 
mean associated risk of missing a metastasis (false negative) was 6.8%. 
Three studies evaluated the association between tumor 
characteristics and axillary Iymph node metastasis, and sentinel Iymph 
node dissection efficacy. Ali authors agreed that, tumor size and 
Iymphovascular invasion are directly related to the risk of metastatic 
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invasion of the axilla. One study emphasized the reverse correlation 
between body mass index (SMI) and sentinel Iymph node accuracy. 
However the other two authors contributed the increased failure rate to a 
decreasing radioactive node count with increasing age and SMI. However, 
with surgeon awareness and caution, along with the combination of vital 
blue dye, increased age and SMI did not significantly affect the failure 
rate for accu rate sentinel Iymph node localization. Successful sentinel 
node detection was independent of tumor location and history of breast 
su rgery211 ,251 ,252. 
The data reported in 20 studies suggest that while vital blue dye 
and radiocolloid mapping were effective, the combination of both was 
more sensitive than either method alone 
43,191, 198,200,203,204,206,212,219,221 ,224,228-230,239,245,246,248-250 
ln conclusion, the review of the literature on sentinel Iymph node 
biopsy published between January 1991 and July 2005 has shown 
advantages of sentinel Iymph node biopsy over traditional axillary Iymph 
node dissection. 
The data in the literature have shown that sentinel Iymph node 
biopsy is a less invasive and safer technique in comparison to traditional 
axillary Iymph node dissection. Even though certain post-operative 
adverse events have been reported after sentinel node biopsy, a 
significant decrease of reported short and long-term post-operative 
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morbidity has been observed when compared to traditional axillary Iymph 
node dissection. 
Sentinel Iymph node biopsy is efficacious for breast cancer staging 
in patients with tumors smaller than 1 cm in diameter. The overall false 
negative rate was 6.8% (SD 2.8) and ranged from 0% to 46%. 
Approximately 75% of the patients submitted to sentinel node biopsy were 
negative for metastasis and could be spared the axillary Iymph node 
surgery. Tumor size and Iymphovascular invasion are directly related to 
the risk of metastatic invasion of the axilla. Successful sentinel node 
detection was independent of tumor location and history of breast surgery. 
Even though increased age and BMI are not contraindications to sentinel 
Iymph node biopsy, extra caution is required because the radioactive node 
counts are lower than in younger patients and patients lower BMI. 
6 PURPOSE, MATERIALS AND METHODS 
6.1 RATIONALE AND PURPOSE 
Increased public awareness for breast cancer has led to an 
increased number of women attending and routinely complying with a 
screening program which include mammographie imaging rather than 
relying on a simple self-examination of the breast, to detect any breast 
abnormalities. This has led to the detection of an increased number of 
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non-palpable lesions and consequently to an increased frequency of 
detection of mammographie findings suspicious for malignancy253,254. 
As a result, the number of minimal or T1 breast cancer diagnosed is also 
increasing ("Minimal breast cancer" is considered a non-palpable 
infiltrating malignant tumor of greater diameter less than 10 mm. or a non-
infiltrating (in situ) malignant tumor of any size). 
Once the diagnosis of breast cancer has been confirmed, the most 
important predictive factors of 10- and 20-year survival are the 
histological type of malignancy and the staging of the disease. The two 
most important requirements of a staging method are: first, the staging 
methodology must provide an accu rate assessment of the extent of 
disease and second, this assessment must yield accurate prognostic 
information that can be used to guide therapy. 
Breast cancer staging is based primarily on the metastatic status 
of the axillary Iymph nodes. Conventionally, this information is acquired 
by the histopathological examination of dissected Level 1 and Il axillary 
Iymph nodes. In addition to requiring general anaesthesia, axillary Iymph 
node dissection is associated with significant morbidity, with up to 60% of 
the patients experiencing post-operative Iymphedema of the involved 
extremity, neuropathy of the arm and the formation of neuroma or 
seroma 169,172,177,179-181,196-198,256-260. 
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The first Iymph node or clusters of nodes to be mapped by 
Iymphoscintigraphy, referred to as the sentinel Iymph node(s), are the first 
to receive metastatic invasion if the tumor has metastasized. Thus, 
Iymphoscintigraphy permits the identification of the node(s) most likely to 
have been infiltrated by metastasis by the specific primary breast cancer. 
Sentinel Iymph node biopsy is considered a less invasive 
technique for the staging of breast cancer. Nevertheless, it still requires 
the dissection of the axilla, which is always accompanied by direct and 
indirect complications either post-operative or from the general 
anaesthesia used. Seing a less invasive technique though, the 
complications associated with sentinel Iymph node biopsy are reported to 
be up to 80% lower than conventional axillary Iymph node dissection261 -
264 
If the presence of Iymph node metastasis can be reliably detected 
by a minimally invasive imaging technique, it may be possible that axillary 
Iymph node dissection could be avoided. Considering the morbidity 
associated with the surgical invasion of the axilla, the use of a potential 
minimally invasive staging technology for breast cancer could probably 
result in a significant decrease of post-operative morbidity and 
consequent improve patient care and quality of life. 
The radiopharmaceutical presently used for the labelling of the 
sentinel node for conventional sentinel Iymph node biopsy is filtered 
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99mTechnetium Sulphur Colloid. This radiopharmaceutical maps the 
Iymphatic pathway and Iymph nodes that drain Iymph from the specific 
breast area, regardless of the presence of metastasis. Therefore, the 
presence of metastasis in the Iymph nodes mapped can only be identified 
if the nodes are dissected and examined histologically. 
On the other hand, if the radioactive agent attaches specifically to 
malignant cells and marks them as "hot nodes" so they can be identified 
by a scanner, it may allow the detection of metastatic Iymph nodes 
without surgical dissection of the axilla. If a non-invasive technique was 
implemented that would accurately detect the presence of metastasis in 
the axilla, it could potentially eliminate the need to axillary dissection 
overall and consequently the problem of post-operative morbidity. 
ln order for Iymphoscintigraphy with 99mTechnetium Sestamibi to be 
accepted and implemented as a test for staging of breast cancer it is 
imperative that it is proven to be valid, reproducible with high sensitivity, 
specificity, positive predictive value and most important a very high 
negative predictive value. Considering that a false negative result may 
lead to inadequate treatment of a cancer patient, the false negative rate is 
the most important parameter to be assessed. 
The purpose of the current study was to evaluate the accuracy and 
the clinical utility of Iymphoscintigraphy with 99mTechnetium Sestamibi as 
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a staging procedure for breast cancer. The study was designed to capture 
a representative sample of the female population diagnosed with early 
stage primary breast cancer with without any clinical indication ofaxillary 
Iymph node metastasis. 
6.2.1 STUDY OBJECTIVE 
The objective of the present study is to assess the accu racy of 
Iymphoscintigraphy with 99mTechnetium Sestamibi to detect axillary Iymph 
node metastasis from a primary breast cancer. 
6.2.2 STUDY HYPOTHESIS 
The hypothesis tested is that 99mTechnetium Sestamibi can 
accurately identify axillary Iymph node metastasis by Iymphoscintigraphy 
alone without the need for further surgical dissection. 
6.3 STUDY DESIGN: 
This was a prospective non-randomized study for which patients 
were recruited from two Montreal hospitals, the Hôpital du Sacré Cœur de 
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Montréal and the Hôpital Hôtel Dieu de Montréal, between January 2000 
and December 2001. 
6.3.1 PATIENTS 
The study enrolled female patients diagnosed with primary breast 
cancer, by either cytology or histology, with non-palpable Iymph nodes (no 
clinical indication ofaxillary metastasis). 
Ali patients were referred by their treating physician to either of the 
two hospitals for further investigation of clinical or mammographic 
findings that were suspicious for breast cancer. Ali patients underwent 
either a Fine Needle Aspiration for cytological assessment (FNA-C) of 
tumor tissue or a tumor biopsy, either incisional (tumor tissue sampling) 
or excisional (complete tumor excision) for histological examination. 
Patients for whom the diagnosis of breast cancer was confirmed and who 
fulfilled the study's inclusion criteria, described below, were eligible for 
enrolment in the study. The treating physician and the hospital staff, 
informed the patient about the procedure and any possible adverse events 
associated with the use of radiopharmaceuticals, prior to enrolment of the 
patient in the study. They also informed the patient that since, according 
to study protocol, ail patients were submitted to a conventional Level 1 
and Il axillary Iymph node dissection, there were no personal advantages 
to be gained by the patients from their participation in the study. Patients 
who accepted to participate in the study were enrolled. 
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6.3.2 INCLUSION CRITERIA 
The following inclusion criteria were applied: 
.:. Female patient with a diagnosis of primary operable breast cancer 
confirmed by histology or cytology, 
.:. Scheduled axillary Iymph node dissection, 
.:. Axillary Iymph nodes negative for metastasis upon physical 
examination, 
.:. Patients with a history of malignancy, other than breast, must be 
disease free for >5 years 
.:. The procedure has been explained to the patient and the patient has 
agreed to participate in the trial and has signed a consent form. 
6.3.2.1 Description and Justification of Inclusion Criteria: 
Female patient with a confirmed diagnosis of primary operable breast cancer 
by histology or cytology, 
There are three parts in this criterion that merit attention: 
a. Confirmed Cancer Diagnosis 
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Surgical staging of cancer can only be justified if the 
diagnosis of cancer has been confirmed by a methodology 
accepted as gold standard. In the case of breast cancer, 
histological or cytological confirmation of malignancy is 
obligatory. Given the high morbidity ofaxillary dissection this 
would be entirely justified and ethically required. 
b. Primary Breast Cancer 
The main purpose of sentinel Iymph node biopsy is to detect 
regional metastasis in patients with early breast cancer who 
have no clinical sign that metastasis has occurred. Hence, 
patients with recurrent or metastatic cancer would not require 
sentinel node detection since in their case metastasis is 
known. 
c. Operable Breast Cancer 
Inoperable breast cancer i.e. inflammatory is weil advanced 
and metastasis once again is expected. Therefore, the 
sentinel Iymph node biopsy is of no value. 
Scheduled for axillary Iymph node dissection 
It would be unethical to schedule an invasive procedure for a 
patient only for the purposes of the study. Only patients who 
have been scheduled already for surgery could be enrolled. This 
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was also useful from a practical perspective in enrolling patients 
in the study. 
Axillary Iymph nodes negative for metastasis upon physical examination 
Lymph nodes that can be palpated are easily localized and 
removed and do not require the guidance of imaging techniques 
or radiopharmaceuticals. 
Patients with a history of malignancy, other than breast, must be disease free 
for more than 5 years 
ln order to minimize the probability of detecting a Iymph node 
metastasis from a primary cancer other than breast cancer, 
patients with a previous diagnosis of cancer other than breast 
cancer needed to be disease free for at least 5 years in order to 
participate in the study. 
The procedure has been explained to the patient and the patient has agreed to 
participate in the trial and has signed a consent form. 
Every effort was made to communicate to the patient the 
advantages and disadvantages of sentinel Iymph node biopsy 
and to describe the technique to the patients or the 
accompanying person if the patient was not capable of 
understanding or communicating in the same language as the 
hospital personnel. Only patients who fully understood the 
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procedure and the study and signed the informed consent form 
were enrolled. 
6.3.3 EXCLUSION CRITERIA: 
Patients with any one of the following criteria were not eligible to 
participate in the study: 
.:. Inoperable breast cancer (peau d'orange, inflammatory 
cancer, infiltration to the skin or chest wall), 
.:. Clinical suspicion of metastasis in the axillary, infraclavicular 
or supraclavicular Iymph node, 
.:. Distant metastasis, 
.:. Bilateral breast cancer, 
.:. Recurrence of breast cancer, 
.:. Previous ipsilateral axillary Iymph node dissection, 
.:. Patient previously treated by chemotherapy, radiotherapy or 
immunotherapy, 
.:. Nuclear medicine test less than 3 days before scheduled 
surgery. 
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6.3.3.1 Description and Justification of Exclusion Criteria: 
1. Inoperable breast cancer (peau d'orange, inflammatory cancer, 
infiltration to the skin or chest wall), 
As mentioned above, in section a3, inoperable breast cancer 
i.e. inflammatory is weil advanced and metastasis is expected. 
Therefore, it forfeits the purpose of sentinel Iym ph node 
biopsy. 
2. Clinical suspicion of metastasis in the axillary, infraclavicular or 
supraclavicular Iymph node 
3. Distant metastasis (metastasis in organs or tissues other than 
intramammary or axillary Iymph nodes) 
4. Bilateral breast cancer (breast cancer diagnosed in both breasts) 
5. Recurrence of breast cancer (patients with a history of breast cancer, 
less than 5 years ago, rediagnosed with breast cancer) 
The above exclusions b, c, d and e are based on the fact that 
the main purpose of sentinel Iymph node biopsy is to detect 
regional metastasis in patients with early breast cancer who 
have no clinical sign that metastasis has occurred. Hence, 
patients with recurrent or metastatic cancer would not require 
sentinel node detection since, in their case, metastasis is 
certain. 
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6. Previous ipsilateral axillary Iymph node dissection, 
Any surgical procedure, regardless of seve rit y, can be the 
cause for the development of cicatricial (scar) tissue, which 
would increase the difficulty of the repeat procedure. When the 
procedure involves a sensitive area such as the axilla with 
vital tissues like the axillary nerve and vessels in close 
proximity, the difficulty and probability of complications 
increases even more. In these cases, until new techniques are 
adequately investigated and proven, conventional techniques 
are considered safer and should be used exclusively. 
7. Patient exposed to preoperative chemotherapy, radiotherapy or 
immunotherapy, 
.:. Patient exposed to adjuvant therapy in the past have two 
reasons not to be eligible for sentinel Iymph node biopsy . 
• :. First, the resulting architectural distortion and fibrous tissue 
formed after radiotherapy increases the difficulty of surgery, 
as described above in paragraph "f" . 
• :. Second, these patients are survivors of metastatic cancer, 
which increases the probability that the current breast cancer 
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is not a primary malignancy, which as explained in the first 
inclusion criterion, is one of the basic prerequisites for a 
patient to be eligible for sentinel Iymph node biopsy. 
8. A nuclear medicine test performed less than 3 days before 
scheduled surgery 
If a nuclear medicine test was performed 3 days or less prior 
to the Iymphoscintigraphy, the radiopharmaceutical used for 
the first test may not have washed out and may interfere with 
the radiopharmaceutical used for Iymphoscintigraphy. 
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6.3.4 STUDY PROCEDURES 
The following diagram describes the study procedures. 
Figure 21: Study Procedures 
Visit 18 
Preliminary Lymphoscintigraphy 
(Nuclear icine Deo't) 
SLN 
biopsy 
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Upon enrolment it was explained to the patients that they will need 
to undergo two Iymphoscintigraphy tests. One will be done at least one 
week before the surgery and the other at least 2 hours and not longer 
than the night before the surgery. The first (preliminary) 
Iymphoscintigraphy was performed to verify if Iymphatic drainage from 
the specifie area of the breast where the tumor is located can be 
mapped. The second (preoperative) was done in order to map the 
sentinel Iymph node(s) and guide the surgeon during surgery. 
For the preliminary Iymphoscintigraphy, patients were presented 
with a choice between two radiopharmaceuticals; the conventional 
99mTechnetium Sulphur Colloid or 99mTechnetium Sestamibi. 
99mTechnetium Sestamibi has not been previously tested for 
Iymphoscintigraphic mapping. In order to avoid jeopardizing the 
identification and dissection of the sentinel Iymph node during surgery 
the second Iymphoscintigraphy was always performed with the 
conventional 99mTechnetium Sulphur Colloid since Sestamibi. 
Patients' choice was mainly based on whether they were willing to try a 
method still under investigation or they would prefer a validated and 
conventional method instead. Ail patients were informed that both 
radioactive agents have been used for different indications and proven 
to be safe. Depending on their choice, patients were enrolled in one of 
the two groups described below: 
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Group 1: Preliminary Iymphoscintigraphy with 1,000 MicroCi of 
99mTechnetium Sestamibi 
Preoperative Iymphoscintigraphy with 425 - 495 MicroCi of 
99mTechnetium Filtered Sulphur Colloid 
Group 2: Preliminary Iymphoscintigraphy with 425 - 495 MicroCi of 
99mTechnetium Filtered Sulphur Colloid 
Preoperative Iymphoscintigraphy with 425 - 495 MicroCi of 
99mTechnetium Filtered Sulphur Colloid 
6.3.4.1 Visit 1: Preliminary Lymphoscintigraphy 
The sa me injection technique was followed with both agents. The 
radiopharmaceuticals were diluted in 6 cc of natural saline and injected 
in six 1 cc aliquots in separate sites subdermally at the periphery of the 
breast lesion or at the site of the previous excisional biopsy, if the tumor 
has been previously removed, followed by injections of 0.2 ml saline. 
The patient was asked to massage the area of injection mildly in a 
circular motion. 
The areas of the axilla that accumulated radioactivity from the 
radiopharmaceutical, referred to as the "hot nodes" were identified by 
two methods. First by gamma-camera imaging with planar scans of the 
involved breast and axillary area, both anterior and 30° oblique 
projections, were acquired at 5, 15 and 30 min. and at 2 and 3 hours 
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after the injection of the radioactive agent. Second, with the use of the 
digital readout of the gamma-probe counts that measures the intensity of 
radioactivity in the hot node. Ali outcomes were recorded and the skin 
above the first Iymph node to be labelled was marked, for reference at 
the day of surgery. 
6.3.4.2 Visit 2, Step 1: Pre-Operative Lymphoscintigraphy 
Pre-operative Iymphoscintigraphy followed 1 to 3 weeks after the 
preliminary testing. This time, ail patients were tested with 
99mTechnetium Sulphur Colloid. Between 3 and 24 hours later, the 
patient was taken to surgery for sentinel Iymph node biopsy and axillary 
Iymph node dissection. Before and during surgery the probe was used to 
guide the surgeon to the location of the highest radioactivity which 
should represent the sentinel Iymph node. The activity level of the node 
was recorded before dissection (in vivo) as weil as after dissection (ex 
vivo) by a 10-second cou nt. The nodes that had ex vivo rad ioactive 
counts of at least 10% that of the hottest Iymph node in vivo were 
considered to be sentinel Iymph nodes. 
Once the sentinel Iymph node was identified and dissected, the 
surgeon proceeded to the dissection of Level 1 and Il axillary Iymph 
nodes. Ali removed Iymph nodes were sent to pathology for histological 
analysis. Frozen sections of the sentinel node were performed when 
possible. 
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6.3.5 DATA SOURCES, STORING AND ANALYSIS: 
Data were abstracted fram patient charts at the Hôpital du Sacré 
Cœur de Montréal and Hôpital Hôtel Dieu by the primary investigator 
(Fotini Sam palis) and entered in an individual case report form for each 
patient. The data was then entered and stored in Excel spreadsheets. 
Data analysis was performed with SPSS.11.0 for Windows. 
6.3.6 STUDY VARIABLES: 
The variables used in this study and the source of the data are 
described in the following section. These variables are included in the 
study "Case Report Form" included in Appendix 15. 
The data abstracted were the basic patient demographic 
information, past medical history, mammographie report, the original 
histology report confirming breast cancer, and the histology report of 
the sentinel and axillary Iymph nodes excised, details regarding the 
supplementary surgical treatment and/or adjuvant therapy suggested by 
the oncology board and follow-up for the duration of the study. 
The following data were abstracted each patient's chart: 
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6.3.6.1 PATIENT'S CHART 
a. Basic demographics 
i. Medical Record Number (MRN) 
ii. Date Of Birth 
iii. Ethnic Background 
b. Medical history unrelated to breast disease 
c. Medical history related to breast disease 
d. Latest mammographic report for the breast lesion under 
investigation 
i. Type of lesion (microcalcifications, soft tissue 
nodule, combination of both) 
ii. Location (quadrant) 
e. The initial cytology or pathology report used for the 
validation of breast cancer 
6.3.6.2 NUCLEAR MEDICINE REPORT 
Lymphoscintigraphy (preliminary and pre-operative) 
i. Date of procedure 
ii. Type of radiopharmaceutical used 
iii. Amount of radiopharmaceutical used 
iv. Time between the injection of the radiopharmaceutical 
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and Iymphoscintigraphic imaging on gamma-camera 
v. Gamma-camera imaging results (whether or not 
Iymphoscintigraphy mapped the Iymphatic drainage 
from the area of the breast where the primary 
malignancy was located) 
vi. The number of gamma-probe counts per 10 seconds 
6.3.6.3 SENTINEL LYMPH NODE BIOPSY SURGICAL REPORT 
a. Date of surgery 
b. Time interval between the first Iymphoscintigram and the 
biopsy 
c. Time interval between the second radiopharmaceutical 
injection and the biopsy 
d. Peri-operative gamma probe counts per 10 seconds 
6.3.6.4 PATHOLOGY REPORT 
a. Tumor Details 
i. Histological type 
ii. Grade 
iii. Size 
b. Sentinel Lymph Node Details 
i. Positive or negative for metastatic infiltration 
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ii. Number of additional sentinel nodes excised 
c. Axillary Lymph Nodes excised 
i. Positive vs. negative for metastatic infiltration 
ii. Number ofaxillary nodes excised 
6.3.7 OUTCOME MEASURES 
6.3.7.1 PRIMARY OUTCOME: 
The primary outcome was the presence of metastasis in the 
axillary Iymph nodes which was diagnosed by histopathological 
assessment. The aim of the study was to evaluate the accuracy of 
99mTechnetium Sestamibi to detect the presence of metastasis in axillary 
Iymph nodes. 
Figure 22. Axillary Iymph node metastasis 
lary Iymphatic pathway 
ph node metastasis 
-------t:ireRI!':T cancer 
Detection of metastasis was measured with two methods. The first was 
an imaging technique with the use of scintigraphie scans obtained with a 
conventional gamma-camera. The second method was a digital measure 
of the gamma -probe counts which represent the intensity of radioactivity 
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in the hot node (Figure 23). The y-probe used was the Navigator 
Guidance System 511 KeV with a scintillation crystal that provides high 
sensitivity for the detection of rad ioactively labelled cells. 
Figure 23.Gamma probe and digital readout 
6.3.8 METHODS TO ADDRESS STUDY OBJECTIVE: 
Objective 1: To assess the accuracy of 99mTechnetium Sestamibi 
Iymphoscintigraphy in identifying axi/lary Iymph node 
metastasis in patients with confirmed breast cancer 
The hypothesis tested is that 99mTechnetium Sestamibi 
Iymphoscintigraphy can accurately detect axillary Iymph node metastasis 
in patients with confirmed primary breast cancer. 
The accuracy of 99mTechnetium Sestamibi to identify axillary Iymph node 
metastasis is based on the comparison between the preliminary 
Iymphoscintigraphy results, both imaging and digital counts, and the 
histological evaluation of the axillary Iymph nodes excised. The unit for 
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the statistical analysis was the patient and not the number of Iymph 
nodes excised since the outcome of interest is the detection of 
metastasis and not the absolute number of Iymph nodes tested. 
For the evaluation of the accuracy of Iymphoscintigraphy with 
99mTechnetium Sestamibi to detect axillary Iymph node metastasis the 
following pai rs of observations are possible: 
Axillary Lymph Node 
Metastasis 
Detection Method 
+ -
+ (Accu rate) (#1) (Error) (#2) 99"1"m Sestamibi 
Lymphoscintigraphy -(Accu rate) 
- (#4) 
Table 14: Evaluation of Lymphoscintigraphy with 99mTc Sestamibi 
results 
1. Sestamibi has detected metastasis and metastasis is confirmed 
in at least one of the axillary Iymph nodes dissected (#1). 
Sestamibi correctly detected metastasis; the result is true positive. 
2. Sestamibi has detected metastasis but no metastasis is 
confirmed in any of the axillary Iymph nodes dissected (#2). 
Sestamibi falsely identified a metastasis; the result is false positive. 
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3. Sestamibi has not detected metastasis but metastasis is 
confirmed in at least one of the axillary Iymph nodes dissected 
(#3). 
Sestamibi failed to detect axillary Iymph node metastasis; the result 
is false negative. 
4. Sestamibi has not detected metastasis and no metastasis is 
confirmed in any of the axillary Iymph nodes dissected (#4). 
Sestamibi accurately did not detect axillary Iymph node metastasis; 
the result is true negative. 
The association between the gamma probe counts and presence of 
axillary node metastatis was evaluated with simple logistic regression. In 
this analysis the dependent variable was the presence of metastasis (0 = 
No, 1 = Yes) and the independent variable was the gamma probe counts 
entered as a continuous scale variable .. If a significant association was 
found a receiver-operating curve was used, to identify the eut-off values 
for the number of counts that best discriminate between the presence 
and absence of metastatsis. 
Although the objective of the study was aimed at asesing 
Iymphoscintigraphy with Setamibi thet two groups described above were 
compared for baseline and testing parameters including delay to testing 
and pathology. These comparisons were conducted in order to determine 
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whether the patients that agreed to have Iymphoscinitgraphy with 
Seatamibi were comparable to those not agreeing to this procedure. This 
would allow the assessment of the likelihood of selection bias in the 
study. 
6.4 RESULTS 
6.4.1 PATIENT DEMOGRAPHieS 
One hundred and ten women with a mean age of 57 (SD = 9.9) 
years, ranging between 31 and 69 years diagnosed with a primary 
malignant breast tumor without palpable Iymph nodes were enrolled in 
the study. The patient age distribution is shown in Figure 24. 
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Figure 24: SLN patient age distribution 
Of the 110 participating patients 47 (42.7%) patients were enrolled 
in Group 1 (preliminary Iymphoscintigraphy with 99mTechnetium 
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5estamibi) and 63 (52.3%) patients in Group 2 (preliminary 
Iymphoscintigraphy with 99mTechnetium 5ulphur Colloid). The youngest 
patient in Group 1 was 31 years old and the eldest 69 with a mean (50) 
age of 55 years (10.1). The age of the 63 patients who were enrolled in 
the second group ranged between 35 and 70 years, with a mean (50) 
age of 56 (9.8) years. 
The patients in the two groups were compared with respect to age, time 
between injection of the radiopharmaceutical and gamma-camera 
imaging and the time interval between their first and second 
Iymphoscintigraphy. 5imilarity of age between the different groups of 
patients tested is important considering that there is a significant 
association between the risk for breast cancer and patients' age. 
5tudent's t-test analysis showed no statistically significant difference for 
age between the two groups (p=0.588). 
Taking into account that the half life of 99mTechnetium is 6.5 hours 
and that the rad iopharmaceutical clears or washes out of the cells at 
different rates, it is important to maintain the same delay between the 
times of injection and imaging between the two groups in order to ensure 
similar imaging conditions. Ali women were submilted to 
Iymphoscintigraphic imaging 5 minutes to 7 hours after the first injection. 
The mean (50) delay was 57.4 (64.6) minutes. 5tandard consecutive 
gamma camera images were taken at 15, 30, 60 and 180 minutes after 
the radiopharmaceutical injection. For two (4.3%) patients in the first 
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group and 2 (6.3%) in the second group the last imaging was delayed for 
over 3 hours (300 & 420 minutes). These 4 patients were excluded from 
the analysis of mean imaging delay. The mean (SO) time interval 
between the second injection and peri-operative detection of the sentinel 
Iymph node was 3.0 (3.24 ) hours with a range between 30 minutes 
and 24 hours. The delay for the majority (89%) of the patients was 
between 2.52 and 3.75 hours. 
Given that the risk of metastasis from a primary cancer increases 
with time, it is important that the time interval between the preliminary 
and preoperative Iymphoscintigraphy is similar between the two groups. 
For ail the patients enrolled in both groups, this time interval ranged 
from 2 to 227 days, with a mean (SO) delay of 15.7 (27.6) days (95% CI: 
10.4, 20.9). The 227 day delay was due to personal reasons of the 
patient and was excluded from the comparison of mean time interval 
between tests. For 104 (94.5%) patients, the time interval between the 
preliminary Iymphoscintigraphy and surgery ranged between 2 and 35 
days, with a mean (SO) time interval of 10.5 (7.5) days (95% CI 9.1, 
12.0). No statistically significant difference was found between the two 
groups with respect to the time interval between the preliminary 
Iymphoscintigraphy and surgery (p=0.270). The mean (SO) time interval 
was 14 (7) days (95% CI 4.8, 24.6) after Sestamibi and 23 (6) days (95% 
CI 10.7,22.1) after Sulphur Colloid. 
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The results described above show that the patients included in the 
study were not different with respect to demographics and test 
parameters. This would suggest a low likelihood of selection bias. 
6.4.2 GENERAL TUMOR CHARACTERISTICS 
Among the malignant tumors there were 10 ductal cell carcinomas 
in-situ (DelS), 92 infiltrating ductal carcinomas, and 8 lobular infiltrating 
carcinomas. The distribution of malignant tumors in Group 1 was 5 
DelS, 45 infiltrating ductal carcinomas and 3 lobular infiltrating 
carcinomas. In Group 2 there were 5 DelS, 47 infiltrating ductal 
carcinomas and 5 lobular infiltrating carcinomas. The size of the tumors 
in Group 1 ranged from 5.1 to 75.3 mm, with a mean (SD) size of 
20.8mm (15.1). In Group 2 the tumor size ranged from 4.3mm to 
69.8mm. The tumors were almost evenly distributed between the left and 
the right breast with a slight predominance of the left (54.5% vs. 41.8% 
respectively). Of the left breast tumors the majority (20%) were located 
in the left upper inner quadrant followed by the left lower and upper 
outer quadrants with an equal distribution of 11 % each. In the right 
breast 21 % of the tumors were located in the right upper outer quadrant 
followed by 10% in the right upper central quadrant. The tumor location 
was similar between the two Groups. 
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6.4.3 PRELIMINARY LYMPHOSCINTIGRAPHY 
6.4.3.1 Lymphoscintigraphic Imaging 
Of the 47 Iymphoscintigraphies with Sestamibi, 10 (23.4%) detected 
Iymph node metastasis in the axilla ipsilateral to the affected breast and 
37 were negative. 
6.4.3.2Axillary Lymph Node Pathology 
The mean (80) number of total axillary Iymph nodes excised per 
patient, including the sentinel Iymph node and Level 1 and Il nodes, was 
12 (5) and ranged from 2 to 34 Iymph nodes. Of the total axillary Iymph 
nodes excised, 14 were positive for metastasis and 96 were negative. 
The mean (SO) number of nodes excised for Group 1 was 13(3)and 
12(6) for Group 2. 
6.4.3.3 Preliminary Lymphoscintigraphy versus Axillary Lymph Node 
Pathology 
6.4.3.3.1 99mTc-Sestamibi Lymphoscintigraphy Imaging 
Of the 10 patients with positive for metastasis 99mTechnetium 
Sestamibi Iymphoscintigraphies, 6 (60%) were true positive and 4 (40%) 
were false positive. Of the 37 patients with negative Sestamibi 
Iymphoscintigraphies, 2 patients delayed 170 and 175 days respectively 
between preliminary Iymphoscintigraphy and surgery. Because the 
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probability that metastasis may have occurred during the 5.8 month 
delay, the results of the preliminary Iymphoscintigraphy were no longer 
applicable at the time of surgery. For this reason these two patients 
were excluded from the analysis. Of the remaining 35 patients with 
negative Sestamibi Iymphoscintigraphies, 31 (88.6%) were true negative 
and 6 (17.1 %) were false negative (Tables 15 and 16). The sensitivity 
and specificity of Iymphoscintigraphic imaging with 99mTechnetium 
Sestamibi were 50% and 88.6% respectively. The positive predictive 
value was 60%, the negative predictive value 83.8% and the accuracy of 
the technique to detect axillary Iymph nodes invaded by metastatic cells 
was 78.7%. 
Axillary Lymph Node 
Sestamibi Imaging Metastasis Total 
Positive Negative 
Positive 6 4 10 
Negative 6 31 37 
Total 10 35 35 
Table 15: Lymphoscintigraphic imaging results compared to axillary 
Iymph node pathology 
True Positive 6/10 60.0% 6 
True Negative 31/35 88.6% 31 
False Positive 4/10 40.0% 4 
False Negative 6/35 17.1% 6 
Table 16: Lymphoscintigraphic imaging results compared to axillary 
Iymph node pathology 
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6.4.3.3.2 Gamma-Probe Counts per 10 seconds 
Logistic regression showed a statistically significant (p<0.001) 
association between the counts measured every 10 seconds with the 
gamma probe during 99mTechnetium Sestamibi Iymphoscintigraphy and 
axillary Iymph node metastasis (Table 17). 
95.0% CI for 
Variable Parameter S.E. P-value Odds Odds Ratio lestimate (B) Ratio Lower Upper 
Counts /10see. 0.002 0.001 0.001 1.002 1.001 1.003 
Table 17: Logistic regression results for association between gamma 
probe counts and axillary Iymph node metastasis 
The Receiver Operating Characteristic (ROC) curve showed 1,350, 
1,962, and 3,080 as the three possible eut-off points between positive 
and negative for metastasis gamma-probe counts per 10 sec detected 
with 99mTechetium Sestamibi (Figure 25). 
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Figure 25: ROC curve of gamma-probe counts versus metastatic status 
ofaxilla 
At a eut-off at 1,350 counts the sensitivity and specificity of gamma 
counts would be 100% and 69.7% respectively. The Positive Predictive 
Value (PPV) would be 54.5%, the Negative Predictive Value (NPV) 100% 
and the accuracy of the test 77.8%. The proportion of false negatives 
would be 0%. 
With a eut-off of 1,962 counts the sensitivity would be 100% and 
the specificity 80.0%. The PPV would be 58.8%, the NPV 100.0% and 
the accuracy 84.4%. There would be no false negative results. 
Finally with a eut-off of 3,080 counts the sensitivity and specificity 
of gamma counts would be 100% and 94.3% respectively. The PPV 
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would be 83.3%, the NPV 100% and the accuracy of the test 95.6%. 
There would again be no false negative results (Table 18). Based on 
these results the eut-off of 3.080 would be selected since it was the one 
with the highest specificity and positive predictive value. 
Gamma Axillary Lymph Node Pathology 
eounts/10see. 
1,350 eounts POS NEG SENS SPEC PPV NPV %FN 
POS 12 10 100% 69.7% 54.5% 100% 0% 
NEG 0 23 
1,962 eounts POS NEG SENS SPEC PPV NPV %FN 
POS 10 7 100% 80.0% 58.8% 100% 0% 
NEG 0 28 
3,080 eounts POS NEG SENS SPEC PPV NPV %FN 
POS 10 2 100% 94.3% 83.3% 100% 0% 
NEG 0 33 
Table 18: ROC curve of gamma probe counts vs. axillary Iymph node 
pathology 
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77.8% 
ACC 
84.4% 
ACC 
95.6% 
6.5 DISCUSSION 
Once a mammographic abnormality has been confirmed to be 
malignant, the next step in patient management is to describe the cancer 
according to its stage and metastasis. This information is required for 
the decision of the appropriate type of adjuvant therapy. Staging of 
breast cancer is primarily based on Iymph node metastasis of the 
ipsilateral axilla. 
Axillary Iymph node dissection is the standard of care for the 
surgical staging of operable breast cancer. However, axillary dissection 
is associated with a high risk of both immediate and late post-operative 
complications, mainly Iymphedema and sensory motor disturbances172 -
184. Aiming to reduce the complications ofaxillary dissection, the 
Steering Committee on Clinical Practice Guidelines for the Care and 
Treatment of Breast Cancer of Canada revised the Guidelines giving the 
option to patients of having sentinel Iymph node biopsy under the 
condition that they are informed about the technique and their surgeon is 
qualified to practice the procedure 195 . 
Even though sentinel Iymph node biopsy is less invasive than 
conventional axillary Iymph node dissection, it still requires axillary 
surgery. Surgical invasion of the axilla is associated with a non-
negligible risk for complications that is not yet weil established because 
sentinel Iymph node biopsy is still regarded as an experimental 
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procedure. Consequently, in most centers, it is performed concurrently 
with a further axillary Iymph node dissection of level 1 and Il Iymph 
nodes. 
According to Guidelines, if metastasis is diagnosed in the sentinel 
node a full axillary dissection should follow. On the other hand, if the 
sentinel node is negative for metastasis, no further axillary dissection is 
recommended, given that the surgeon is qualified. 
Considering the above problems, the introduction of a non-invasive 
technique that is accu rate in the detection of metastatic Iymph nodes 
and staging of breast cancer would minimize the need for axillary Iymph 
node dissection, its associated morbidity and reduce the false negative 
results and the probability of inaccurate staging. The current study 
evaluated the accuracy and the clinical utility of Iymphoscintigraphy with 
99mTechnetium Sestamibi, a radioactive agent that attaches specifically 
to malignant cells and marks them as "hot nodes" so they can be 
identified. 
The accuracy of Iymphoscintigraphy with 99mTechnetium Sestamibi 
was evaluated with two different methods. The first was the assessment 
of the gamma-camera image. The sensitivity of 99mTechnetium Sestamibi 
Iymphoscintigraphy imaging was 50% the negative predictive value was 
83.8% and the proportion of false negative results was 17.1 %. Because 
of the high probability of a false negative result Iymphoscintigraphic 
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imaging with 99mTechnetium Sestamibi cannot be considered reliable for 
the detection ofaxillary Iymph node metastasis. 
The second method used in this study was the digital outcome of 
the gamma probe used to detect and measure the intensity of 
radioactivity in the hot node. Logistic regression showed a statistically 
significant (p<0.001) association between the gamma probe counts and 
axillary Iymph node metastasis. Ail three eut-off points identified by ROC 
analysis had similar sensitivity estimates and false negative rate of 
100%. By using the eut-off at 3,080 counts the specificity and positive 
predictive value were maximum at 94.3% and 83.3% respectively. 
The above results suggest that the use of a malignant cell specifie 
radioactive agent for Iymphatic mapping combined with the gamma probe 
digital readout of the intensity of radioactivity in the hot node, may offer 
an accu rate non-invasive procedure for the detection ofaxillary Iymph 
node metastasis from breast cancer of the ipsilateral breast. Even if 
these results seem very encouraging, the small number of patients that 
agreed to be tested with an experimental radioactive agent (Sestamibi) 
and the even smaller number of patients with axillary Iymph node 
metastasis present a limitation to this analysis. Furthermore, since this 
methodology has not been previously studied there is no comparative 
data for the results of the current study. 
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A limitation of the current is that it is non-randomized and bias 
may have been introduced first because the women accepting a method 
being tested for the first time for this indication may differ from women 
who would reject it and opt for the conventionally used method. On the 
other hand, selection bias may occur since the surgeon may select the 
patient most likely to understand and accept experimental versus 
conventional technology. Comparison of the two patient groups however, 
would suggest that the likelihood of bias is low. 
The strengths of the study are that patients were enrolled in two 
different centers where the patients were operated by different surgeons 
and the surgery was not influenced in any way by the type of radioactive 
agent used in the preliminary Iymphoscintigraphy. Furthermore, 
recording of the gamma probe counts during the preliminary 
Iymphoscintigraphy took place in the nuclear medicine departments of 
each hospital at least 1 week prior to surgery. The surgeons detecting 
the sentinel node and performing the biopsy and axillary Iymph node 
dissection were objective since they were blind to the type of radioactive 
agent used in the preliminary testing. Therefore, no bias could be 
introduced in the way the surgery was performed between the two 
groups. 
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6.6 CONCLUSION: 
The current study indicates that the use of 99mTechnetium 
Sestamibi Iymphoscintigraphy imaging cannot be considered accu rate 
for the detection ofaxillary Iymph node metastasis. 
The results of this study present a strong association between the 
intensity of radioactivity in the hot node as measured by the gamma-
probe counts and the presence ofaxillary metastasis. These results are 
encouraging as a first evaluation of this procedure and merit further 
research. Such research should be performed in centers specialized in 
the management of breast cancer and among nuclear medicine 
physicians and surgeons highly experienced in the procedure of sentinel 
Iymph node biopsy. 
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7 SUMMARV 
The purpose of the thesis was to describe and evaluate the 
effectiveness of two microinvasive procedures for the diagnosis, 
treatment, and staging of breast cancer. 
The first part of the thesis proved that the ASSI offers a superior 
therapeutic effectiveness, is less invasive, and more co st effective than 
wire localization excisional biopsy for the management of 
mammographie abnormalities with high risk for breast cancer. In 
addition, the ASSI was shown to be safe and weil tolerated by most 
patients. The strong volume-performance association shows that the 
effectiveness of the ABSI will improve if the surgeons are properly 
trained. 
The second part of the thesis proved that Iymphoscintigraphy with 
99mTechnetium Sestamibi, if practised correctly, offers a highly accu rate 
and non-invasive technique for the detection ofaxillary Iymph node 
metastasis from primary breast cancer. With proper training and 
experience, the implementation of Iymphoscintigraphy with 
99mTechnetium Sestamibi can help minimize the morbidity associated 
with conventional axillary Iymph node dissection. Furthermore, it can 
reduce the probability of missed metastasis observed with the increased 
practise of sentinel Iymph node biopsy for the staging of breast cancer. 
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ln conclusion, the results of this thesis demonstrate that both the 
ABBI and Iymphoscintigraphy with 99mTechnetium Sestamibi can help 
improve the effectiveness of the current management of mammographie 
abnormalities and specifically breast cancer. Proper training of surgeons 
on both techniques in highly qualified training centers with a high 
volume of cases can help improve the practise of these techniques in 
Canadian hospitals. This may in turn increase the treatment benefits for 
the patients and reduce the healthcare costs for the management of 
breast disease and specifically breast cancer in Canada. 
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9 APPENDIX 
APPENDIX 1: THE TNM STAGING SYSTEM FOR BREAST CANCER 
ln the TNM system, TNM stands for Tumour, Nodes, and Metastases. Each of 
these is categorized separately and classified with a number to give the final stage9 . 
a. ! classifies the extent of the primary tumour, and is normally given as TO through 
T 4. TO represents a tumour that has not even started to invade the local tissues. 
This is called "In Situ". T4 on the other hand represents a large primary tumour 
that has probably invaded other organs by direct extension, and which is usually 
inoperable. 
b. N classifies the amount of regional Iymph node involvement. It is important to 
understand that only the Iymph nodes draining the area of the primary tumour 
are considered in this classification. Involvement of distant Iymph nodes is 
considered to be metastatic disease. The definition of just which Iymph nodes 
are regional depends on the type of cancer. NO means no Iymph node 
involvement while N4 means extensive involvement. In general more extensive 
involvement means some combination of more nodes involved, greater 
enlargement of the involved nodes, and more distant (But still regional) node 
involvement. 
c. M may be either MO if there are no distant metastases, or M1 if there are 
metastases. 
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APPENDIX 2: TNM CLiNICAL CLASSIFICATION 
TNM CLINICAL CLASSIFICATION 
TX Primary tumour cannot be assessed 
TO No evidence of primary tumour 
Tis Carcinoma in situ: intraductal or lobular carcinoma 
T1 Tumour ~ 2 cm in greatest diameter 
T1 a = Tumour ~ 0.5 cm in greatest diameter 
T1 b = Tumour 0.51 - 0.99 cm in greatest diameter 
T1 c = Tumour 1.0 - 2.0 cm in greatest diameter 
T2 Tumour 2.1 - 4.99 cm in greatest diameter 
T3 Tumour > 5.0 cm in greatest diameter 
T4 Tumour of any size with direct extension to the chest wall or skin 
T4a Extension to the chest wall (includes ribs, intercostal muscles and serratus 
anterior muscle, but not pectoral muscle 
T4b Edema (including peau d'orange) or ulceration of the skin of the breast, or 
satellite skin nodules confined to the same breast 
T4c Both T4a + T4b 
T4d Inflammatory carcinoma 
N - REGIONAL LYMPH NODES 
NX Regionallymph nodes cannot be assessed (i.e. previously removed 
NO No regional Iymph node metastasis 
N1 Metastasis to moveable ipsilateral axillary node(s) 
N2 Metastasis to ipsilateral axillary node(s) fixed to one another or other structures 
N3 Metastasis to ipsilateral internai mammary Iymph node(s) 
M - DISTANT METASTASIS 
MX Presence of distant metastasis cannot be assessed 
MO No distant metastasis 
M1 Distant metastasis including metastasis to supraclavicular Iymph nodes 
M1 can be further specified according to the following notation: 
Pulmonary PUL Bone marrow MAR 
Osseous OSS Pleura PLE 
Hepatic PEP Peritoneum PER 
Brain BRA Skin SKI 
Lymph nodes LYM Other OTH 
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APPENDIX 3: TNM PATHOLOGICAL CLASSIFICATION 
pT = Primary Tumour 
The pT categories correspond to the T categories in the clinical classification 
pN = Regional Lymph Nodes 
pNX 
Regionallymph nodes cannot be assessed (no axillary Iymph node dissection or 
previously removed) 
pNO No regional Lymph node metastasis 
pN1 Metastasis on moveable ipsilateral axillary nodes 
pN1a = only micrometastasis (none < 0.2 cm) 
pN1b = metastasis to Iymph node(s), any > 0.2 cm 
pN1bi = metastasis in 1 - 31ymph nodes, any > 0.2 cm and ail < 2.0 cm in 
greatest diameter 
pN1bii = metastasis to four or more Iymph nodes, any > 0.2 cm and ail < 2.0 cm 
in greatest diameter 
pN 1 biii = extension of tumour beyond the capsule of a Iymph node metastasis < 
2.0 cm in greatest diameter 
pN1biv= metastasis to a Iymph node ~2.0 cm in greatest diameter 
pN2 
Metastasis to ipsilateral axillary Iymph nodes that are fixed to one another or to 
other structures 
pN3 Metastasis to ipsilateral internai mammary Iymph nodes 
pM Distant Metastasis 
The pM categories correspond to the M categories in the clinical classification 
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Appendix 4: TNM Staging & Classification of Breast Cancer 
Stage Tumour (T) Classification Node (N) Metastasis (M) 
0 Tis NO MO 
1 T1 NO MO 
liA Ta N1 MO 
T1 N 1 * MO 
T2 NO MO 
liB T2 N1 MO 
T3 NO MO 
iliA TO N2 MO 
T1 N2 MO 
T2 Na MO 
T3 N1, N2 MO 
IIIB T4 Any N MO 
Any T N3 MO 
IV Any T Any N M1 
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APPENDIX 5: AB BI SURGICAL EQUIPMENT 
Monitor for imaging of digital 
mammographie images 
Computer with software for 
ealeulation of stereotaetie 
eoordinates 
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ABBI 
Digital 
mammographer 
cabinet 
1. Stereotactic LoRad table 
This is an adjustable height operating table with cushioning on top 
for increased comfort and a circular opening positioned at the upper 
central part, which allows the woman's breast to hang through. The table 
is designed to allow 360 0 access to the area of interest of the breast. 
The table surface specifications are: 
.:. Height: the table can be moved from 34 inches to 57 inches (86.4cm 
- 144.8cm) 
.:. Length: 72 inches (182.9cm) 
.:. Width: 28 inches (71.1 cm) 
.:. Leg support extensions on either side: 17 inches (43.2cm) 
Cautery LoRad Table Extensions 
Page 221 
2. C-arm: 
The C-arm is a metal base mounted on a pivot mechanism below the surface 
of the table and can be rotated up to 180°. It ho Ids the needle guidance stage, a 
device that aids the insertion of the biopsy needle, which guides the physician during 
the needle insertion, the coring devise and the components and accessories used to 
obtain the stereo images. By rotating the devise, it makes it possible to select the best 
approach for reaching the lesion that will allow a complete excision with the removal of 
the least possible breast tissue. This may be lateral (outer), medial (inner), or anterior 
(frontal) to the breast. For example, for a lateral approach the C-arm is turned at 90° 
to the table and the incision is made at the lateral part of the breast. 
C-arm 
Needle guide and coring device 
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Mammography camera 
3. ABBI control panel (Fig. 5): 
The ABBI panel consists of a numerical and graphical display of 
the X, Y and Z coordinates which are transferred from the computer. It 
controls the movement of the coring device in the breast and indicates 
its proximity to the lesion. 
x, Y, Z coordinates 
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4. AB BI Surgical Component (Fig. 6), 
The ABBI surgical component is comprised of a coring device 
that enters the breast and excises the lesion. The movement of the 
device in the breast is guided by the stereotactic coordinates obtained 
from the control panel. 
Needle guide 
Wire snare 
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Activation 
lever 
Knife return 
lever 
T-crc)ss··oar 
eject lever 
Needle 
assembly 
The ABBI surgical component consists of: 
4.1. ABBI cannula: 
The ABBI cannula is the main part of the coring device. It is 
cone shaped and made of insulated material that protects the 
specimen inside the cannula. The cannula also contains a radiolucent 
sleeve fitted in its interior wall which can slide back and forth in order 
to allow imaging at any time during the procedure. Perioperative 
images are done for two reasons; first, to confirm the proper position 
of the needle guide, that is described in the following section (4.2), 
and second, to confirm the safety of the poste ri or margin or the 
opposite side of the breast, to ensure that the coring device does not 
penetrate through the breast. The cannula is available in diameters of 
5, 10, 15 and 20 mm. 
4.2. 16-gauge needle guide: 
The needle guide is installed in the center of the coring device. 
Once the stereotactic coordinates of the lesion have been calculated 
by the computer (section 1) and transferred to the ABBI control panel 
(section 3), the needle is quickly inserted in the breast, ideally in the 
center of the target lesion. The coordinates in the ABBI control panel 
guide the position of the needle in the breast. 
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4.3. T -cross bar: 
The T -cross bar is a T -shaped sharp edged metal, which is 
inserted along with the needle in the target area of the lesion. Once 
the position of the needle is confirmed to be satisfactory, the T-
crossbar is ejected into the target. The T shape of the crossbar 
attaches into the target and stabilizes the needle into the lesion. 
4.4. Circular Knife Blade or Wire Snare: 
A circular knife blade is located at the edge of the ABBI 
cannula. This is used to cut the distal end of the specimen. At the 
same time, cautery is applied at the exterior wall of the cannula for 
haemostasis of the surrounding breast tissue. 
4.5. Activation Lever: 
The activation lever is placed at the center of the device. It 
consists of a handle, which controls the movement of the circular 
knife blade. Once the cannula has been inserted in the breast and its 
position is confirmed, the activation lever is pushed to the right in 
order to activate the blade to cut the distal end of the specimen. 
4.6. Cautery Adapter: 
The cautery adapter is at the upper part of the device. It 
consists of a 1 cm metal adaptor, which receives one end of the cord 
that connects the cautery device with the ABBI cannula. The 
electrical current is transferred from the cautery device through the 
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cord to the adaptor, which in turn provides cautery while the wire 
snare closes simultaneously to transect the distal portion of the 
breast specimen. 
4.7. Knife Return Lever: 
The knife return lever is positioned at the lower part· of the 
device and consists of two small handles on either side of the device. 
This lever has two functions. When the handles are pushed in, it 
allows a circular ring surrounding the needle assembly to move back 
and forth so that it can be accurately positioned at the distance of the 
Z-axis, which refers to the distance the needle will move in the breast 
in order to reach the target. Once the ring is positioned the handles 
are released. From this point after, the distance the needle can enter 
in the breast is locked and secured so that it cannot move further 
than the manually predefined depth. 
4.8. Needle Assembly: 
The needle assembly contains the needle and the T -cross bar. 
At the exterior of the assembly is a ring. By turning this ring, it 
releases the specimen to be removed from the cannula along with the 
t-cross bar. 
5. Operating Window 
The operating window is a 5 X 5 cm square opening at the 
upper part of a perpendicular 17 X 15 cm metal plate. The breast is 
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compressed between this metal plate and the imaging receptor. The 
target les ion is positioned as close to the center of the operating window 
as possible. The surgery is performed through the operating window. 
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6. The ABBI Cabinet: 
The ABBI cabinet hou ses the components or levers that drive 
the C-arm and the Table. 
Operating 
window 
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7. Digital Image Receptor: 
The digital mammography system eonverts X-rays into an eleetronie 
signal. The mammographie image is portrayed in the ABBI System 
Operator Workstation. 
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8. AB BI Operator Workstation (Fig. 10): 
The Operator Workstation is a computer system that is connected 
to the Digital Image Receptor. The Operator Workstation connects to the 
ASSI control panel and the display through seriai data ports. The Digital 
Imaging System computer uses DOS, a Disk Operating System, to 
manage the flow of information to and from the various parts of the 
system. 
The interface to the system is via DOS commands, which can 
either be typed or selected from menus to perform certain tasks so as to 
facilitate the viewing of digital mammograms and the measurement and 
calculation of the horizontal, vertical, and longitudinal location of the 
lesion. 
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9. Three Dimensional Stereotactic Imaging 
Targets are selected on the ABBI System computer monitor and 
automatically transferred to needle, marker and cannula, providing 
placement to within =/- 1 mm of accuracy. Stereotactic digital images are 
th en taken at + 150 and -150 angles. These data are transmitted to the 
computer as the X (horizontal) and Y (vertical) dimensions forming an 
isosceles triangle. 
--r' /-
Isosceles triangle 
Target lesion 
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ln order to estimate the location of the lesion, the distance 
between the skin and the lesion is calculated using basic trigonometry. 
The length of the perpendicular line (z) dividing the triangle's base (a) in 
ha If is the distance between the skin and the lesion. This provides the 
length of the distance from the skin to the lesion. This length is 
calculated by the trigonometric formula (a/2) Tan 75° = Z. 
a. The added option that allows the operator to adjust the intensity of 
the background and reverse the image to a negative view provides 
i ncreased detection accu racy. 
b. Multiple target positions and a 1 cm round target image facilitate the 
selection of the center of the lesion, which is required for accurate 
localization. 
(a'2)Thl75"=Z 
Isosceles triangle formed 
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APPENDIX 6A: ARTICLES USED IN ABBI LITERATURE REVIEW 
1 
Journal Author Year Country 
1 AJR Smathers 2000 USA 
2 AJR Rebner 1999 USA 
3 AJR Leibman 1999 USA 
4 Am J Surg Matthews 1999 USA 
5 Am J Surg D'angelo 1997 USA 
6 Am Surg Sheth 1999 USA 
7 Ann Surg Oncol Bloomston 1999 USA 
8 nn. Surg Oncol Velanowich 1999 USA 
9 Br J Radio Damascelli 1998 USA 
10 Breast J Ferzli 1999 USA 
11 Breast J Kelley 1998 USA 
12 Breast J Yang 2000 USA 
13 Can J Surg Perelman 2000 CanadalTor 
14 Eur. Radiol. Insausti 2002 Spain 
15 Eur. Radiol. Lifrange 2001 Belgium 
16 J Am Coll Surg Schwartzberg 2000 Usa 
17 J Am Coll Surg Ferzli 1997 Usa 
18 J Gynecol Poil pot 2000 France 
19 J Med Liban Atallah 2000 Liban 
20 J Surg One Portincasa 2000 Italy 
21 Pathologe Ammann 2000 Germany 
22 Schweiz Oertli 1998 Sweden 
23 Surg End Ferzli 1997 USA 
24 Surgery La Raja 1999 USA 
25 Adv. Anat. Pathol Wong 2000 USA 
26 Swiss Surg Marti 2000 Sweden 
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APPENDIX 6B1: ARTICLES REPORTING AB BI ADVERSE EVENTS 1 
COMPLICATIONS 
AUTHOR YEAR N* COMPLICATION #AE AE SE 95% CI 
Wound infection 3 1.18% 0.0068 -0.001 0.025 
Insausti 2002 255 Haematoma 4 1.57% 0.0078 0.000 0.031 
Vasovagal 3 1.18% 0.0068 -0.001 0.025 
Yang 2000 100 Bleeding 2 2.00% 0.0140 -0.007 0.047 
Vasovagal attack 4 11.76% 0.0553 0.009 0.226 
Haematoma 2 5.88% 0.0404 -0.020 0.138 
Perelman 2000 34 Wound infection 1 2.94% 0.0290 -0.027 0.086 
Bruising 1 2.94% 0.0290 -0.027 0.086 
Anxiety attack 1 2.94% 0.0290 -0.027 0.086 
Technical problems 13 38.24% 0.0833 0.219 0.546 
Atallah 2000 67 Haematoma 8 11.94% 0.0396 0.042 0.197 
Haematoma 9 10.00% 0.0316 0.038 0.162 
Bleeding 3 3.33% 0.0189 -0.004 0.070 
Rebner 1999 90 Wound problems 2 2.22% 0.0155 -0.008 0.053 
Pneumothorax 1 1.11% 0.0110 -0.011 0.033 
Venous thrombosis 1 1.11% 0.0110 -0.011 0.033 
Leibman 1999 54 Haematoma 3 5.56% 0.0312 -0.006 0.117 T -bar fracture 3 5.56% 0.0312 -0.006 0.117 
Matthews 1999 110 Haematoma 2 1.82% 0.0127 -0.007 0.043 Wound infection 1 0.91% 0.0090 -0.009 0.027 
Sheth 1999 230 Bleeding 1 0.43% 0.0043 -0.004 0.013 
Bloomston 1999 99 Haematoma 2 2.02% 0.0141 -0.008 0.048 Equip. malfunction 4 4.04% 0.0198 0.002 0.079 
Velanowich 1999 104 Technical failure 30 28.85% 0.0444 0.201 0.376 
Haematoma 2 1.52% 0.0106 -0.006 0.036 
Ferzli 1999 132 Vasovagal attack 1 0.76% 0.0075 -0.007 0.022 
Technical problems 31 23.48% 0.0369 0.163 0.307 
La Raja 1999 127 Haematoma 1 0.79% 0.0078 -0.007 0.023 
Damascelli 1998 77 Haematoma 3 3.90% 0.0221 -0.004 0.082 
Kelley 1998 654 Haematoma 11 1.68% 0.0050 0.007 0.027 Cellulites 1 0.15% 0.0015 -0.001 0.005 
TOTAL 2949 154 5.22% 0.0041 0.044 0.060 
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APPENDIX 682: STUDIES REPORTING NO ADVERSE EVENTS 1 
COM PLiCATIONS 
Author Year N 
Oertli 1998 36 
D'Angelo 1997 23 
Ferzli 1997 34 
Ferzli 1997 54 
Portincasa 2000 165 
Ammann 2000 40 
Marti 2000 144 
Schwartzberg 2000 150 
Poilpot 2000 33 
Lifrange 2001 36 
Smathers 2000 101 
n (studies without complication) 816 
Total cases without complication 2133 
Total cases overall 2949 
% no complications 72.33% 
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APPENDIX 6C: ADVERSE EVENTS 1 COMPLICATIONS REPORTED 
WITH THE AB BI 
Complications # 
cases 
%AE %n SO SE 95% CI 
Technical failure 81 52.60% 2.75% 0.16 0.003 0.022 0.033 
Adverse Events # %AE 
cases 
%n SO SE 95% CI 
Haematoma 47 30.52% 1.59% 0.13 0.002 0.011 0.020 
Vasovagal 8 5.19% 0.27% 0.05 0.001 0.001 0.005 
Wound infection 7 4.55% 0.24% 0.05 0.001 0.001 0.004 
Bleeding 6 3.90% 0.20% 0.05 0.001 0.000 0.004 
Anxiety attack 1 0.65% 0.03% 0.02 0.000 0.000 0.001 
Bruising 1 0.65% 0.03% 0.02 0.000 0.000 0.001 
Cellulites 1 0.65% 0.03% 0.02 0.000 0.000 0.001 
Pneumothorax 1 0.65% 0.03% 0.02 0.000 0.000 0.001 
Venous thrombosis 1 0.65% 0.03% 0.02 0.000 0.000 0.001 
Total complications 154 2.48% 0.16 0.003 0.019 0.030 
Overall sample size (N) 2949 
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APPENOIX 60: ARTICLES REPORTING MARGIN STATUS AFTER THE 
ABBI 
No. AUTHOR N. ABBls Ca Clear p-value SE 95% Confidence Pts Margins Intervals 
1 Perelman 34 34 7 0 0.0000 0.0000 0.0000 0.0000 
2 Atallah 67 67 12 67 1.0000 0.0000 1.0000 1.0000 
3 Smathers 101 101 27 15 0.1485 0.0354 0.0792 0.2179 
4 Schwartzberg 150 150 39 150 1.0000 0.0000 1.0000 1.0000 
5 Ammann 40 40 12 3 0.0750 0.0416 -0.0066 0.1566 
7 Marti 144 135 32 23 0.1704 0.0313 0.1090 0.2318 
9 Rebner 89 71 11 32 0.4507 0.0527 0.3473 0.5541 
10 Leibman 53 53 7 7 0.1321 0.0465 0.0409 0.2232 
11 Yang 80 80 17 8 0.1000 0.0335 0.0343 0.1657 
13 Bloomston 99 99 18 3 0.0303 0.0172 -0.0035 0.0641 
16 Matthews 107 110 28 20 0.1818 0.0373 0.1087 0.2549 
total 964 940 210 328 0.349 0.015 0.3188 0.3790 
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APPENDIX 6E: ARTICLES REPORTING SUBSEQUENT 
SUPPLEMENTAL SURGERY AFTER THE AB BI 
Supplemental Surgery 
~UTHOR YEAR ABBI p- 95% 
Lumpectomy MRM* n valu SE Confidence 
e Intervals 
Perelman 2000 34 Unspecified Unspecified 4 0.12 0.055 0.009 0.226 
~tallah 2000 67 Unspecified Unspecified 12 0.18 0.047 0.087 0.271 
Flebner 1999 90 5 2 7 0.08 0.028 0.022 0.133 
Leibman 1999 54 4 2 6 0.11 0.043 0.027 0.195 
MaUhews 1999 110 14 5 19 0.17 0.036 0.102 0.243 
Bloomston 1999 99 12 5 17 0.17 0.038 0.097 0.246 
Ferzli 1999 132 Unspecified Unspecified 20 0.15 0.031 0.090 0.213 
Damascelli 1998 77 Unspecified Unspecified 32 0.42 0.056 0.306 0.526 
rotai 663 117 0.18 0.015 0.151 0.209 
* MRM = Modified Radical Mastectomy 
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APPENDIX 6F: SUMMARY OF OVERALL CLiNICAL RESULTS OF 
COMPARATIVE STUDIES 
N (patients) 
Study ABBI WL 
Velanovich et 104 520 
al 1999 
D'Angelo et 
al 1997 23 23 
NA = Not Available, 
WL = Wire Localization 
CNB Outcomes 
Positive margins (cancer) 
Reexcision rate 
245 Technical success Sensitivity 
Specificity 
Residual cancer rate 
Malignant 
Positive margins (cancer) 
Mean procedure time 
Mean blood loss 
Residual abnormalities 
Residual cancer 
Cost 
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Number of procedures (%) 
ABBI WL 
63.6% 50.9% 
7.5% 23.5% 
92.5% 98.7% 
100% NA 
100% NA 
71.4% 70.4% 
21.7% 21.7% 
100% 100% 
18 (9-38) min. NA 
14 (9.7) cc 20 (9.8) cc 
8.7% NA 
60.0% 40.0% 
1500 USD 2500 USD 
APPENDIX 6G: COMPARATIVE PATIENT SATISFACTION AND 
COSMETIC RESULTS 
N (patients) Number of procedures (%) Study Outcomes 
ABBI WL ABBI WL 
Subjective comfort 
Excellent 21 
Good 2 23 
Poor 1 
D'Angelo 23 23 
Cosmetic satisfaction 
Excellent 23 0 Acceptable 0 23 
Cosmetic satisfaction 95% 25% Excellent 5% 55% Acceptable 0% 20% Unacceptable 
Chun 20 20 
Overall satisfaction 
Satisfied 75% 90% 
Dissatisfied 25% 10% 
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APPENDIX 7: PATIENT INFORMATION AND CONSENT FORM 
TITlE OF THE STUDY: 
DEVElOPMENT & EVALUATION OF THE ADVANCED BREAST 
BIOPSY INSTRUMENTATION (ABBI) SYSTEM 
NATURE AND PURPOSE OF THE STUDY 
The purpose of this research study is to look at the role of the Advanced 
Breast Biopsy Instrumentation (ABBI) procedure in performing a breast 
biopsy using an image-guide machine (similar to a mammogram; a 
breast X-ray). Recently, you have had a mammogram where an abnormal 
area was found. This abnormal area may or may not be cancer, but is 
questionable enough to perform a biopsy (remove and diagnose the 
breast tissue under the microscope). This biopsy may be performed in a 
number of ways. Or you may already have a diagnosis of cancer made 
with a stereotactic (using a needle) or ultrasound-directed breast 
biopsy. Since this abnormal area is not palpable (you or your doctor 
cannot feel it), an image-guided biopsy needs to be done. The ABBI 
procedure is a type of image-guided biopsy where the whole area can be 
removed with a minimally invasive approach. This method used for a 
breast biopsy is a diagnostic procedure accepted in Canada and in 
the United States. 
STUDY PROCEDURE 
Normally, the day of the ABBI procedure you will be asked to come to the Radiology 
Department, where you will have your breast imaged to see if you are a candidate for 
this type of biopsy. The doctor will then present this project to you which is to evaluate 
the ABBI procedure for therapeutic purposes. Vou will then have a reflexion period 
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and if you decide to participate in the study and after signing this informed consent, a 
pill that you take by mouth may be given to you to help calm your nerves during the 
biopsy. Vou will be asked to lie on your stomach on a specially designed raised 
padded table, making sure you are as comfortable as possible. Your breast will be 
placed through a round opening in the table. The table is then raised so the radiologist 
and surgeon can work from below. Slight pressure is then applied to the breast and 
mammographic (X-ray) images are used to find the abnormal area. Next, the doctor 
will use a sm ail needle to numb the breast to inject a local anaesthetic (you will feel a 
stinging sensation and some burning as the anaesthetic is injected). A small cut 
approximately 2.5 cm (1-1 % inch) is made in your breast then a core of tissue is then 
removed using a special tool called a "cannula". 
The pressure paddle will be released from your breast, you will roll onto your back, 
and the wound will be closed with sutures. Vou will be seen for a follow-up visit with 
your doctor the following week to discuss the pathology and to have your wound 
examined. 
After the biopsy, your breast tissue will be sent to the X-ray department to make sure 
that the questionable area on mammogram has been removed. After the tissue is X-
rayed, it is then sent to the pathology department where a doctor will look at the tissue 
under the microscope for diagnosis and margin determination. 
Vou will be able to relax for as long as you need. Vou can leave the hospital the same 
day, when you feel ready. Vou may want to have a friend accompany you home. 
The Advanced Breast Biopsy Instrumentation or ABBI is a minimally 
invasive procedure, which is performed under local anesthesia. Patients 
who have been submitted to an ABBI biopsy report the feeling of a 
tingling or burning sensation upon administration of the local anesthetic. 
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The procedure is tolerated very weil by 98.5% of the patients. Under 
10% have reported minimum pain and less than 2% have complained of 
neck discomfort. If at any time during the procedure you feel pain the 
surgeon will locally in je ct more anesthetic. The topical anesthetic used 
is "Xylocaine". 
The ABBI biopsy, if positive for cancer, will be followed by a standard lumpectomy 
(removing the tumour with a rim of normal breast tissue around it) or mastectomy 
(removal of the breast). Sentinel Iymph node (SLN), the first Iymph nodes of the 
axillary basin under the arm) biopsy or complete Iymph node dissection (take out ail 
the Iymph nodes) will be used to make sure the cancer has not spread to the Iymph 
nodes under the arm. This is performed in the operating room under general 
anaesthesia (you are put to sleep) and will be covered with a separate informed 
consent. These choices are the standard of surgical care for women diagnosed with 
breast cancer. 
After your surgery, your doctor will follow you on a routine basis. The time you will 
need to spend in this study will be about 1 hour for the ABBI biopsy. If your pathology 
is positive for breast cancer, your doctor may require follow-up visits every 3 months 
for the first year, then every 6 months for the following 2 years, then after that, you will 
be seen every year. 
Ali women who have a lumpectomy to treat their tumour will undergo 4-6 weeks of 
radiation therapy. These treatments are necessary to complete your breast 
preservation treatment. 
If you wish, you can talk to the study doctor or to your personal doctor about what you 
should do. Talking things over can help you make the right choice. 
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Plan of Treatment 
Your regular medical treatment will not actually be part of the research study but will 
prepare you for the study. This treatment will include: 
Bilateral Mammograms and Breast Biopsy 
The experimental treatment that you will receive by taking part in this research study 
is: 
The evaluation of margins around the ABBI breast biopsy. 
Storage of Blood and/or Tissue Samples 
By participating in this research, blood and/or other body tissues will be removed from 
you, will be analyzed and used by the Investigators and/or sponsors. The amount of 
blood removed is approximately 10-15 ml (2-3 teaspoons). With regard to the 
tissues, please see the attached consent form. 
Benefits of Being a Part of this Research Study 
We cannot tell you whether you will or will not benefit from taking part in this study. On 
the other hand, by taking part in this research study, you may increase our overall 
knowledge of your disease and how to treat future patients. The findings of the study 
may eventually result in a more conservative approach to breast cancer, similar to the 
discovery that lumpectomy was just as effective as mastectomy in treating breast 
cancer and the SLN biopsy was more accu rate than the more radical axillary 
dissection in staging breast cancer. Performing and ABBI excision of your tumour has 
the potential of removing less of the healthy breast tissue and causing less of a 
cosmetic deformity. 
Risks of Being a Part of this Research Study 
There is no additional risk involved with the study since you have been advised that 
there is an area of your mammogram that needs to be biopsied and the ABBI 
procedure is an approved breast biopsy method. In addition, the ABBI breast biopsy 
will be followed by the standard treatment for women who want to save their breast, or 
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a lumpectomy or mastectomy followed by a SLN biopsy if this is your choice. You 
may have side effects from the standard treatment of your disease. These possible 
complications may occur with breast cancer surgery, and include infection, bleeding, 
and problems with wound healing. The potential complications of the ABBI procedure 
are the same as with any surgical procedure. 
Ali women treated with lumpectomy have 4-6 weeks of radiation therapy to the 
remainder of the breast to complete the treatment. 
The study doctors will immediately tell Vou if during the study they discover that the 
ABBI procedure causes other new and unknown side effects. If the new findings make 
it unwise for Vou to continue, the doctors will stop your treatment. You will then be 
offered other suitable treatment for your disease. 
Alternatives of Being Part of this Research Study 
Alternatives of being part of this research study are: 
There are three possible methods to sample/biopsy abnormalities that are discovered 
on mammograms and are not palpable. 
1. Stereotactic Core Biopsy (ultrasound or mammogram) - A similar table is used 
to sample the breast in and around an abnormal area. Smaller core needles are 
used for this procedure, but additional mammograms are needed. The advantage 
of this technique is that just a puncture wound is made in the breast about 2-3 mm 
in size. The disadvantage of this procedure is that the biopsy is just a sampling 
and the entire lesion is not removed. There is a possibility that the right area may 
not be sampled (sampling error) or the specimen obtained may not be adequate to 
make the diagnosis. 
2. ABBI Breast Biopsy - The advantage of this technique over the stereotactic core 
is that the entire abnormality is removed and thus sampling errors should not 
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occur. The advantage over the needle directed excisional biopsy is that the entire 
abnormal area may be removed. In addition, less tissue is removed compared to 
needle directed excisional biopsy, thus preserving more normal and healthy breast 
tissue. The disadvantage is that it is a larger incision in the breast 25-40 mm, (1-1 
Y2 inches) is needed compared to a stereotactic core biopsy. 
3. Needle Directed Excisional Biopsy - This technique involves a trip to the 
radiology suite where a guide wire is placed under local anaesthesia. The patient 
is then brought to the operating room and under IV sedation or general 
anaesthesia, the surgeon biopsies the breast tissue. The advantage of this method 
over a stereotactic core is that the entire lesion is removed, but at the expense of 
making 50-100 mm (2-4 inch) incision in the breast. It is also more costly than the 
other two biopsies, since a formai operating room is needed, with anaesthesia. 
Pregnant women cannot participate in this study. 80 if Vou are pregnant, become 
pregnant, or breast feeding while taking part in this research study, tell your study 
doctor immediately. 
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APPENDIX 8: ADVANCED BREAST BIOPSY INSTRUMENTATION: 
CASE REPORT FORM 
M RN: ------- Date of Birth: 1 1 (VY/MM/DD) 
ETH NIC BACKGROUND: 
D CAUCASIAN 
D HISPANIC 
D ASIAN 
D AFRICAN AMERICAN 
D INUIT 
D OTHER: SPECIFY 
MEDICAL HISTORY UNRELATED TO BREAST: 
Medical Condition: Year Management: 
MEDICAL HISTORY RELATED TO BREAST: 
Medical Condition: Year Management: 
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Mammographie Evaluation: 
Date of Last Mammogram: __ / __ / __ (MM/DDIYY) 
Level of suspicion: 
o Category 1 
o Category Il 
o Category III 
o Category IV 
Indication for Procedure: 
Soft Tissue Nodule 
Microcalcifications 
D 
D 
D Combined Soft Tissue Nodule & Microcalcifications 
Quadrant: 
o UO 
OUI 
o LO 
Ou 
DC 
Mammographie Size of Lesion: ____ (mm): 
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Digital Size of Lesion: ____ (mm) 
AB BI approach: D Lateral 
D Superior 
D Oblique 
D Interior 
D Medial 
Breast Compression: ___ (mm) 
Z-axis (mm) 
Estimated Blood Loss: ___ (cc) 
Posterior Margin: ___ (mm) 
A = Time of 1 st specimen image: __ : __ (24 hour format) 
B = Time of final stereo image: __ : __ (24 hour format) 
Procedure time = B - A = min. 
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Post-operative breast image: 
NEGATIVE = No residual tumour detected 
POSITIVE = Residual tumour detected 
Specimen image: 
NEGATIVE = No tumour detected 
POSITIVE = Tumour detected 
D 
D 
D 
D 
Macroscopic (gross) margins of the excised lesion: 
Under macroscopic inspection the tumour is excised within: 
D NEGATIVE = healthy margins 
D POSITIVE = involved margins 
Re-excision performed: 
NO D 
VES D 
Estimated Blood Loss: _____ (cc) 
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Histological Assessment: 
HISTOLOGie DIAGNOSIS: 
D Fibrocystic Breast 
D Benign Tumour 
D Atypic Hyperplasia 
D DCIS 
D Infiltrating Ductal Ca 
D DCIS + Infiltrating Ductal Ca 
D LCIS + Lobular Invasive Focally 
Size Of Lesion: ____ (mm) 
Size Of Specimen: (mm) 
Microscopie i margins of the excised lesion: 
Under microscopie inspection the tumour is excised within: 
D NEGATIVE = ~ 1 mm healthy peripheral tissue) 
Safe Surgical Margins 
D POSITIVE = « 1 mm healthy peripheral tissue) 
Involved (invaded) margins 
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Post-Operative Therapy: 
D SUPPLEMENTARY PARTIAL MASTECTOMY 
D No SUPPLEMENTARY SURGERY REQUIRED 
Adjuvant Therapy: 
D CHEMOTHERAPY 
D RADIOTHERAPY 
D TAMOXIPHEN 
Follow-Up: 
DATE: _----'_~/ __ (MM/DDNY) 
Recurrence: 
D NO 
D YES (IPSILATERAL BREAST) 
D YES (CONTRALATERAL BREAST) 
D REGIONAL METASTASIS - AXILLARY LYMPH NODES 
D DISTANT METASTASIS (specify): ______ _ 
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APPENDIX 9: PATIENT SATISFACTION SURVEY - QUESTIONNAIRE 
% 95% Confidence 
1. Reason for choice of center: Intervals 
a. Physician referral 85 78.0 92.0 
b. Friend 1 family member 15 8.0 22.0 
c. Internet 1 media 0 0.0 0.0 
d. Other 0 0.0 0.0 
2. Understanding of other therapeutic or diagnostic options: 
a. Excellent 5 0.7 9.3 
b. Very good 65 55.7 74.3 
c. Good 15 8.0 22.0 
d. Moderate 15 8.0 22.0 
e. Poor 0 
3. Knowledge of the ABBI and wire localization excisional biopsy 
excisional biopsy procedures 
a. Excellent 2 
-0.7 4.7 
b. Very good 45 35.2 54.8 
c. Good 15 8.0 22.0 
d. Moderate 25 16.5 33.5 
e. Poor 13 6.4 19.6 
4. Reasons for choosing the ABBI: 
a. Physician trust 65 55.7 74.3 
b. Previous experience with the ABBI 4 0.2 7.8 
c. Previous bad experience with wire localization excisional biopsy 6 
excisional biopsy 1.3 10.7 
d. Friend 1 family member good experience with the ABBI 1 
-1.0 3.0 
e. Friend 1 family member bad experience with wire localization 1 
excisional biopsy excisional biopsy -1.0 3.0 
f. Preference for local anesthesia vs general 20 12.2 27.8 
g. Shorter waiting list 3 
-0.3 6.3 
5. Knowledge of advantages and disadvantages of the ABBI: 
a. Excellent 2 
-0.7 4.7 
b. Very good 33 23.8 42.2 
c. Good 30 21.0 39.0 
d. Moderate 22 13.9 30.1 
e. Poor 13 6.4 19.6 
6. Patient satisfaction in the facility: 
a. Excellent 35 25.7 44.3 
b. Very good 40 30.4 49.6 
c. Good 20 12.2 27.8 
d. Moderate 5 0.7 9.3 
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e. Poor 0 
7. Ouration of waiting between scheduling and procedure: 
a. 1 -2 weeks 45 35.2 54.8 
b. 2 -4 weeks 35 25.7 44.3 
c. 5 -8 weeks 20 12.2 27.8 
d. 9 -12 weeks 0 
e. 12 -16 weeks 0 
f. more than 16 weeks 0 
8. Ouration of waiting between procedure and results: 
a. 1 - 2 weeks 51 41.2 60.8 
b. 2 -4 weeks 49 39.2 58.8 
c. 5 - 8 weeks 0 
d. 9 -12 weeks 0 
e. 12 -16 weeks 0 
f. 16 weeks 0 
9. Comfort during procedure: 
a. Excellent 11 4.9 17.1 
b. Very good 57 47.3 66.7 
c. Good 12 5.6 18.4 
d. Moderate 13 6.4 19.6 
e. Poor 7 2.0 12.0 
10. Comfort after the procedure: 
a. Excellent 6 1.3 10.7 
b. Very good 63 53.5 72.5 
c. Good 21 13.0 29.0 
d. Moderate 6 1.3 10.7 
e. Poor 4 0.2 7.8 
11. Satisfaction with procedure: 
a. Excellent 23 14.8 31.2 
b. Very good 51 41.2 60.8 
c. Good 18 10.5 25.5 
d. Moderate 1 
-1.0 3.0 
e. Poor 7 2.0 12.0 
12. Regrets for choosing the ABBI: 
a. Many 8 2.7 13.3 
b. Few 12 5.6 18.4 
c. None 80 72.2 87.8 
13. Ouration of hospital stay after the surgery: 
a. 30 minutes or less 78 69.9 86.1 
b. 30 min. to 1 hour 17 9.6 24.4 
c. 1 - 2 hours 4 0.2 7.8 
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d. 2 - 5 hours 1 
-1.0 3.0 
e. 5 - 10 hours 0 
f. 1 - 2 days 0 
14. lime to normallevel of activity: 
a. Sa me day 49 39.2 58.8 
b. 1 -2 days 23 14.8 31.2 
c. 2 - 5 days 18 10.5 25.5 
d. 5 -10 days 10 4.1 15.9 
e. more than 10 days 0 
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APPENDIX 10: UNIT COSTS PER AB BI AND PER WIRE 
LOCALIZATION OPEN BIOPSY 
xcisional Breast Biopsy 
OST CATEGORIES xcisional 
239.36 
~~ __ ~I~I ____ ~11~$7_.80 __ ~ 
'---_------'I~I ____ ~11$548.40 
'---_----'1 L--I ___ ---'11$ 9 68.84 
'---_----'11'--___ ---'11$1 76.00 
~ __ ~II~ ____ ~I~IN/A ____ ~ 
~ __ ~II~ ____ ~11~$4_.72 __ ~ 
'---__ ~II 1 L--I$ 8_1 .9_0 _-----l 
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APPENDIX 11: ESTIMATES USED FOR COST ANALYSIS 
Point Estimate 
ABBI WL 
Number of Cases 1000 1000 
Cast per Case $653 $2,027 
Total Cast For 1,000 Cases $653,000 $2,027,000 
Supplemental Surgery Rate 14.9% 30.3% 
Number with Supplemental Surgery 97.297 614.181 
Cost~er case of Supplemental Surgery $7,697 $7,697 
Total Cast for ail Supplemental Surgery $748,895 $4,727,351 
$1,401,89 $5,352,4 
Total for Management 5 $6,754,351 56 $5,352 
$1,402 $6,754 -$5,352 
Worst Case 
ABBI WL 
Number of Cases 1000 1000 
Cast per Case $653 $2,027 
Total Cast For 1,000 Cases $653,000 $2,027,000 
Supplemental Surgery Rate 17.2% 27.8% 
Number with Supplemental Surgery 112.316 563.506 
Cast per case of Supplemental Surgery $7,697 $7,697 
Total Cast for ail Supplemental Surgery $864,496 $4,337,306 
$1,517,49 $4,846,8 
Total for Management 6 $6,364,306 09 $4,847 
$1,517 $6,364 -$4,847 
Intermediate Case 1 
ABBI WL 
Number of Cases 1000 1000 
Cast per Case $653 $2,027 
Total Cast For 1,000 Cases $653,000 $2,027,000 
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Supplemental Surgery Rate 12.7% 27.8% 
Number with Supplemental Surgery 82.931 563.506 
Cost per case of Supplemental Surgery $7,697 $7,697 
Total Cost for ail Supplemental Surgery $638,320 $4,337,306 
$1,291,32 $5,072,9 
Total for Management 
° 
$6,364,306 86 $5,073 
$1,291 $6,364 -$5,073 
Intermediate Case 2 
ABBI WL 
Number of Cases 1000 1000 
Co st per Case $653 $2,027 
Total Cost For 1,000 Cases $653,000 $2,027,000 
Sup~emental Surgery_ Rate 17.2% 32.8% 
Number with Supplemental Surgery 112.316 664.856 
Cost per case of Supplemental Surgery $7,697 $7,697 
Total Cost for ail Supplemental Surgery $864,496 $5,117,397 
$1,517,49 $5,626,9 
Total for Management 6 $7,144,397 00 $5,627 
$1,517 $7,144 -$5,627 
Best Case 2 
AB BI WL 
Number of Cases 1000 1000 
Cost~er Case $653 $2,027 
Total Cost For 1,000 Cases $653,000 $2,027,000 
Supplemental Surgery Rate 12.7% 32.8% 
Number with Supplemental Surgery 82.931 664.856 
Co st per case of Supplemental Surgery $7,697 $7,697 
Total Cost for ail Supplemental Surgery $638,320 $5,117,397 
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$1,291,32 $5,853,0 
Total for Management 0 $7,144,397 77 $5,853 
$1,291 $7,144 -$5,853 
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APPENDIX 12: AB BI SURGICAL METHOD DESCRIPTION 
The following section provides a detailed technical description of 
the ABBI method. This description is included here because it may be 
useful to the reader to appreciate the ABBI procedure. 
Ali ABBI patients had agreed and given their written consent to 
undergo the procedure. Ali ABBI biopsies were performed at the day-
surgery clinic under local anaesthesia. Prior to the procedure each 
patient was briefed about the ABBI equipment and was then given a 
description of the procedure. 
The ABBI table is draped and the patient's breast sterilized 
according to standard protocol. The patient lies prone on the ABBI table. 
Special cushions are provided for additional comfort. The affected breast 
is allowed to hang through an opening in the table and is compressed 
between the compression plate and the image receptor. 
Once the patient is positioned, a scout (straight forward) image is 
taken to confirm that the lesion is located at the center of the surgical 
window. The approach requiring the shortest distance from the skin to 
the lesion is chosen, in order to minimize the amount of tissue removed. 
Stereotactic digital images are th en taken at +150 and -150 angles and 
the lesion is localized within the three dimensions described earlier. 
These three dimensions are transmitted to the ABBI panel and the ABBI 
device is mounted on the LoRad table and electronically moved to the X 
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and Y positions of the target. At this point the preparation for the biopsy 
is completed and the surgical procedure will be initiated. 
During the procedure the surgeon informed the patient of each 
step to follow and warned her before any expected discomfort so as to 
avoid movement. Under local anaesthesia a 2mm. skin incision is made 
upon target X and Y-axis and the 16G-needle guide is inserted into the 
breast, to the longitudinal depth (Z-axis) of the target lesion. At this 
moment, an image is taken of the breast in order to confirm that the 
location of the ejected needle is indeed less than 1 mm from the target 
and ideally at the center of the target. Adjustments are possible at this 
point in the procedure if they are required in order to position the needle 
more accurately. Once the proper position is confirmed, the T-crossbar 
is deployed to stabilize the needle in the tumor. 
At this time, more local anaesthesia is given and the incision is 
extended to 3 cm. (1.5 cm. on either side of the needle). Skin flaps are 
adequately prepared and deep tissue anaesthesia is injected around the 
periphery of the cannula. The ABBI coring device is then slowly inserted 
into the breast as the circular blade cuts through the tissue. The cannula 
is advanced beyond the needle and T-crossbar. At this point an optional 
final confirmation image can be taken before the specimen is completely 
transected. The wire snare is activated and transects the distal end of 
the specimen, while cautery is applied to the surrounding tissue. The 
tissue inside the cannula is protected from cautery to prevent damage. 
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After the removal of the ABBI device from the breast, digital 
images of the breast are taken and examined carefully for residual tumor 
or calcifications, which may be an indication of residual disease. 
Removing detected calcifications may help achieve a complete excision 
of the lesion and avoid further supplementary surgery in the future. The 
surgical cavity remains open and is easily examined under direct vision 
for any suspicious findings, such as calcifications or residual tumor, 
which may need to be excised. After satisfactory inspection the surgical 
cavity is tamponaged and the incision covered. The patient is then 
turned to the supine position and is allowed to rest while the excised 
specimen is imaged by digital mammography and reviewed by the 
surgeon and radiologist to confirm that the les ion is present and excised 
within acceptable gross margins. Haemostasis and subcuticular suturing 
of the incision complete the ABBI procedure. 
The pathologist receives the unfragmented specimen in the ABBI 
room where the specimen images are viewed in order to ensure that the 
macroscopic margins (the outer margins of the specimen as seen by the 
unaided eye) for findings suspicious of malignancy (such as 
calcifications or parts of the tumor that have been incompletely excised). 
This is followed by orienting the edges of the specimen as it was 
previously located in the breast as lateral, medial, superior and inferior. 
This will help the pathologist orient the location of any residual tumor 
found in the microscopic margins (assessment of the exterior margins of 
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the excised specimen for malignancy at the cellular level with the aid of 
a microscope) of the specimen. Whenever possible a frozen section is 
performed for a preliminary diagnosis. Further histological analysis of 
the malignant tumors excised follows, reporting the tumor type and size, 
as weil as the microscopic margins. 
The patients were asked to rest for 10- 15 minutes before leaving 
the clinic. Before their departure they were asked to answer a patient 
satisfaction questionnaire. 
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APPENDIX 13: SENTINEL LYMPPH NODE BIOPSY LlTERATURE 
REVIEW 
N JOURNAL AUTHOR YEAR Country DESIGN PTS SLNB BOTH %FN 
1 jama 198 ALBERTINI 1996 USA prospective 62 57 62 0 
2 n zmedj 43 ALLEN 2001 Canada prospective 36 34 36 0 
3 breast cancer 232 BADGWELL 2002 USA retrospecti ve 222 222 3.1 
4 minerva chir 203 BARILLARI 2002 Ita1y prospective 60 60 60 2 
5 ann surg onco1 204 BARNWELL 1998 USA prospective 42 38 42 0 
6 j surg onco1 206 BARRANGER 2004 France retrospecti ve 185 180 180 3.2 
7 breastj 207 BEITSCH 2001 USA prospective 85 85 16 
8 ann surg onco1 208 BLAND 2002 USA 
9 j am coll surg 191 BORGSTEIN 1998 Netherlands prospective 130 122 122 1.7 
10 breastj 209 BRADY 2002 USA prospective 14 13 0 
11 br j surg 247 BRANAGAN 2002 UK prospective 
12 arnj surg 227 BURAK 2002 USA prospective 96 
13 tumori 210 CARCOFORO 2002 Italy prospective 210 
14 amj surg 242 CHAO 2001 USA retrospective 203 8 
15 breastj 211 COX 2002 USA prospective 1352 1352 
16 intj onco1 224 CREAGER 2002 USA retrospective 678 21 23 6 
17 JNuclMed 196 DECICCO 1998 ltaly 
18 j exp clin cancer 249 D'EREDITA 2001 Italy prospective 80 80 32 3.8 
19 worldj surg 248 D'EREDITA 2003 Italy prospective 115 109 59 5.9 
20 j surg once1 200 GIPPONI 2004 Italy prospective 334 326 153 8.6 
21 J Clin Once1 218 GIULIANO 2000 USA propsective 133 132 
22 jpn j clin onco1 215 IMOTO 1999 Japan prospective 88 65 6 
23 surgery 219 ISIDDA 2002 Japan prospective 44 42 44 2 
24 breastj 220 ISIDKAWA 2002 Japan 
25 amj surg 221 JADERBORG 1999 USA prospective 91 64 67 7.8 
26 arch surg 222 KAMATH 2001 USA prospective 101 
27 ann surg oncol 223 KANE 2001 USA prospective 150 150 46 
28 cancer 225 LEE 2002 USA prospective 65 
29 j clin pathe1 226 LEERS 2002 Netherlands retrospective 257 
30 radio1ogy 227 LIBERMAN 1999 USA retrospective 33 9 
31 Ann Surg. 241 MCMASTERS 2001 USA prospective 2203 7.8 
32 breast ca 217 NOGUCID 2000 Japan prospective 126 123 0 
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33 j am coll surg 250 O'HEA 1998 USA prospective 60 59 59 5 
34 j am coll surg 228 OLSON 2000 USA prospective 223 200 223 5 
35 Eur. J Nucl Med 197 PAGANELLI 1998 Italy retrospective 5 
36 int j biol markers 229 PELEY 2001 Hungary prospective 68 68 68 21 
37 tumori 230 PELOSI 2002 Italy prospective 201 194 
38 amsurg 216 PENDAS 1999 USA prospective 478 466 
39 j am coll surg 231 PORT 2002 USA retrospective 32 24 
40 Br J Cancer 201 REITSAMER 2004 Austria Prospective 333 358 
41 amj surg 233 SACHDEV 2002 USA prospective 212 
43 jpn j clin oncol 234 SATO 2001 Japan prospecti ve 110 
42 breastj 235 SATO 2001 Japan prospective 75 74 0 
44 oncologist 236 SCHLAG 2000 Germany prospective 146 146 4 
45 j surg oncol 214 SCHRENK 2001 Austria prospective 247 227 
47 j surg oncol 237 SCHRENK 2002 Austria prospective 263 
46 Rozhl Chic. 238 SCHRENK 2005 Austria retrospective 2326 15.6 
48 J Am Coll Surg 240 SCHRENK 2003 USA retrospective 3501 3501 8 
49 surgery 239 SHIMAZU 2002 Japan prospective 155 93 5.6 
50 ann surg oncol 245 SHIVERS 2002 USA prospective 965 965 4 
51 Ann surg 243 TAFRA 2001 USA prospective 529 13 
52 breast ca res 246 TSUGAWA 2000 Japan prospective 48 48 48 5 
54 j nat! ca instit 230 VERONESI 1999 Italy prospective 376 371 371 6.7 
53 lancet 205 VERONESI 1997 Italy prospective 163 163 2.5 
55 jpn j clin oncol 244 WADA 2003 Japan retrospective 569 569 16 
56 j am coll surg 212 WONG 2001 USA prospective 1436 1287 1287 4.3 
58 breastj 202 WONG 2002 USA prospective 2206 
57 amsurg 212 WONG 2002 USA prospective 2206 2206 
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APPENDIX 14: SENTINEL LYMPPH NODE BIOPSY LlTERATURE 
REVIEW % - FALSE NEGATIVE 
ref.# JOURNAL AUTHOR YEAR Country DESIGN PTS SLNB %FN 
43 n z medj ALLEN 2001 Canada prospective 36 34 0 
191 j am coll surg BORGSTEIN 1998 Netherlands prospective 130 122 1.7 
198 jama ALBERTINI 1996 USA prospecti ve 62 57 0 
200 j surg oncol GIPPONI 2004 ltaly prospective 334 326 8.6 
203 minerva chir BARILLARI 2002 Ital y prospective 60 60 2 
204 ann surgoncol BARNWELL 1998 USA prospective 42 38 0 
205 lancet VERONESI 1997 Italy prospective 163 163 2.5 
206 i surg oncol BARRAN GER 2004 France retrospective 185 180 3.2 
207 breastj BEITSCH 2001 USA prospecti ve 85 85 16 
209 breasti BRADY 2002 USA prospective 14 13 0 
212 .i am coll surg WONG 2001 USA prospective 1436 1287 4.3 
215 j~n j clin oncol IMOTO 1999 Japan prospective 88 65 6 
217 breast ca NOGUCIll 2000 Japan prospective 126 123 0 
219 surgery ISHIDA 2002 Japan prospective 44 42 2 
221 amj surg JADERBORG 1999 USA prospective 91 64 7.8 
223 ann surg oncol KANE 2001 USA prospective 150 150 46 
224 inti oncol CREAGER 2002 USA retrospecti ve 678 21 6 
227 radiology LlBERMAN 1999 USA retrospecti ve 33 9 
228 .i am coll surg OLSON 2000 USA prospective 223 200 5 
intj biol 
229 markers PELEY 2001 Hungary prospective 68 68 21 
239-242.245.246.248-
230 j nad ca instit VERONESI 1999 250 prospective 376 371 6.7 
232 breast cancer BADGWELL 2002 USA retrospective 222 222 3.1 
23S breastj SATO 2001 Japan prospective 75 74 0 
236 oncologist SCHLAG 2000 Germany prospective 146 146 4 
238 Rozhl Chir. SCHRENK 2005 Austria retrospective 2326 15.6 
239 surgery SIllMAZU 2002 Japan prospective 155 5.6 
240 J Am Coll Surg SCHRENK 2003 USA retrospective 3501 3501 8 
241 Ann Surg. MCMASTERS 2001 USA prospective 2203 7.8 
242 amj surg CHAO 2001 USA retrospecti ve 203 8 
243 Ann surg TAFRA 2001 USA prospective 529 13 
245 ann surg oncol SHIVERS 2002 USA prospective 965 4 
246 breast ca res TSUGAWA 2000 Japan prospective 48 48 5 
248 worldj surg D'EREDITA 2003 Italy prospective 115 109 5.9 
j exp clin 
249 cancer D'EREDITA 2001 Italy prospective 80 80 3.8 
250 j am coll surg O'HEA 1998 USA prospective 60 59 5 
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APPENDIX 15: SENTINEL LYMPH NODE BIOPSY EVALUATION: CASE 
REPORT FORM 
MRN: Date of Birth: 1 1 (YY/MM/DD) 
ETHNIC BACKGROUND: 
D CAUCASIAN 
D HISPANIC 
D ASIAN 
D AFRICAN AMERICAN 
D INUIT 
D OTHER: SPECIFY 
MEDICAL HISTORY UNRELATED TO BREAST: 
Medical Condition: Year Management: 
MEDICAL HISTORY RELATED TO BREAST: 
Medical Condition: Year Management: 
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BREAST BIOPSY HISTOLOGICAL ASSESSMENT: 
DATE OF BIOPSY: _1_1_ (YY/MMlDD) 
TYPE OF BIOPSY: __________________ _ 
HISTOLOGie DIAGNOSIS: 
DCIS 
Infiltrating Ductal Ca 
DCIS + Infiltrating Ductal Ca 
D 
D 
D 
D LCIS + Lobular Invasive Focally 
SENT/NEL L YMPH NODE B/OPSY 
1 ST L YMPHOSCINTIGRAPHY 
Date of 1 st injection _1_1_ (YY/MM/DD) 
Tracer 1 st injection ______ _ MicroCi 
-------
Hours of SLN detection after injection ______ _ 
Counts 1 10 sec. 
-------
Intra-mammary Iymph node detection ______ _ 
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2ND L YMPHOSCINTIGRAPHY 
Date of 2nd injection / Surgery: _1_1_ (YY/MM/DD) 
Tracer 2nd injection _____ _ MICROCi _____ _ 
Hours of SLN detection (SURGERY) after injection _____ _ 
Preoperative Counts /10 sec. _____ _ 
Intraoperative counts _____ _ 
SENT/NEL & AX/LLARY L YMPH NODE B/OPSY - H/STOLOG/CAL ASSESSMENT: 
NUMBER OF SLN EXCISED _____ _ 
SLNPATHOLOGY: _____ _ 
NUMBER OFAXILLARY NODES EXCISED _____ _ 
AXILLARY LN PATHOLOGY _____ _ 
TUMOUR PATHOLOGY 
TYPE OF LESION _____ _ 
SIZE OF LESION (mm) _____ _ 
GRADE _____ _ 
QUADRANT ______ _ 
COMPLEMENTARYTUMOUR ______ _ 
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